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SUMMARY 
 
Approximately one third of the global population is latently infected with 
tuberculosis (TB) and there are approximately 9.6 million new cases of TB 
disease per year resulting in 1.5 million deaths. Eleven percent of cases 
globally occur in children and 81% of the burden of TB disease is borne by the 
developing world and countries with emerging economies (BRICS). The 
African region accounts for 28% of new TB cases globally. 
TB remains a significant public health concern globally, particularly amongst 
children and immunocompromised individuals. Diagnosis of childhood TB is 
an on-going challenge, as children usually do not present with the same signs 
and symptoms as adults, and are often misdiagnosed. Tuberculosis infection 
in children is seldom confirmed through sputum culture, as good sputum 
samples can rarely be collected. Only 15% of cases from children are sputum 
smear positive by acid-fast staining, and only 30%–40% are Mycobacterium 
tuberculosis (MTB) culture positive. Up to 40% of children present with 
extrapulmonary manifestations of TB disease. The most common 
manifestation is tuberculous lymphadenopathy. Good specimens for TB 
detection can be obtained from these cases through fine needle aspiration 
biopsy (FNAB), a cost-effective and practical out-patient procedure for 
obtaining specimens from enlarged superficial lymph nodes. 
The conventional laboratory techniques that have been used globally for TB 
diagnosis are Ziehl-Neelsen (ZN) staining for acid fast bacilli (AFB) 
microscopy, culture and more commonly now LED microscopy, cytological 
determination with auto-fluorescence staining and molecular Xpert® MTB/RIF 
(Cepheid) detection. AFB-microscopy requires minimally 5000 AFB per 
millilitre of specimen to yield a consistently positive result and observation of 
between 100 and 300 microscopic fields in order to obtain accurate results. 
Culture for MTB is the gold standard diagnostic method but has a slow 
turnaround time and requires laboratory resources that are not available in 
most parts of the world. 
Recent systematic reviews of studies evaluating commercially available 
nucleic acid amplification test (NAAT) technologies confirm very high 
specificity, with sensitivity approaching, but not reaching, that of culture. The 
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complexity and insufficient robustness of existing commercial NAAT protocols 
and their need for precision instruments, a high degree of technical support, 
and quality assurance make them unsuitable for most low-resource 
TB-endemic countries. In addition, none of these techniques have been fully 
validated for diagnosing TB in children and specifically not for extrapulmonary 
specimens. 
In light of these challenges, there is promise in two technologies that have 
been developed and under evaluation over the last few years; the Xpert® 
MTB/RIF kit (Cepheid) for rapid detection of MTB and rifampicin resistance 
endorsed for use by the WHO; and the Ustar EasyNATTM TB IAD kit (Ustar 
Biotechnologies, Hangzhou) for detection of MTB, selected by the WHO as a 
technology on assessment for use in TB endemic countries. In this study, their 
performance was assessed against the conventional laboratory diagnostic 
techniques of smear AFB microscopy, cytology and mycobacterial culture of 
fine needle aspirates from lymph nodes of children suspected of TB 
lymphadenopathy in Tanzania. 
Age-defined clinical assessments were done for all 75 participants and TB 
treatment initiated based on these and/or laboratory diagnostic outputs. All 
laboratory diagnostic modalities were primarily assessed against TB culture 
as the conventional reference standard. As has been evidenced in earlier 
studies, the sensitivities for both smear microscopy and TB culture were very 
low in these extrapulmonary specimens. Lacking a true reference standard, 
composite reference standards (CRSs) were created to assess the 
performance of the test modalities under study. An alternative method for 
assessing diagnostic accuracy under these conditions is latent class analyses 
(LCA), which was utilized to further assess the performance of all diagnostic 
modalities in the study. 
The overall outcomes of the project demonstrated that cytomorphology was a 
feasible and effective technique for detection of TB in lymph node aspirates 
(sensitivity: LCA 100%, specificity: LCA 94.7%) that may complement TB 
culture (sensitivity: LCA 74.5%, specificity: LCA 90.3%). Further, it was shown 
that Xpert (sensitivity: CRS 58% LCA 70.7%, specificity: CRS 93% LCA 
94.2%) was superior in performance to EasyNAT (sensitivity: CRS 19% LCA 
29.2%, specificity: CRS 100% LCA 100%) and ZN (sensitivity: CRS 14% LCA 
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19.1%, specificity: CRS 100% LCA 100%) analyses, respectively. Combining 
two or more tests significantly improved the diagnostic efficacy, but including 
either EasyNAT testing or ZN microscopy to a diagnostic algorithm that 
already had Xpert testing added no value. 
These findings indicate that combining clinical assessment, cytology and 
Xpert MTB/RIF can provide for rapid and accurate diagnosis of childhood 
tuberculous lymphadenitis. Larger diagnostic evaluation studies on Xpert 
MTB/RIF would be required, to assess its use as a solitary initial test for 
tuberculous lymphadenitis in children. 
 
 INTRODUCTION 1 
INTRODUCTION 
 
TUBERCULOSIS, EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS 
The Mycobacterium tuberculosis complex (MTBC), comprises of several 
mycobacterial species which cause tuberculosis (TB) in a variety of hosts: M. 
tuberculosis, M. africanum, M. canetti (all cause TB in humans), M. microti 
(infect voles), M. bovis (mainly infect cattle), M. caprae (infect sheep and 
goats), M. pinnipedi (infect seals and sea lions) and the vaccine strain Bacillus 
Calmette-Guérin (BCG) (Smith et al., 2006). More recently, two novel 
members of the MTBC were discovered through sequence analyses: M. 
mungi that infects banded mongoose in Botswana and; M. suricattae that 
infects meerkats in Southern Africa (Alexander et al., 2010; Dippenaar et al., 
2015). Mycobacterium tuberculosis (MTB) is the main causative agent of 
human tuberculosis. It is a member of the family Mycobacteriaceae: aerobic 
bacilli (rod-shaped bacteria) with cell walls impervious to Gram staining (gram 
negative). 
Approximately one third of the global population is latently infected with TB. 
There were an estimated 9.6 million new cases of TB disease globally in 
2014, with 1.5 million deaths (WHO, 2015a). Between 10.4% and 11% of 
cases globally occur in children (WHO, 2015a; Perez-Velez and Marais, 2012) 
and 81% of the burden of TB disease is borne by the developing world and 
countries with emerging economies (Brazil, Russia, India, China and South 
Africa [BRICS]). The African region accounts for 28% of new TB cases (WHO, 
2015a). 
Tuberculosis remains one of the commonest causes of childhood mortality in 
the world. Recent modelling data suggest that over 650,000 children develop 
TB every year in the 22 countries with the highest TB burden (Dodd et al., 
2014). The World Health Organization (WHO) estimated 1 million new 
childhood TB cases worldwide in 2014 (WHO, 2015a). Case reporting 
depends on a number of factors that vary per region and can range from 5% 
in low-burden countries to 20-40% in high-burden countries (Swaminathan 
and Rekha, 2010). Prevalence reports from a rural setting in Ethiopia showed 
that 46.3% of reported cases of TB were in children (<15yrs) (Ramos et al., 
2010), while a study conducted in the Kilimanjaro Region of Tanzania 
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estimated the childhood TB burden to be 13% of the total burden of the 
country (Mtabho et al., 2010), making it one of the regions with the highest 
childhood TB prevalence in the world. 
 
Figure 1: Estimated global TB incidence rates, 2014. 
Source: Global Tuberculosis Report 2015, World Health Organization (WHO, 2015a). 
 
The key mode of transmission of TB is inhaled aerosols containing MTB, 
formed when persons with pulmonary tuberculosis cough or sneeze. The 
primary site of infection in the lungs is known as a Ghon focus, usually visible 
on chest X-ray. In asymptomatic individuals, this may be an indicator of latent 
TB infection (LTBI). It is important to distinguish between infection and 
disease (active TB) in tuberculosis. The introduction and establishment of the 
bacterium in an individual constitutes infection while bacterial proliferation in 
the lungs or other tissues, conferring development of persistent and non-
remitting symptoms, denotes active infection or disease. In TB disease, the 
bacteria replicate in macrophages and affect the surrounding tissue, causing 
abnormal cell death (necrosis). This occurs within structures known as 
tubercles in the lungs, also visible on X-ray examination. 
Although TB primarily manifests in the lungs (pulmonary), it can affect multiple 
systems of the body outside of the lungs and chest cavity. This is known as 
extrapulmonary TB (EPTB) with a large variety of presentations and 
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manifestations in both adults and children. Though not well reported, the 
global incidence of EPTB in 2012 was 18% of all new cases (WHO, 2013a), 
with a potentially higher prevalence. Progression to death has been found to 
be significantly higher in EPTB patients than in pulmonary TB (PTB) patients. 
Immune suppression and old age has been shown to predispose patients to 
EPTB development (Fortún et al., 2014a). 
Active TB in adults can develop either from recent infection or a reactivated 
LTBI, whereas in children it usually results from recent infection. It is found 
that children with TB disease usually have far fewer bacteria in their lungs 
(paucibacillary in nature) than in adults and it is rare for children to be the 
source of transmission to adults or other children (Logitharajah, 2008), 
although it is possible in older children or those with cavitating TB disease 
(Schaaf et al., 2007). Childhood TB is therefore often considered an indicator 
of TB transmission in the community in high endemic settings, with children 
older than 3 years being infected through contact within the community rather 
than through household contact (Marais et al., 2009). 
 
IMMUNOLOGY OF TB INFECTION AND DISEASE 
Once in the lungs the bacteria invade and replicate in alveolar macrophages. 
T-lymphocytes, B-lymphocytes and fibroblasts surround these macrophages, 
all of which aggregate to form granulomas. At this point, there may be one of 
three outcomes of TB infection. First, the host immunity may be able to 
eliminate the infection completely through successful phagocytosis. Second, 
by inhibiting fusion of phagosomes with lysosomes, MTB prevents its own 
digestion, thriving within macrophages, multiply within the lung and other 
tissues; developing disease. Third, the host immune response acts to prevent 
dissemination of the mycobacteria, which become dormant leading to LTBI 
(Ernst, 2012). As such 90% of people infected with MTB develop LTBI 
(Skolnik, 2011). These different outcomes of the infection are often not 
clear-cut and patients may present in transition states. The lifetime risk of 
developing active TB from LTBI (re-activation) in immune-competent adults is 
10%. Re-activation occurs after several years, leading to clinical disease 
referred to as secondary infection. 
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CD4+ T-cells play a major role in the formation of granulomas, as they 
produce cytokines such as interleukin-12 (IL-12) and interferon gamma (IFN-
γ), which are activating agents for macrophages. As CD4+ T-cells counts are 
usually low in advanced HIV infection, HIV positive patients have an 
increased risk (up to 40-fold) of being infected with TB (Brites and Gagneux, 
2012). Accordingly, it has been found that LTBI patients co-infected with HIV 
have an incremental risk of reactivation, of 10% per year (Mainous and 
Pomeroy, 2010). 
 
DISEASE PREVENTION 
Since the development of the Bacillus Calmette-Guerin (BCG) vaccine 
(attenuated live bovine tuberculosis bacillus, Mycobacterium bovis) in the 
1920’s, there has been no other vaccine against TB endorsed for use in 
humans. BCG protects against miliary TB and TB meningitis in 
immune-competent children, but does not confer protection against primary 
infection or reactivation of latent pulmonary infection in both children and 
adults (WHO, 2004). 
There have been some vaccine candidates in development since the year 
2000. These candidates fall into four categories based on their expected 
modes of action. The first are prime vaccines, designed to replace the BCG 
vaccine, through their modification or genetic attenuation of MTB. The second 
are prime-boost vaccines, designed to improve the limited immunity conferred 
by the BCG vaccine. This is through transportation of MTB deoxyribonucleic 
acid (DNA) into human cells, where the DNA is transcribed into antigens, or 
by combining different MTB antigens with adjuvants that boost the body’s 
natural immunity. The third are immunotherapeutic vaccines designed to 
shorten the timeframe of TB treatment regimens. The fourth are whole-cell 
vaccines constructed from inactivated mycobacteria related to MTB, such as 
Mycobacterium vaccae. The first TB vaccine efficacy trial since 1968, was on 
the prime-boost vaccine MVA85A. The trial, run in South Africa between 2009 
and 2011, demonstrated that MVA85A did not confer significant added 
protection against TB to infants vaccinated BCG (Tameris et al., 2013). 
Apart from vaccination, the focus of disease prevention should be the 
reduction of risk factors associated with TB. These factors include poor 
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ventilation, overcrowding, immune-compromising conditions and drugs, 
diabetes, smoking, alcohol abuse, and some social-economic and behavioural 
factors (Narasimhan et al., 2013). 
 
TB DIAGNOSIS 
In adults, common signs and symptoms of TB disease include fever, chills, 
night sweats, loss of appetite, weight loss, and fatigue. These are used in 
clinical assessment to guide treatment choices. Pulmonary TB usually 
presents with a Ghon focus and other lung changes that may be detected 
through chest radiography (X-ray). A productive cough is common in adults 
whereby sputum samples can be tested for MTB to diagnose TB in adults. 
Children often do not present with these signs, symptoms or cough in primary 
TB infection and it is therefore difficult to diagnose. (Please refer to section: 
‘Disease Progression and Manifestations of TB in Children’ for this 
information). 
Laboratory based TB diagnostics 
Diagnosis of latent TB infection: 
About three to twelve weeks after primary infection with MTB, cell-mediated 
immune priming occurs in immune-competent patients. This immune memory 
persists through the person’s lifetime, unless lost due to immune system 
dysfunction or old age. The Mantoux or tuberculin skin test (TST) is a 
delayed-type hypersensitivity reaction occurring through this immunity, to a 
purified protein derivative of a human-infective strain of M. tuberculosis 
injected intradermally. In clinical routine LTBI is defined as a positive M. 
tuberculosis-specific immune response (e.g. TST) in the absence of active TB 
disease. False-positive TST results have been observed in children inoculated 
with BCG up to 18 weeks prior to Mantoux testing, as well as those exposed 
to non-tuberculous or environmental mycobacteria (NTM), long after neonatal 
BCG vaccination (Farhat et al., 2006; Ota et al., 2006; Burl et al., 2010). 
A negative TST result does not exclude the possibility of TB infection because 
many disseminated forms of TB, including miliary and meningitis, can induce 
anergy or absence of the normal immune response to the skin test. Up to 15% 
of children who have clinical TB have negative TST results. A false-negative 
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TST result has also been associated with recent measles infection, high-dose 
corticosteroid treatment, irradiation, other immunosuppressive therapy, or 
immune-compromising medical conditions such as HIV infection (Cruz and 
Starke, 2010). 
Another method of testing for LTBI is the interferon-gamma release assay 
(IGRA). Commercially available assays include the T-SPOT® TB (enzyme 
linked immunosorbent spot test, Oxford Immunotec, Oxford, UK) and the 
QuantiFERON® TB Gold (Cellestis, Carnegie, VIC, Australia). The antigens in 
these assays do not cross-stimulate BCG-primed lymphocytes and potentially 
overcome the problem of determining whether the condition is LTBI or a 
reaction to vaccination (Ewer et al., 2003; Liebeschuetz et al., 2004; Pai et al., 
2004). Both TST and IGRAs however, do not distinguish between active and 
latent TB infection, but indicate exposure to TB (leading to the cell-mediated 
immune priming). The recommendation for diagnosis of LTBI is therefore; a 
positive TST result, epidemiologic information (exposure to a known source 
case) and a compatible clinical picture. 
Diagnosis of active pulmonary and extrapulmonary TB: 
Direct visualisation techniques: 
Ziehl-Neelsen staining is the most widely available technique for the 
detection of TB in smears (sputum or other fluids) from samples of active TB 
patients. It is a special bacteriological stain used to identify acid-fast bacilli 
(AFB), mainly mycobacteria, as these organisms are not decolorized by the 
acid:alcohol mixture used in the technique once carbol-fuchsin stains the 
lipid-rich cell wall. It is therefore not specific to MTB. AFB microscopy requires 
minimally 5000 AFB per millilitre of specimen to yield a consistently positive 
result (Charnace and Delacourt, 2001). In addition, the procedure requires 
observation of between 100 and 300 microscopic fields in order to obtain 
accurate results (Somoskovi et al., 2001). Only up to 15% of cases of children 
are found to be sputum AFB smear positive (Eamranond and Jaramillo, 
2001). Notwithstanding, adolescent children frequently develop sputum 
smear-positive adult-type disease and sputum microscopy has diagnostic 
value in this subset of children (10 to 14 years) (Marais et al., 2005). 
Cytomorphology is quickly becoming one of the more reliable visual detection 
methods for identifying MTB (Mittal et al., 2011). Smears of host cells from the 
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focus of infection are stained using Papanicolaou (PAP) stain and the 
microscopic examination requires well-trained staff. The cell morphology is 
used as a proxy for the presence of AFB and has been found to be fairly 
accurate in indicating the presence of MTB (Wright et al., 2008). 
Some microorganisms are able to re-emit light upon light excitation known as 
autofluorescence. One such organism is MTB which fluoresces under 
light-emitting diode (LED) lighting using specific filters within the cyan range of 
light (Kumar et al., 1998). A large study comparing routine PAP stained slides 
of samples from MTB infected lymph nodes and the same glass slides viewed 
under fluorescence microscopy, demonstrated that cytomorphology had 
84.9% sensitivity in detecting presence of MTB, but had low specificity of only 
50.9%. Autofluorescence demonstrated lower sensitivity of 65.9%, but 
improved specificity of 73.0%. On combining the two techniques, the 
specificity improved to 81.8% (Wright et al., 2004). MTB autofluorescence 
assays are relatively sensitive (<106 bacilli/ml of sputum can be detected). 
Moreover, the use of microplates allows for examination of only 200 
microlitres of sputum per sample without a loss of sensitivity (Patino et al., 
2008). 
LED bulbs emit a very narrow spectrum of light and have a longer life span 
and lower energy requirements than the conventional mercury light bulbs 
used in microscopes. LED bulbs are also able to excite auramine and other 
commonly used fluorescent stains without the need of UV lighting (Marais et 
al., 2008; Annam et al., 2009b). 
Growth-based detection techniques: 
Bacterial culture remains the gold standard for TB detection in a variety of 
specimens from patients suspected of TB disease. The current WHO 
endorsed growth-based tests for TB have been standardized mainly for 
sputum specimens (Dorman, 2010) and these techniques are usually feasible 
only in reference laboratory or high-resource settings, not for resource-limited 
TB-endemic regions. They are expensive, require specialised training and 
appropriate laboratory infrastructure (biosafety level 3). Amongst others, they 
include culture in liquid media using MGIT (Becton Dickinson) and BacT/TB 
ALERT (BioMérieux). Liquid culturing is found to be more sensitive and faster 
in TB growth detection than solid media, but is prone to contamination. 
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Sputum TB culture positivity can be detected within 10 to 14 days of 
inoculation, but culture-negative reports require up to 6 weeks for 
confirmation. 
Both solid and liquid media are used to assess drug susceptibility (and 
resistance) of cultured mycobacteria through drug minimum-inhibitory-
concentration (MIC) determination. Colorimetric methods, such as the nitrate 
reductase assay (NRA) and colorimetric redox indicator (CRI) methods 
performed on cultures on solid media, reduce the time to detection compared 
to conventional MIC-based drug sensitivity testing (DST). These are being 
encouraged for use in resource-limited settings, as they are cost-effective and 
highly sensitive and specific for most of the first-line anti-TB drugs (Coban et 
al., 2014; Arentz et al., 2013). 
TB disease in children is seldom confirmed through bacterial culture, as 
standard sputum samples can rarely be obtained from children less than 10 
years of age. If sputum collection is successful, only 30%–40% of the cases 
are mycobacterial culture positive (Shingadia and Novelli, 2003; Planting et 
al., 2014). Culture also generally has low sensitivity in EPTB specimens 
(Khan et al., 2006; Trajman et al., 2008; Polesky et al., 2005). 
The microscopic observation drug susceptibility assay (MODS) is a novel 
method of mycobacterial growth and drug susceptibility assessment, with 
good sensitivity and a mean-time-to-positivity of 8.24 days (Wikman-
Jorgensen et al., 2014). It uses an inverted light microscope to rapidly detect 
‘spindle and cord formation’ in selective broth culture that is indicative of 
mycobacterial growth (Moore et al., 2006). The assay is performed directly on 
sputum samples, which are difficult to obtain from children who also present 
with paucibacillary disease, therefore requiring further investigation into its 
use in paediatric specimens (Logitharajah, 2008).  
Volatile organic compounds, phage amplification and biomarkers: 
There are tools, still in the early phase of development, that have 
demonstrated potential for use in the clinical setting. The Breathalyzer 
screening test is designed to detect volatile organic compounds (VOC) from 
the breath of patients with active pulmonary TB. VOCs may comprise of 
metabolic biomarkers, from the MTB organism such as cyclohexane and 
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benzene derivatives, and from the infected host as products of oxidative 
stress such as alkanes and alkane derivatives. A study using gas 
chromatography or mass spectroscopy (breathalyzer screening) assessed the 
feasibility of this technology in diagnosing TB. The technique was 84% 
sensitive and 64.7% specific in detecting active pulmonary TB. It has potential 
use in clinical practice but is highly specialised and very expensive (Phillips et 
al., 2010). Cricetomys rats are being trained to detect TB in sputum 
specimens purportedly through their ability to identify VOCs being emitted 
from these specimens (Mgode et al., 2012; Reither et al., 2015), and more 
recently are potentially able to detect different genotypes of MTB (Mgode et 
al., 2015). 
Phage amplification assays, that use bacteriophages (bacterial viruses) to 
detect the presence of viable MTB within 24 hours of specimen preparation, 
are promising for rapid TB detection in clinical respiratory specimens.  The 
technology is based on mycobacteriophages replicating within live host 
mycobacteria in-vitro. The unabsorbed phages are inactivated using a 
virucidal solution and Mycobacterium smegmatis is mixed with the specimen 
on agar plates whereby progeny phages infect, replicate in and lyse the M. 
smegmatis, forming clear zones or plaques. These plaques on agar plates 
represent the number of viable tubercle bacilli in the original specimens. If 
there are no plaques, it indicates that there were no viable mycobacteria. 
There are currently limited studies in support of this technology (Prakash et 
al., 2009). 
For biomarkers such as adenosine deaminase, interferon gamma and 
lysozyme (muramidase), further developments and studies are still required to 
determine their use and feasibility in TB detection (Dinnes et al., 2007). 
Diagnostic antibody and antigen detection techniques: 
With the inaccuracy, inaccessibility or expense of most of the technologies 
mentioned, serological tests hold the potential to pre-empt missed pulmonary 
and extrapulmonary TB diagnoses. Unfortunately, recent meta-analyses on 
studies from 1990 to 2010 have shown that all serology-based assays, 
including enzyme-linked immunosorbent based assays (ELISA) incorporating 
MTB specific antigens including lipoarabinomannan (LAM), have been highly 
inconsistent in sensitivity and specificity (Flores et al., 2011; Steingart et al., 
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2011). Presently, the 2011 WHO recommendation that serological tests not 
be used for the diagnosis of pulmonary and extrapulmonary TB still stands, 
due to the highly inconsistent sensitivity and specificity of these tests and the 
low quality of studies conducted (WHO, 2011a). 
Nucleic acid based technologies: 
Polymerase chain reaction (PCR) and other nucleic acid based methods for 
TB detection have the advantage of speed (compared to culture) and 
sensitivity (compared to microscopy) (Boehme et al., 2007), including in 
paucibacillary specimens or those with minute amounts of nucleic acid. 
Pyrosequencing is a method of deoxyribonucleic acid (DNA) sequencing 
based on the "sequencing by synthesis" principle. It differs from Sanger 
sequencing, in that it relies on the detection of pyrophosphate release on 
nucleotide incorporation, rather than chain termination with 
dideoxynucleotides. A 2013 meta-analysis determined that pyrosequencing is 
a highly sensitive and specific tool that significantly reduces the time taken to 
test for rifampicin (RIF) resistance in TB (Guo et al., 2013), and more recently 
specifically in EPTB specimens for most first- and second-line drugs, although 
sensitivity in RIF resistance determination in this case was limited (67%) 
(Georghiou et al., 2016). 
Whole genome sequencing (WGS), the complete DNA sequencing of an 
organism's genome at a point in time, is now seen as a new frontier for 
management of drug resistance in patients and even prediction of drug 
resistance mechanisms when developing new drug targets (Witney et al., 
2015; WHO, 2015b). Due to the financial and technical investments required 
for most sequencing technologies, they are usually restricted to reference 
level and research laboratories. 
High-resolution melting-curve analysis (HRMA) is gaining credence as a 
screening technology for drug-resistance mutations, without the need for 
specific probes, which has a low turnaround time and is potentially more cost 
effective than other nucleic-acid based technologies. A study on RIF 
resistance in MTB, using HRMA compared to a line-probe assay (LPA) that 
utilizes nucleic acid amplification technology and conventional MIC-based 
DST from culture, showed that HRMA has potential as a rapid screening 
method for drug resistance detection in TB (Malhotra et al., 2015). More 
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studies are needed before global health authorities can endorse HRMA-based 
tests for use in TB assessment. 
Systematic reviews over the last decade have shown that nucleic acid 
amplification tests (NAAT) have significant potential in TB diagnostics. They 
are highly sensitive in pulmonary TB diagnosis and highly specific in 
extrapulmonary forms of TB (Dinnes et al., 2007) and some have been 
recommended for use alongside the conventional tests for TB (Ling et al., 
2008). Swifter developments are therefore being encouraged for rapid and 
efficient NAAT based DSTs for TB (Wells et al., 2013). 
Some commercial NAATs for TB detection currently available include the 
Roche LightCycler® Mycobacterium detection kit (Roche Applied Science, IN, 
USA), the Loopamp TB Detection (FIND, Switzerland/ Eiken, Japan), the 
AnyplexTM TB series of assays (Seegene, Seoul, Korea), the Genedrive 
MTB/RIF ID (Epistem, United Kingdom), the ProbeTec Direct (DTB), the Pure 
LAMP (Eiken Chemical Company, Japan) and semi-automated ProbeTec ET 
system (Becton Dickinson, NJ, USA) and FluoroType MTB (Hain Lifescience, 
Germany), amongst others. These technologies have either been found to 
have significant flaws, have insufficient evidence to be recommended for use 
by expert review panels or are still under development (HIV i-Base/Treatment 
Action Group, 2015). 
Commercial NAAT systems for TB detection in respiratory specimens, that 
are currently FDA approved, include the real-time PCR based COBAS 
TaqMan® MTB (Roche Molecular Systems, CA, USA) and the AMPLIFIEDTM 
M. Tuberculosis Direct Test including the enhanced AMPLIFIED M. 
Tuberculosis Direct Test (Gen-Probe, CA, USA) and BDProbeTecTM (Becton 
Dickinson, NJ, USA) (Rie et al., 2010). These systems are in use in tertiary 
healthcare facilities or at reference laboratories, and do not fit the 
point-of-care (POC) diagnostic requirements of resource-limited TB-endemic 
settings. 
WHO-endorsed nucleic acid based tools to date include the molecular line 
probe assays (LPAs) for first-line or multi-drug resistance (MDR) TB detection 
(GenoType® MTBDRplus [Hain Lifescience, Nehren, Germany], INNO-LiPA 
Rif. TB [Innogenetics, Gent, Belgium]) and the real-time PCR based Xpert® 
MTB/RIF ([GeneXpert] Cepheid, Sunnyvale CA) for TB detection and 
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assessment for rifampicin resistance (WHO, 2010, 2013a). Line probe assays 
use a PCR/hybridization technique to identify members of the MTBC, while 
simultaneously identifying drug-resistant strains by detecting the most 
common single nucleotide polymorphorisms (SNPs) associated with 
resistance. They have lower sensitivity when testing direct sputum, implicating 
the need to test culture isolates, increasing cost, specimen manipulation and 
the potential for cross contamination. The Xpert® MTB/RIF system is 
designed to test direct sputum specimens (refer to the section The Xpert® 
MTB/RIF test [Cepheid]), significantly shortening the time to detection. All the 
listed NAAT have been standardized for respiratory specimens.  
Following a 2013 systematic review of the performance of Xpert® MTB/RIF, 
the WHO updated its recommendation for the use of Xpert® MTB/RIF on 
extrapulmonary specimens (WHO, 2013b). The Xpert® MTB/RIF was 
recommended for use in preference over conventional microscopy and culture 
for CSF specimens and as a replacement test as-needed, for conventional 
tools for specific non-respiratory specimens in both adults and children (WHO, 
2013c). This update notwithstanding, the studies chosen for the systematic 
review were found to be very heterogeneous in sample processing and 
‘representative patient spectrum’ amongst other limitations, and further 
studies with defined guidelines were encouraged (Denkinger et al., 2014). 
 
TB TREATMENT AND DRUG RESISTANCE 
TB exposure, bacillary load of the positive case and anatomic foci of infection, 
are key considerations in disease management for both adults and children. 
Antibiotics against TB have been in development for less than a century. 
Streptomycin was first isolated in 1943 (Comroe, 1978) and isoniazid was 
synthesized in the early 20th century, but its activity against tuberculosis was 
first reported in the early 1950s (Rieder, 2009). 
Figure 2 illustrates the different categories of anti-TB medications that have 
been developed over the years and their mechanisms of action. For many 
years, preventive treatment with isoniazid (INH) a nitroimidazole, for a period 
of 9 months had been recommended to reduce the risk of progression of LTBI 
into active disease (Wilkinson, 2000). More recently a combination of INH and 
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rifapentine (an inhibitor of bacterial RNA synthesis) for a reduced duration of 3 
months, has been suggested for high-risk groups, including children exposed 
to TB in households and HIV positive patients (Sterling et al., 2011). 
 
 
Figure 2: TB drug categories and their modes of action. 
Source: https://www.niaid.nih.gov/sitecollectionimages/topics/tuberculosis/tb4.jpg 
 
Table 1 defines: the anti-TB drug categories, drug-resistance profiles, TB 
patient categories based on treatment history, WHO-recommended regimens 
for TB treatment by category, and definitions of the different treatment 
outcomes. Fixed-dose combinations (FDC) are defined dose combinations of 
anti-TB drugs developed into single tablets, to reduce the pill burden, aimed at 
enhancing patient drug compliance. 
During the Intensive phase of treatment, the drugs kill off TB bacilli in patients, 
with the patients usually becoming asymptomatic and non-infectious. The 
Continuation phase is usually longer, with the aim of eliminating any viable 
bacilli due to the fastidious nature of TB infection. Patients can therefore be 
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cured from TB infection, but there is significant anti-TB drug resistance being 
observed now in many settings worldwide. 
Table 1: Definitions, categories and regimens of TB treatment 
 
Source: Doctoral thesis of Serej Ley (Ley, 2014), sources of information: World 
Health Organisation. 
 
Under sub-optimal drug concentrations, micro-organisms can mutate (nucleic 
acid changes at the genetic level) to avoid drug action, known as drug 
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resistance (DR). There are several situations that can lead to patients having 
sub-optimal drug concentrations in the body mainly; poor compliance to 
treatment regimens by patients on anti-TB therapy, often through inadequate 
treatment guidance or supervision by healthcare personnel, or intermittent 
drug supply; interactions with other drugs the patients are taking that compete 
with the mechanism of action of the anti-TB drugs and; the metabolizer 
phenotype (the range of metabolizers [enzymes that change the constitution 
of a consumed drug] that a patient presents with based on their genetic 
make-up) of a patient (Marc et al., 2005; Garcia-Martin, 2008). 
In the case of MTB, drug resistance develops exclusively through 
chromosomal mutations, in particular, single-nucleotide polymorphisms 
(SNPs) sequentially accumulating (Ramaswamy and Musser, 1998), 
(O’Malley and Melief, 2015). Over the years, mutations associated with DR in 
MTB have been identified in several genes including katG, gyrA and the 
promoter region of mabA/inhA operon. The target of rifampicin for example, is 
the rpoB gene in MTB coding for the β-subunit of RNA polymerase. There is 
an 81bp region in this gene wherein point mutations associated with 95% of 
RIF resistance cases have been identified, and are now used as markers to 
identify RIF resistance in clinical specimens (Helb et al., 2010). 
The prevalence of drug resistance in a community guides treatment 
timeframes and regimens (Perez-Velez and Marais, 2012). Two definitions of 
MTB drug resistance are particularly relevant for patient management: 
multidrug-resistant (MDR) TB with strains resistant to both isoniazid (INH) and 
rifampicin (RIF); and extensively drug-resistant (XDR) TB, with additional 
acquisition of resistance to any member of the quinolones and at least one of 
the following second-line anti-TB injectable drugs: kanamycin, capreomycin or 
amikacin. Bedaquiline, a diarylquinoline anti-TB drug developed in 2012, is in 
phase III clinical trial stage investigating its safety and efficacy. WHO issued 
interim policy guidelines in 2013 for its use in treatment of MDR-TB, once all 
other drug are found resistant (WHO, 2013d). Delamanid, a nitroimidazole is 
in phase III clinical trial stage for treatment of MDR-TB as well (RESIST-TB, 
2015). Unfortunately, there is already a case presenting with drug resistance 
to both these drugs (Bloemberg et al., 2015). The study emphasizes the need 
for the use of appropriate companion drugs when bedaquiline and delamanid 
 INTRODUCTION 16 
are used. Carbapenems, which include ertapenem, imipenem and 
meropenem, are also used in MDR and XDR TB treatment regimens and 
relatively well tolerated (Sotgiu et al., 2016). There has been a recent WHO 
guideline update for a MDR TB treatment regimen that is shorter (9-12 
months), with the aim of cost effectiveness and improved patient compliance 
(WHO, 2016). 
 
DISEASE PROGRESSION AND MANIFESTATIONS OF TB IN CHILDREN 
Table 2 is an excerpt from a review by Perez-Velez and Marais (2012) 
summarizing disease manifestations, age-related risk for disease progression, 
immune characteristics, tuberculin skin test (TST) and interferon gamma 
release assay (IGRA) presentations, during the different phases of disease 
progression in untreated childhood TB. This is with a proviso that the same 
trends may not be seen in immune-compromised children. 
Age is the most important variable that determines risk of progression to 
disease in immune-competent children. Primary infection before 2 years of 
age frequently progresses to serious disease within the first 12 months, 
without significant prior symptoms. If these children present with any 
symptoms, they are fairly non-specific including fever, anorexia, and weight 
loss, with or without cough. Primary infection between 2 and 10 years of age 
rarely progresses to disease, and if there is progression, it is associated with 
significant clinical symptoms which represent a window of opportunity in which 
to establish a clinical diagnosis. Primary infection after 10 years of age 
frequently progresses to adult-type disease including cough, fever, night 
sweats, haemoptysis, and weight loss (Marais B. J., 2004). 
If there is a successful immune response to primary infection, asymptomatic 
healing can occur within four to six weeks of initial exposure to MTB. During 
this time erythema nodosum, a hypersensitivity response may occur on the 
skin. Tuberculosis can be cured after primary infection, or the disease may 
manifest, or become dormant (LTBI) from which reactivation (endogenous) 
may occur, resulting in post-primary tuberculosis. Endogenous reactivation 
occurs when dormant bacteria (confined in macrophages but not killed) 
establish infection when the child becomes severely malnourished or 
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immuno-compromised while exogenous re-infection occurs through fresh 
contact with TB, usually in areas of high TB prevalence. 
Table 2: Clinical syndromes associated with tuberculosis in children 
Clinical syndromes associated with tuberculosis in children* 
Disease phase & 
timing 
Clinical syndrome Group at 
greatest risk 
Immuno-
pathogenesis 
Results on 
TST and 
IGRA 
Manifestations on 
imaging 
Primary infection 
Incubation, 0-6 wk 
 
Asymptomatic 
 
All ages 
 
No adaptive 
immunity 
 
Negative 
 
None 
Immune conversion, 
1-3 mo 
Self-limiting 
symptoms (mild, 
viral-like); 
hypersensitivity 
reactions (fever, 
erythema nodosum, 
phlyctenular 
conjunctivitis) 
All ages Acquisition of 
adaptive 
immunity 
Generally 
positive; 
infection 
may be 
lifelong; no 
test for 
reinfection 
Transient hilar or 
mediastinal 
lymphadenopathy 
detected in 50-70% of 
cases; transient Ghon 
focus usually not 
detected 
Early disease 
progression† 
     
2-6 mo Uncomplicated lymph 
node disease 
<10 yr of age Inadequate 
innate 
immunity, 
adaptive 
immunity, or 
both 
Generally 
positive‡ 
Hilar or mediastinal 
lymphadenopathy 
without airway 
involvement; Ghon 
focus without cavitation 
 Progressive Ghon 
focus 
<1 yr of age 
severely 
compromised 
immune system 
Inadequate 
innate 
immunity, 
adaptive 
immunity, or 
both 
Generally 
positive‡ 
Ghon focus with visible 
cavitation 
 Disseminated 
(miliary) disease, 
tubercular meningitis, 
or both 
<3 yr of age or 
severely 
compromised 
immune system 
Inadequate 
innate 
immunity, 
adaptive 
immunity, or 
both 
Generally 
positive‡ 
Discrete lung nodules 
(1-2 mm in diameter) 
on chest film, 
hepatosplenomegaly, 
retinal lesions with 
hydrocephalus, basal 
meningeal 
enhancement, brain 
infarcts or tubeculomas 
on CT of the head 
4-12 mo Complicated lymph 
node disease (airway 
compression, 
expansile caseating 
pneumonia, 
infiltration of adjacent 
anatomical structures 
[bronchus, esophagus, 
pericardium, phrenic 
nerve]) 
>1 yr of age Exuberant 
lymph node 
responses, 
with 
inadequate 
innate 
immunity, 
adaptive 
immunity, or 
both 
Generally 
positive‡ 
Hyperinflation, 
atelectasis, or collapse 
of lung; expansile 
consolidation of 
segment or entire lobe; 
tracheoesophageal or 
bronchoesophageal 
fistula; pericardial 
effusion; 
hemidiaphragmatic 
palsy 
 Pleural disease 
(exudative effusion, 
empyema in rare 
instances, or 
chylothorax with 
ductus thoracicus 
infiltration) 
>3 yr of age Hypersensitivi
ty response to 
tuberculoprote
in 
Generally 
positive‡ 
Effusion, sometime 
large, usually in one 
lung; pleural thickening 
and loculations detected 
on ultrasonography 
 Peripheral 
lymphadenitis (most 
frequent extrathoracic 
disease manifestation, 
usually in the neck) 
1-10 yr of age Inadequate 
local control 
Generally 
positive‡ 
Ultrasonography 
usually not needed, but 
may reveal matting and 
adjacent soft-tissue 
edema 
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Late disease 
progression § 
     
8-24 mo Adult-type pulmonary 
disease (difficult to 
differentiate among 
primary infection, 
reactivation, and 
reinfection; 
reactivation may 
occur >20yr after 
initial infection) 
>10 yr of age, 
but can occur in 
children as 
young as 8 yr of 
age 
Overly 
aggressive 
innate 
immunity, 
adaptive 
immunity, or 
both 
Generally 
positive‡ 
Apical cavities in one 
or both lungs; minimal 
or no lymph-node 
enlargement (previously 
referred to as 
postprimary 
tuberculosis) 
1-3 yr Osteoarticular disease 
(e.g. spondylitis, 
arthritis, 
osteomyelitis) 
>1 yr of age Inadequate 
local control¶ 
Generally 
positive‡ 
Periarticular osteopenia, 
subchondral cystic 
erosions, narrowing of 
joint space 
>3 yr Urinary tract (kidney, 
ureter, bladder) 
disease 
>5 yr of age Inadequate 
local control¶ 
Generally 
positive‡ 
Renal calcifications, 
cavitation, 
hydronephrosis, 
calyceal dilatation, 
ureter stricture 
* Adapted from Wallgren (1948) and Lincoln and Sewell (1963) (Wallgren, 1948), (Lincoln and Sewell, 1963). Age ranges, risk 
groups, and timelines are intended to provide general guidelines only; children infected with the human immunodeficiency virus 
are particularly susceptible to tuberculosis and may present with atypical features. For the phases of disease, the times shown are 
the interval between initial exposure and the onset of the disease phase. IGRA denotes interferon -release assay. 
† At least 90% of disease manifestations occur within 12 months after infection. 
‡ Because test results may be negative in immunocompromised patients, a negative result cannot be used to rule out infection. 
§ Late disease progression is generally rare, but adult-type pulmonary disease is common in adolescents. 
¶ In cases of inadequate local control, manifestations are usually restricted to the local focus of disease, although disease can 
disseminated from any active focus. 
Source: Perez-Velez and Marias (2012) 
TB disease in children can manifest in the lungs as a Ghon focus, pneumonia, 
pleural effusion, or lobar collapse, especially of the middle lobe (Brock’s 
syndrome). Lobar collapse develops from substantial hilar lymphadenopathy 
(lymph enlargement) causing obstruction and compression of bronchi. Twenty 
to forty percent of children with TB disease present with extrapulmonary 
(outside the lungs) manifestations, while 10–30% present with both pulmonary 
and extrapulmonary manifestations concurrently (Cruz and Starke, 2007). The 
percentage presenting with EPTB goes up further to 50% in young and/or HIV 
co-infected children (Newton et al., 2008). Extrapulmonary and miliary 
tuberculosis occur mostly following primary infection rather than after 
reactivation. Miliary TB is defined by its millet-seed like appearance and can 
affect a variety of organs, including the lungs. Risk of progression to miliary 
TB or tuberculous meningitis depends on age and immune status (Marais et 
al., 2006a), with infants and children co-infected with HIV being at highest 
risk. 
The most common extrapulmonary manifestations of TB in children include; 
tuberculous lymphadenitis - mostly superficial (67%), tuberculous meningitis 
(13%, occurring most often in infants and toddlers), pleural TB (6%), miliary 
TB (5%), and skeletal TB (4%) (Cruz and Starke, 2010). Tuberculous 
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lymphadenitis (lymph node infection) may be mediastinal, intra-abdominal or 
peripheral. Peripheral lymphadenitis is typically superficial and often presents 
as a non-specific swelling which may be mistaken for malignant in nature. The 
lymph nodes usually measure 2 to 4 cm and lack the classical inflammatory 
characteristics of pyogenic nodes (Anunobi et al., 2008). Cervical is the most 
common presentation of superficial tuberculous lymphadenitis in children. 
Other sites include anterior cervical, posterior triangle, submandibular, and 
supraclavicular nodes. Untreated lymph nodes may caseate (necrosis in 
which tissue is changed into a dry mass resembling cheese), spread to 
nearby organs and tissues, and lead to formation of sinus tracts. 
Generally, diagnosis of TB in children is complicated by non-specific clinical 
presentations. Fever and cough may be observed in infants, but in children 
between 5 and 10 years of age, symptoms are rarely observed indicative of 
TB disease as in adolescents and adults. In lymphatic disease, systemic 
symptoms occur only in 50% of children, abnormal chest radiographs are 
seen in approximately 33% of children and most are positive on TST testing, 
which is not confirmatory for active TB infection (Cruz and Starke, 2010). 
Interpreting radiological features of TB lymphadenitis with certainty is also 
difficult. 
 
SPECIMEN COLLECTION METHODS IN CHILDHOOD TUBERCULOSIS 
Collection of bacteriologic specimens is a major challenge in cases of 
suspected paediatric TB. 
Pulmonary specimens 
Sputum collection for TB diagnosis is usually not feasible in young children 
as they tend to have paucibacillary disease and are also unable to 
expectorate. Adolescent children between the ages of ten and fourteen years 
frequently develop sputum smear-positive adult-type disease and obtaining 
good quality sputum specimens from this group is more likely (Marais et al., 
2005). Sputum induction is a specialised technique that requires 
nebulisation and suction instruments. In some studies this method has been 
shown to have significantly more bacterial yield than gastric aspirates from 
children of all ages (Zar et al., 2005; Hatherill et al., 2009). Sputum induction 
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can be done as an outpatient procedure but its use outside of hospital settings 
is limited since infection control measures need to be in place. 
More recently the Lung Flute, a plastic device made by Medical Acoustics 
(USA) and a non-invasive method for sputum collection, is gaining popularity 
for rapid diagnosis of pulmonary TB. Collection of own sputum is facilitated by 
creation of vibrations in the lungs when the individual exhales into the flute, 
which helps to loosen and liquefy sputum in the alveolar cavities (Fujita et al., 
2009). Further studies are needed on sputum yield by this method, both in 
adults and in children, for TB diagnosis. 
Sputum is commonly swallowed, particularly when a person is as rest. 
Gastric aspiration is therefore a plausible alternative for sputum collection. It 
is an invasive procedure, not easily performed on an outpatient basis. It 
requires prolonged fasting and sample collection over three consecutive days, 
which makes it less feasible for low-income settings due to the hospitalization 
requirement. An alternative that is less invasive and may be performed on an 
outpatient basis is nasopharyngeal aspiration. This method does not require 
fasting and has a comparable bacterial yield to gastric aspiration.  
The string test involves a nylon string being swallowed by the child, so that it 
remains in situ for 4 hours absorbing swallowed sputum, with the trailing string 
being retained outside the mouth. It is less invasive than gastric aspiration 
and is tolerated well in children of 4 years and older (Chow et al., 2006). The 
string test was shown to have superior sensitivity compared to induced 
sputum in one study (Vargas et al., 2005). Another means of obtaining 
bacteriologic respiratory specimens is broncho-alveolar lavage (BAL), an 
intricate procedure recommended for intubated patients and those who 
require diagnostic bronchoscopy. 
Extrapulmonary specimens 
Urine and stool samples are generally obtained non-invasively, but due to 
their nature, confer limited bacterial load based on the focus of disease. 
Collection of blood specimens in children is not only challenging, especially in 
infants and emaciated patients, but is also only useful in disseminated TB 
disease or when using antigen/antibody detection assays, which are currently 
not recommended for use (WHO, 2011a). Bone marrow aspiration is an 
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invasive procedure that requires well trained personnel, elaborate equipment 
and stringently sterile conditions (Marais, 2006). Lumbar puncture for 
cerebrospinal fluid has similarly stringent requirements, is an invasive 
procedure that requires hospitalisation and usually has a low mycobacterial 
yield. 
Fine needle aspiration biopsy (FNAB) is a robust and simple technique 
using a fine needle to aspirate bodily fluids, including from lymph nodes, that 
can be performed in any outpatient setting, with minimal side-effects, 
providing creditable bacteriologic diagnostic value (Marais et al., 2006b). It is 
an important tool and often the only way to diagnose extrapulmonary TB in 
children (Cotton et al., 2004). The value of FNAB in diagnosis of 
mycobacterial lymphadenitis in adults is well documented (Samaila and 
Oluwole, 2011; Nayak et al., 2003; Kocjan and Miller, 2001). Although there 
are few studies on FNAB in children (van Wyk et al., 2011; Balaji et al., 2009; 
Wright et al., 2008; Bruijnesteijn van Coppenraet et al., 2004), one study 
comparing FNAB against gastric aspirates and induced sputum in children 
with pulmonary TB and peripheral lymphadenopathy, showed that FNAB had 
superior diagnostic yield and significantly reduced time-to-diagnosis (Wright et 
al., 2009a). Compared to core needle biopsy that uses a larger needle to 
obtain tissue samples, the risk of sinus or fistula formation, permanent 
damage to nerves or seeding of tumours (if present) along the needle track for 
FNAB is minimal (DeMay, 1996). As an inexpensive outpatient procedure, 
FNAB is easy to perform in resource-limited settings and may pre-empt the 
infection risks that accompany alternative specimen collection procedures. 
 
PROMISING NAATS FOR EPTB DIAGNOSIS IN CHILDREN 
The complexity and insufficient robustness of many existing commercial 
NAAT protocols, their requirement for precision instrumentation, quality 
assurance, high levels of investment and technical support make them 
unsuitable for most resource-limited TB-endemic settings. Additionally, the 
technical skills required have resulted in variable performance, even in 
experienced molecular laboratories whether in low- or high-resource settings. 
Furthermore, none of these techniques have been fully validated for 
diagnosing TB in children and specifically not for extrapulmonary specimens. 
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In light of these challenges, there is promise in two technologies that have 
been developed and under evaluation over the last several years; the Xpert® 
MTB/RIF kit (Cepheid) endorsed for use by the WHO as the initial diagnostic 
test in individuals suspected of MDR-TB or HIV/TB (WHO, 2010); and the 
Ustar EasyNATTM TB IAD kit (Ustar Biotechnologies, Hangzhou) selected by 
the WHO as a category 1: commercialized/-isable stage innovative technology 
on assessment for use in TB endemic countries (WHO, 2011b). 
 
The Xpert MTB/RIF test (Cepheid) 
This is a commercially available semi-quantitative assay designed to detect 
M. tuberculosis complex DNA directly from human clinical sputum specimens. 
It integrates and automates sample processing and simultaneous detection of 
MTB complex and rifampicin (RIF) resistance. This is done through real-time 
PCR using five overlapping probes that are complementary to the 81 base 
pair rifampicin-resistance determining region (RRDR) of the M. tuberculosis 
rpoB gene (Figure 3). There is an internal PCR amplification control probe for 
SPC (Bacillus globigii) that determines if PCR has taken place. The system 
indicates an “invalid” result should this probe not bind, indicating PCR 
inhibition. 
 
Figure 3: Illustration of the 5 probes used in the Xpert MTB/RIF assay. 
Source: Xpert® MTB/RIF (Cepheid) brochure (0089-02): the 5 probes targeting the 
rpoB gene of M. tuberculosis (Cepheid, 2009). 
 
The five test-specific probes are designed to bind to the wild-type (non 
mutated) MTB rpoB sequence. Should any one of the probes do not bind; it is 
an indication of a mutation along that probe binding site and therefore RIF 
resistance. The PCR amplification process is hemi-nested, and the amplified 
target is detected in real time by six colour fluorescent molecular beacons, 
one for each probe (Figure 4). Continuous optical monitoring allows the 
software to automatically stop the reaction as soon as the target is detected, 
further accelerating time to results. MTB detection is reported as ‘very low’, 
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‘low’, ‘medium’ or ‘high’ in concentration and RIF resistance reported as 
‘detected’ or ‘not detected’. 
 
Figure 4: Xpert MTB/RIF six colour fluorescent molecular beacon 
detection for MTB and RIF resistance. 
Source: Cepheid Xpert MTB/RIF Training presentation, Soundiram 2012, p.10: 
http://www.moleculartb.org/gb/pdf/ppt/14_SYMP_ISoundiram_Xperttraining_2902.pdf
Reported as MTB DETECTED if at least two of the five rpoB probes are bound within 
two cycles of each other. A delay of beacon detection (more than 2 cycles) indicates 
a weak mutation, while the absence of beacon detection (no probe binding/no signal 
from probe) indicates a strong mutation.  
As the system fully integrates and automates sample extraction, amplification 
and detection in one cartridge, it eliminates the need for amplicon 
manipulation and thus the risk of cross-contamination of samples (Banada et 
al., 2010). Low-skilled technicians can perform the assay, with a hands-on of 
2 minutes; shorter than that for smear microscopy or culture. The test 
turnaround time is less than 2 hours, similar to smear microscopy and many 
times faster than culture-based techniques and it requires minimal training. 
The assay sensitivity is many times higher than that of smear microscopy 
(10,000 cfu/ml) and close to that of liquid culture (10–100 cfu/ml). The test is 
also highly specific to MTBC detection and there is no cross reaction with 
non-tuberculous mycobacteria. The assay detects mutations in the RRDR 
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which occur in 95 to 98% of all known rifampicin-resistant MTB strains (Helb 
et al., 2010). Through concerted efforts by the Foundation for Innovative New 
Diagnostics (FIND) over the recent years, GeneXpert technology is now 
available for sputum TB detection and rifampicin resistance testing in the 
public sector of 116 of the 145 TB high burden countries eligible for 
concessional pricing (WHO, 2015a). 
A systematic review was done of the performance of the Xpert assay, for 
pulmonary tuberculosis and rifampicin resistance detection on pulmonary 
specimens in adults, from 2009 until February 2013. The assay was found to 
have a pooled sensitivity of 98% in smear-positive, culture-positive specimens 
and as an initial test replacing smear microscopy it had a pooled sensitivity 
and specificity of 89% and 99%, respectively (The Cochrane Collaboration 
and Steingart et al., 2014). 
The number of studies on the performance of Xpert in detecting TB in 
extrapulmonary specimens, with sufficient sample size, is limited. The pooled 
sensitivity and specificity from a systematic review done in 2013 of eleven 
identified studies was 84.9% and 92.5%, respectively (WHO, 2013b). Some of 
these studies had a small sampling of specimens that were aspirates from 
lymph nodes and were not specific on the number of children included in the 
study, if at all. Of the analyses done on lymph nodes, excluding case-control 
studies, the pooled sensitivity and specificity were found to be 89% and 90%, 
respectively. One study on lymph node aspirates specifically, with less than 
15% of the samples being from children, showed a high sensitivity and 
specificity for detection of TB (96.7% and 88.9% respectively) (Ligthelm et al., 
2011). The heterogeneity in performance characteristics across the different 
extrapulmonary sample types was found to be substantial and the data 
available on lymph node aspirate analysis by Xpert in children were very 
limited (WHO, 2013b). There is therefore value in further studying the 
performance of Xpert MTB/RIF in extrapulmonary specimens, specifically 
lymph node aspirates, in children. 
Some of the limitations of the Xpert MTB/RIF assay are that it needs to be 
more robust in regard to its requirement for continuous electrical power and 
should be more cost effective, so as to be considered the ultimate solution for 
TB diagnosis in TB endemic, resource-limited settings. 
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The Ustar EasyNATTM TB IAD (Biotech) 
The Ustar EasyNATTM TB Isothermal Amplification Diagnostic test (Biotech) is 
a commercially available kit for the qualitative detection of MTB in human 
samples. The technique involves manual sample processing and post PCR 
procedures. The assay is a nucleic acid amplification and hybridization 
technique that uses cross primers (double crossing) through a cross-priming 
amplification (CPA) technology from an isothermal DNA amplification system 
by Ustar Biotechnologies Co., Ltd., Hangzhou, China. 
Using multiple cross-linked primers (six to eight primers) targeting the gyrB 
gene of M. tuberculosis, a DNA target sequence is amplified at a constant 
temperature of 63 or 65°C (Figure 5). The denaturing and annealing of DNA 
molecules occurs dynamically. Using multiple displacement and cross 
primers, PCR products are generated as interval tandem repeats of the target 
region based on the H37Rv sequence (BX842572.1, NT 5582-5789) of TB. 
 
Figure 5: Illustration of the Ustar EasyNATTM TB isothermal 
cross-priming DNA amplification technology. 
Source: Fang et al. 2009. 
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Generation of cross-priming sites first occurs in the presence of Bst DNA 
polymerase through extension and displacement activity. Multiple primer 
binding sites are created which allow for multiple extensions and 
displacements, which occur at the cross-priming amplification stage. Mixed 
intermediate and end structures are then present to which the forward and 
reverse detector sequences bind to create single, double-stranded or partial 
double-stranded sequences (Fang et al., 2009). 
Detection occurs when the strands created through detector sequences, bind 
to sites on detection strips provided (Figure 6). The lateral flow detection 
strips are housed individually in sealed plastic devices to prevent leakage of 
amplicons. Results are visualized as bands on the test strips; appearance of 
both control and test bands indicate presence of MTB, while appearance of 
only the control band indicates the test is valid, but that there is no MTB or the 
amount of MTB DNA is below the detection limit. 
In a study conducted on 180 clinical sputum specimens, the sensitivity of 
EasyNAT in smear and liquid culture-positive specimens was 96.9%, and that 
from smear-negative but liquid culture-positive specimens was 87.5%. The 
specificity of the assay in culture-negative specimens from patients with other 
pulmonary diseases was 98.8% (Fang et al., 2009).  
 
 
Figure 6: Principle of strip detection in the Easy NATTM system. 
Source: Ustar Biotechnologies (Hangzhou) Ltd (2013): 
http://www.bioustar.com/Upload/files/videos/Ustar%20TB%20Flyer1.pdf 
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More recently, Ustar Biotechnologies (China) have developed three 
isothermal based NAATs for the detection of TB, as well as rifampicin and 
isoniazid resistance-conferring mutations (WHO, 2013a). A multicentre study 
conducted in China evaluated this TB detection kit, which is based on single 
crossing CPA technology targeting the IS6110 region of the MTB genome, 
and is multiplexed with an internal amplification control reaction (Ou et al., 
2014). The results were promising but not as sensitive and specific as the 
double CPA gyrB gene targeting EasyNATTM IAD kit (Fang et al., 2009). 
The double CPA gyrB gene targeting EasyNATTM IAD kit (2009) kit was 
considered a tool to assess for detection of TB in lymph node aspirates in my 
study. The assay does not require a precision instrument. It does require 
some training, a centrifuge and a water bath or a heating block, making it a 
more viable tool to use in TB-endemic low-resource settings and the time to 
results is just over 2 hours. 
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STUDY RATIONALE 
 
Direct smear microscopy of sputum samples, a diagnostic tool with poor 
sensitivity (missing over half the cases) and lack of differentiation between 
drug-sensitive and drug-resistant TB, remains the primary method of TB 
diagnosis in most low to middle-income TB-endemic countries. Culture of 
MTB is the gold standard diagnostic method, but has a slow turnaround time 
and requires laboratory resources that are not available in the majority of 
resource-limited TB-endemic settings. The paucibacillary nature TB infection 
in most children makes it difficult to diagnose through sputum smear 
microscopy and culture, and good quality samples can rarely be obtained 
from young children (WHO, 2013a). 
Childhood tuberculosis continues to be one of the most important public 
health issues facing health systems in TB-endemic countries. One of the 
major priorities identified in a review of new and improved tuberculosis 
diagnostics, is the development of a rapid test for childhood TB that will not 
depend on sputum specimen testing, but preferably other point-of-care rapid 
detection techniques (Pai et al., 2010). The refinement of existing tools and 
development and testing of new tools for the diagnosis of childhood TB and 
EPTB continues to be the recommendation to-date (Kik et al., 2014).  
At the time at which this study was being initiated (2012), some of the 
developments highlighted in this review (2010 to date) had not been realised. 
Despite these developments and the success of the Xpert MTB/RIF assay, a 
very recent systematic review of the Xpert MTB/RIF assay for diagnosis of 
extrapulmonary tuberculosis, still indicated the need for further studies 
availing primary and secondary-level health facility data, specific to 
TB-endemic regions, and more specifically, an improved representative 
patient spectrum, in this case children (Denkinger et al., 2014). The high 
sensitivity and specificity of the Xpert and EasyNAT kits for detecting TB in 
sputum specimens, as well as their ease of use by non-specialist personnel, 
were reasons for their assessment in the detection of TB in lymph node 
aspirates from children suspected of TB in Dar-es-Salaam. 
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STUDY OBJECTIVE 
 
To evaluate the use of two nucleic acid amplification tests: the Xpert® 
MTB/RIF (Cepheid) automated PCR and the Ustar EasyNATTM TB IAD Kit 
(Biotech) for the diagnosis of TB lymphadenitis in cytological aspirates from 
children seen at a district hospital in Tanzania and comparing these new 
techniques with established FNAB methodologies: Ziehl-Neelsen (ZN) 
staining, cytological determination and liquid culture. 
 
STUDY SIGNIFICANCE 
The study was a feasibility assessment of the two diagnostic kits; Xpert® 
MTB/RIF and Ustar EasyNATTM TB IAD for diagnosis of childhood TB 
lymphadenitis at district public health level in Tanzania. Ease-of-use, utility in 
relation to sample type and collection methods, and robustness were 
therefore investigated. 
The NAATs were expected be at least as sensitive, if not more sensitive than 
the gold standard and/or the other standard methods in use for diagnosing TB 
lymphadenitis. This was with a vision to enhance the diagnostic algorithm, 
and in so doing; improve the management of TB disease in children. Other 
pertinent data were also accrued, such as gender- and age-specific trends of 
TB and HIV infection. The study also contributes to childhood TB diagnostic 
literature, aiding in policy development.  
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STUDY APPROACH 
 
RECRUITMENT SITES 
1. Temeke District Hospital, Dar es Salaam (TDH) 
2. Ifakara Health Institute, Bagamoyo Research and Training Centre 
(IHI-BRTC) 
 
RECRUITMENT PROCESS 
The project was established at the TB clinic of the district hospital and 
convenience sampling was done; children attending the hospital facilities, 
having symptoms per the inclusion criteria, were referred to the study. All 
children suspected of having TB lymphadenitis, following criteria defined in 
the “Guidance for national tuberculosis programmes on the management of 
tuberculosis in children” (WHO, 2006) for diagnosing TB in children, were 
recruited following informed consent. 
Inclusion Criteria 
 Signed written consent or witnessed oral consent in the case of illiteracy of 
the parent/guardian, before undertaking any study related activity 
 Assent provided by the child if more than 7 years of age 
 Child of more than 8 weeks, but less than 16 years of age 
 Child with lymphadenopathy (defined as palpable lymph nodes ≥ 1 cm) 
persisting for more than 4 weeks despite a course of oral antibiotics 
 Child with strong clinical suspicion or microbiological confirmation of 
mycobacterial infection in combination with lymphadenopathy (defined as 
palpable lymph nodes ≥ 1 cm) 
Exclusion Criteria 
TB treatment in the past year (anti TB drugs taken within the last 12 months). 
 
ETHICAL CONSIDERATIONS 
The parent or legal guardian of the participant was appropriately informed 
about the study processes, including possible benefits, risks and 
inconveniences. Consent was obtained from them and the child (if more than 
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7 years of age) to proceed with assessment of the child in determining 
potential TB lymphadenitis and consequent fine needle aspiration (FNA) of 
palpable nodes. 
Do no harm 
 The procedures performed in the study, including FNA, were performed 
professionally and with all infection control measures in place (Appendix 
13) 
 The information solicited in this study was secure and confidential and was 
coded for purposes of the research. Barcode labels (without patient 
details) were used on all data sheets and specimen containers (Appendix 
15). Only authorized medical personnel at the study site had access to 
participant names for purposes of treatment and follow-up. 
The direct benefit to study participants was; enhanced free diagnostic 
assessment for TB disease, compared to the routine national programmatic 
level assessment.  
The kits tested in this study were either endorsed for use (Xpert MTB/RIF), 
or endorsed for assessment (Ustar EasyNATTM TB IAD) by the WHO for TB 
endemic countries. The study was an evaluation of laboratory diagnostic 
tools. TB treatment decisions were not made primarily based on the results 
from the Xpert MTB/RIF (Cepheid) or Ustar EasyNATTM TB IAD (Biotech) 
assays under evaluation, but on the basis of routine clinical and laboratory 
methods, including clinical work-up following the National TB and Leprosy 
Programme (NTLP) guidelines, TST, FNA AFB smear, cytomorphology and 
TB culture results.  
Any sputum test results available (based on sample production) were 
considered, as required for routine diagnostic evaluation according to NTLP 
from patients suspected of having TB. Specimens were stored in the TB 
CHILD specimen bank, in a confidential manner using a number or coding 
system. A Material Transfer Agreement (MTA) was issued by the Medical 
Research Coordinating Committee of the National Institute for Medical 
Research (NIMR) of Tanzania, for the TB CHILD project, to enable shipment 
of isolates that may need to be sequenced at the Swiss Tropical and Public 
Health Institute (Swiss TPH), for quality control. Participants were 
compensated for travel and time according to the site’s research protocol. 
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Dissemination of study outcomes was done through scientific presentation to 
the Regional TB and Leprosy Coordinator (RTLC) and NTLP staff involved in 
the project, and involvement of key collaborators as authors in scientific 
publication. The information obtained from this study was based on good 
clinical Practice (GCP) and good clinical laboratory practice (GCLP) and 
therefore reliable when appropriately analysed.  
 
STUDY ADMINISTRATION 
This study was conducted as a scientific cooperation between the Ifakara 
Health Institute (IHI) Tanzania, Bagamoyo Research and Training Centre 
(BRTC) Tanzania, the Aga Khan Hospital, Dar-es-Salaam (AKHD) Tanzania, 
and the Swiss Tropical and Public Health Institute (Swiss TPH) Basel, 
Switzerland. 
 
DATA STORAGE 
Participant codes, related clinical and medical history, TST and chest x-ray 
(CXR) results, follow-up clinical and medical information and all laboratory 
results have been stored confidentially at BRTC and Swiss TPH. 
 
SAMPLE SIZE 
In the proposal for this study, in determining the target sample size for the 
study, a sample size estimation formula was adopted from Carley et al 2005 
(Carley et al., 2005) for a confidence interval of 0.05 (Table 3). There was no 
prevalence information for extrapulmonary TB in children for Tanzania, 
therefore as per standard statistical protocol; an estimated prevalence of 50% 
was used. The sensitivity targets were determined from earlier studies on 
each kit (Boehme et al., 2010; Naidoo, 2010; Fang et al., 2009). There is still 
no clear information on the prevalence of TB in children in Tanzania (van 
Leth, 2013). 
There were delays in initiation of the study and staffing issues at the 
paediatric and adult outpatient clinics of TDH that caused lapses in 
recruitment of participants for the study.  Thereafter, screening of all children 
for superficial lymph nodes by a study-recruited nurse lead to recruitment of 
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all children aged 8 weeks to 16 years, suspected of having TB lymphadenitis. 
The target sample size could not be achieved due to the aforementioned 
challenges, but extension of the recruitment period to 12 months (April 2012 
until March 2013) enabled recruitment of 79 participants in total. Follow-up of 
each participant was done 5 to 12 months after recruitment (median: 5 
months); the last group of participants recruited were reviewed in mid-August 
2013. 
Table 3: Sample size estimation 
Sensitivity target 
Confidence 
interval (CI) 
Required 
minimum 
group size 
Estimated 
prevalence among 
TB suspects 
Required TB 
cases 
Xpert MTB/RIF     
90% 0.05 140 0.5 280 
Ustar TM TB IAD kit     
90% 0.05 140 0.5 280 
 
 
STUDY WORKFLOW 
A. Information talks with legal guardian 
B. Obtaining Informed Consent: Informed Consent Form (ICF) (Appendix 1) 
additionally assent from child seven years to 16 years of age: Assent for 
Minors Form (Appendix 2) 
C. Obtaining contact information on the participant: Contact Information Form 
(Appendix 3) 
D. Medical history on enrolment: Medical History Enrolment Form (CRF) 
(Appendix 4) 
E. Clinical examination: Clinical Examination Form (CRF) (Appendix 5) 
F. Participant sent for chest X-ray (CXR): X-ray CRF (Appendix 6) 
G. Sputum collection for routine smear microscopy (done by NTLP at TDH 
laboratory or other facility). Result of smear microscopy recorded on 
Medical History Enrolment Form (CRF) (Appendix 4) when received 
H. Clinical assessment done using NTLP TB Score Chart for children under 6 
years of age (Appendix 7) or following criteria defined in the “Guidance for 
national tuberculosis programmes on the management of tuberculosis in 
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children” (WHO, 2006) for children 6 years and older. When a participant 
scored 7 in the score chart (<6 years of age) or was recommended for 
treatment after clinical assessment (6 years of age) they were referred to 
the NTLP TB treatment programme, where they were started on the 
appropriate anti-TB therapy. 
I. Procedures for specimen collection were followed in the order illustrated in 
Figure 7 and Table 4 and as described in the “Procedures” section below. 
 
 
 
 
 
 
 
 
 
 
 
J. Participant management: NTLP officers at the TDH TB clinic were 
informed of all study outputs, including clinical assessments and laboratory 
results, as soon as they were reported. All participants recommended for 
TB treatment based on clinical assessment (including chest X-ray results) 
Medical history enrolment, clinical examination, 
assessment/scoring, sputum for ZN stain (if possible) & CXR 
Pre-screening of TB 
suspects 
Informed consent 
 
FNA of palpable lymph nodes (2 passes), blood draw & TST 
2 thin smears made from first pass of 
FNA for ZN & PAP staining at AKH. 
Blood sent to BRTC for FBP. 
Needle & syringe from 1st pass washed 
out into MGIT culture bottle sent to BRTC 
2nd pass washed into 0.7 ml PBS for 
Xpert & EasyNAT testing at BRTC 
Review of clinical assessment/scoring, CXR & 
diagnostic test outcomes: decision to treat for TB/“not 
TB” & manage or refer for specialist care 
Participant follow-up 5 months after recruitment: record 
of progress & conclusion/further treatment 
options/referral for specialist treatment 
Figure 7: Flow chart of work-up and follow-up of participants 
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and/or laboratory test outcomes were either managed at the TDH TB clinic 
or were issued detailed referral letters for management at NTLP clinics of 
their convenience. Newly diagnosed HIV-co-infected participants were 
also referred to the TDH HIV clinic for registration and appropriate 
management. All participants deduced as not having TB, after clinical 
assessment and receipt of laboratory results, were referred to relevant 
clinics (surgical, medical or HIV) for further management. Diagnosis and 
medication information was recorded on the Diagnosis and Medication 
form (CRF) (Appendix 10) during the first and follow-up visits, as needed. 
K. All participants, both suspected and not suspected of having TB, were 
followed up five to twelve months after recruitment to record clinical 
outcomes and treatment success. Medical history was taken on the 
follow-up visit and the Medical History Follow Up Form (CRF) (Appendix 
11) was filled out accordingly. 
 
Table 4: Participant work-up and follow-up checklist 
Activity Day 1 Day 2 Day 4 Month 5 
Screening / eligibility criteria X    
Informed consent (& assent) X    
Record of contact information X    
Medical History X   X 
Clinical Examination X    
CXR X    
TST application  X   
Sputum collection - morning (if possible)  X   
Blood collection (full blood profile, HIV test)  X   
Sputum collection – spot (if possible)  X   
FNAB collected for:  X   
ZN  X   
Cytology  X   
Culture  X   
Xpert   X   
EasyNAT   X   
TST reading   X  
Review of available findings & treatment recommendation   X X 
Diagnosis and medication assessment   X X 
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PROCEDURES 
A trained clinical officer performed the following procedures per participant: 
1. Fine needle aspiration biopsy (FNAB) and recorded the data on a FNA 
CRF form (Appendix 8) 
2. Venous blood collection for full blood profile analysis (FBP or 
haemogram), HIV rapid testing, or HIV polymerase chain reaction (PCR) 
testing (for children 18 months of age) and recorded the data on a 
Universal sample transfer form (Appendix 9) 
3. Tuberculin Skin Test (TST) intradermal injection and recorded on a TST 
log (Appendix 12). Examination of the TST site after 48 to 72 hours 
entering results into the Clinical Examination Form (Appendix 5). 
 
Fine needle aspiration biopsy (FNAB) procedure (Wright et al., 2009b) 
As per guidelines in SOP: Temeke_EPTB CHILD_FNA_01 (Appendix 13) 
Materials: 
 non-sterile gloves 
 alcohol swabs 
 22 or 23 G cutting needles 
 10 ml disposable plastic syringes 
 glass cytology slides (ground edges and frosted label end) 
 95% ethanol 
 100% methanol 
The procedure was explained to the parent or guardian and child of 7 years 
and older. The parent or guardian was asked to remain with the child and to 
assist with restraining the child during the procedure. 
Procedure: 
 When there were multiple nodes at one site, the largest superficial node 
was chosen for FNA. Multiple sites of enlarged lymph nodes per 
participant were also aspirated when present, and the slides labelled 
accordingly. 
 The skin on and around the lymph node was cleaned well with an alcohol 
swab and the mass immobilised using the forefinger and thumb. The 
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needle was positioned to access the entire mass and to avoid passing 
through muscles and major blood vessels. 
 The needle was inserted firmly and no more than 1 ml suction was applied 
constantly throughout the procedure. The needle tip was moved back and 
forth or up and down “cutting” within the boundaries of the target in a fan-
like fashion through the mass. 
 Suction was released and the needle withdrawn once material was seen in 
the hub of the needle. On some occasions, there was no visible material in 
the hub of the needle, which then was seen on flushing onto slides and 
was usually sufficient for MGIT inoculation.  
 Two needle passes were performed, each to aspirate as much fluid (if any) 
from the mass as possible. A fresh needle and syringe were used per 
pass. 
 The parent or guardian was then asked to apply pressure to the puncture 
wound using dry sterile gauze. 
Smear preparation: 
 From the first FNAB pass the needle was removed from the syringe, 10 ml 
of air pulled into the syringe and the needle reattached. The air was used 
to express the material in the needle onto glass slides, ensuring the 
needle and slides were not in contact. 
 A second glass slide was placed facedown on the first, the material 
allowed to spread gently and keeping both slides together, they were slid 
gently apart to create smears. 
 Whenever possible, 2 smears were prepared for cytological assessment 
by soaking immediately in 95% ethanol and 2 smears were air dried for 5 
minutes then soaked in 100% methanol for ZN staining. 
 The slides were packaged and transported to AKHD laboratory at room 
temperature as per the TEMEKE_EPTB_CHILD_FNAB_Transport_01 
protocol (Appendix 14). 
MGIT tube inoculation: 
 Using the same needle and syringe, an aliquot of liquid media (MGIT liquid 
culture enriched with MGIT PANTA antibiotic/growth supplement [Becton 
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Dickinson] less than 30 minutes prior to inoculation with specimen) was 
drawn into the syringe and expelled back into the MGIT tube, thereby 
using the culture medium to rinse out the syringe and needle in a sterile 
manner (Appendix 16: Procedure for Preparation and                
inoculation of MGIT Tubes). 
 Inoculated MGIT tubes were transported to BRTC within 24 hours 
according to the TEMEKE_EPTB CHILD_FNAB_Transport_01 protocol 
(Appendix 14) along with a Specimen Transfer form Mycobacteriology 
(Appendix 17) each with details of the FNA collection. 
Nucleic acid test sample preparation: 
 The needle and syringe from the second FNAB pass per participant was 
rinsed with 0.7ml phosphate buffered saline (PBS) pre-prepared and 
sterilized in 2ml screw-cap tube. These were then transported in a cooler 
box along with Specimen Transfer Form for Molecular Testing (Appendix 
18), ensuring the specimens were not packed in direct contact with the ice 
packs according to TEMEKE_EPTB CHILD_FNAB_Transport_01 protocol 
(Appendix 14). 
 
Blood collection 
Materials: 
 Safety Needles, 22g or less 
 Butterfly needles 21g or less 
 Syringes 
 Blood collection vacuum tubes designed to draw a predefined volume of 
blood  
o 2ml red-top clot activator tube 
o 4ml purple-top EDTA tube 
 Tourniquet 
 Individually packaged 70% isopropyl alcohol wipes. 
 2x2 Gauze or cotton balls.  
 Sharps disposal container 
 Bandages or tape 
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Procedure: 
A standard protocol for venipuncture was followed (BRTC_CLN_001_V02: 
Collection of blood samples and transport to BRTC and Kingani Laboratory) to 
collect blood from each participant: 
o 1ml of blood in a clot activator tube for rapid HIV testing at TDH TB Clinic 
o 2ml of blood in EDTA for FBP stored and transported to BRTC at 2-8C 
with a Universal Blood sample transfer form (Appendix 9) 
o Only for participants 18 months of age; 4ml of blood was collected in 
EDTA anticoagulant and transported at 2-8C immediately to Muhimbili 
University of Health and Allied Sciences (MUHAS) Laboratories, Dar es 
Salaam, with a Universal sample transfer form (Appendix 9) for HIV PCR 
analysis. 
 
Mantoux/Tuberculin Skin Testing 
Materials: 
 Cotton swab 
 Distilled water 
 1ml insulin syringe with needle 
 Tuberculin PPD RT/23 2 TU vial (Statens Serum Institut Reg. No. 
BOT0600874) at room temperature 
Procedure: 
As per the protocol: TST administration and reading (Appendix 12), one 
upper forearm of each participant was cleansed with cotton wool wet with 
distilled water, allowed to dry and two units (0.1 ml) of purified protein 
derivative containing a human-infective strain of MTB antigen (Tuberculin 
PPD RT/23) injected intradermally. The parent or guardian was then informed 
not to wash the area until the TST was read, between 48 and 72 hours after 
the injection. 
Reading: 
An induration (a raised part of skin and not the whole reddened area) of at 
least 1mm high and more than 5mm in diameter, identified between 48 and 72 
hours after injection, indicated a positive reaction. 
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A positive result indicated sensitivity to tuberculosis and could mean that the 
child either: 
 Had active tuberculosis - often strongly positive: >15 mm, but can be 
negative* 
 Had their BCG vaccine prior to TST - positive, but often <15mm 
 Had latent tuberculosis - had tuberculosis in the past 
For appropriate interpretation, TST results were reviewed along with the 
clinical assessment or scoring. 
It is known that TST results are often negative in HIV co-infected children, and 
weakly positive (5-10 mm) in children exposed to *environmental 
mycobacteria which is not clinically significant unless the participant is 
immune-deficient (Logitharajah, 2008). 
LABORATORY ANALYSIS SITES 
Following the Ministry of Health and Social Welfare, and the National Aids 
Control Programme guidelines of Tanzania, staff at the TDH TB clinic 
performed rapid HIV testing for every participant. Test kits used were Alere 
Determine HIV 1&2 Ag/Ab Combo as first-line and Uni-Gold™ Recombigen® 
HIV-1/2 as confirmatory. The results were recorded in the HIV test register at 
TDH TB clinic. HIV PCR testing for samples from children 18 months and 
younger was done at the MUHAS laboratory, reported on their official report 
form and filed in relevant participant folders at TDH TB clinic. All HIV results 
were also recorded in the Diagnosis and Medication CRF (Appendix 10) per 
participant. Full blood profile analysis was done at BRTC and reported as a 
print out from the equipment that was filed in each participant folder.  
Cytological smear processing, ZN staining and microscopic assessment by a 
pathologist were done at AKHD and reported on FNA CRF form (Appendix 
8). Culture, DST and speciation was performed at BRTC according to the 
‘Preparation and inoculation of MGIT and Results interpretation’ protocol 
(Appendix 19) and reported on a MGIT Culture and Speciation Report Form. 
With the establishment of Xpert testing at IHI Mwananyamala TB Clinic (from 
October 2012), half the FNA-in-PBS specimen (~0.35ml) was analysed 
immediately on collection. The remaining specimen aliquots, and all 
specimens collected prior to October 2012, were frozen in a 2-8°C freezer for 
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not longer than 12 hours. These were then transported to BRTC at 2-8°C, 
where they were frozen at -20°C, for batch analysis to be done at a later date. 
Any “invalid/error” Xpert tests at Mwananyamala were re-tested from frozen 
(-20C) FNA-in-PBS specimens at BRTC (stored for EasyNAT testing). Xpert 
results were printed in standard-format from the analyser and filed in 
participant folders. 
One batch of the frozen (-20C) FNA-in-PBS specimens was analysed using 
the EasyNAT assay in late December 2012. Specimens collected between 
December 2012 and March 2013 were analysed using EasyNAT in May 2013. 
EasyNAT results were reported on the Ustar Result Form (Appendix 24) and 
filed in participant folders. 
 
FNA LABORATORY ANALYSES 
All FNA specimens were assessed through AFB microscopy, cytological 
analysis, liquid (MGIT) culture, Xpert® MTB/RIF (Cepheid) and Ustar 
EasyNATTM TB IAD analysis as described below. 
Ziehl-Neelson staining and AFB microscopy 
At the AKHD laboratory, heat-fixed FNA smears were flooded with 1% carbol 
fuchsin stain (1g basic fuschsin, 5g phenol, 10ml absolute ethanol [Rankem, 
India] per 100ml stain) and gently heated with a flame to encourage steaming 
for 5 minutes without allowing the stain to boil or dry. The slides were then 
washed and decolourized using 25% sulphuric acid (Rankem, India) for 1 
minute or until the smear was light pink in colour. After washing, Methylene 
blue stain (Rankem, India) was used to counter stain the smear for 2 minutes, 
the slides washed and dried, and cover slips mounted. The smears were 
examined at 1000x magnification for 300 fields using light microscopy. The 
results were reported on Appendix 8: FNA CRF, as either “AFB seen” or 
“AFB not seen”. 
Cytomorphological analysis 
A classic Papanicolaou (PAP) stain comprises of 5 dyes in 3 solutions, used 
to differentially stain the components of cells to help distinguish between 
superficial, intermediate, parabasal and metaplastic cells. Papanicolaou 
staining was done at AKHD laboratory by first hydrating the ethanol-fixed 
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slides in reducing concentrations of ethanol for 2 minutes each (70% and 50% 
ethanol) and tap water for 2 minutes. The slides were then soaked in 
haematoxylin stain (Quimica Clinica Aplicada, SA) for 4 minutes, rinsed in tap 
water before differentiating in acid:alcohol for 30 seconds and rinsed in tap 
water again. They were then dehydrated with absolute alcohol for 30 seconds 
and soaked in orange G stain (Quimica Clinica Aplicada, SA) for 1 minute. 
Absolute alcohol was used for 50 seconds to rinse the slides which were then 
soaked in EA50 stain (Quimica Clinica Aplicada, SA) for 2 minutes. The slides 
were rinsed in absolute alcohol for 50 seconds, cleared in xylene (Quimica 
Clinica Aplicada, SA) for 30 seconds and a cover slip mounted with DPX 
mountant (DePeX® BDH, Prolabo, VWR, Ireland). Slides were then scrutinized 
under 1000x magnification with a light microscope.  
The cytomorphological pattern in TB lymphadenitis FNA can vary greatly; 
from nonspecific lymphadenitis or suppurative acute lymphadenitis, to 
necrosis with or without granuloma formation or granuloma alone. The pattern 
may also vary based on the immune status of the patient, where a small 
amount of amorphous necrosis and occasional giant cells may be present in 
immune competent cases including epithelioid histiocytes and epithelioid 
granulomata in a background of reactive lymphocytes and plasma cells. In 
immune compromised patients with TB, smears commonly show abundant 
“dirty” necrosis with neutrophils and cellular debris being prominent (Cibas 
and Ducatman, 2009; Wright et al., 2008). In my study, the presence of 
granuloma and/or necrosis was reported as “consistent with mycobacterial 
infection”. 
Due to the variety in cytomorphological presentation, and the fact that other 
organisms such as fungal infections may present a similar morphological 
picture, aforementioned AFB staining was performed and reported on all 
aspirates in this study, irrespective of the cytological diagnosis. The slide 
(smear) quality, cytomorphology and diagnosis were reported on Appendix 8: 
FNA CRF. The diagnoses were reported as “confirmed TB lymphadenitis” 
(AFB present), “suspected TB lymphadenitis” (cytomorphology consistent with 
mycobacterial infection) or “other” which was then specified (including 
suspicion of malignancy). 
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MGIT culture, speciation and drug susceptibility testing (DST)  
The Mycobacteria Growth Indicator Tube (MGIT) is a 16 × 100 mm round 
bottom tube containing 7ml of modified Middlebrook 7H9 Broth base (Becton 
Dickenson, Cockeysville, MD). A fluorescent compound, sensitive to the 
presence of oxygen dissolved in the broth, is embedded in silicone at the 
bottom of each tube. A large amount of dissolved oxygen in the non-
inoculated medium quenches emissions from the compound and only a little 
fluorescence can be detected. A growth supplement and an antibiotic mixture 
(to prevent growth of other non-MTB organisms) is added according to 
standard protocol, to make a complete medium for mycobacterial growth, just 
prior to inoculation with specimen (Siddiqi and Rusch-Gerdes, 2006). When 
there is bacterial growth in the broth, respiration from these microorganisms 
consumes the oxygen and the BACTEC MGIT 960 System instrument is able 
to detect the increase in fluorescence in the tube.  
Tubes in the BACTEC MGIT 960 System are continuously incubated at 37°C 
and monitored by the system every 60 minutes for increasing fluorescence. A 
tube is flagged as positive when it contains approximately 105 to 106 
colony-forming units per millilitre (cfu/ml), determined by algorithms 
programmed into the system.  Culture tubes which remain negative for a 
minimum of 42 days and which show no visible signs of positivity are 
considered negative for bacterial and mycobacterial growth (Siddiqi and 
Rusch-Gerdes, 2006). 
In my study, each FNA specimen inoculated MGIT tube was incubated at 
37°C for 8 weeks or until flagged positive on the instrument. No growth on the 
instrument after 8 weeks was reported as “negative for MTB”. If flagged 
positive, the growth from the tube was plated on LJ medium (BBLTM Becton 
Dickenson, Cockeysville, MD) for identification and blood agar medium to 
assess for bacterial contaminants (growth other than MTB). If there was 
growth on blood agar medium, the MGIT growth was decontaminated and 
re-inoculated in a fresh MGIT tube. If positive once again on blood agar 
medium, the specimen was reported as “contaminated” (Appendix 19: MGIT 
Culture & Reporting SOP). 
If a sample was negative for blood agar growth and positive for AFB on ZN 
stain from MGIT culture, a TBCheck MPT64 assay (HAIN Lifescience GmbH) 
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was used to confirm MTB complex. Molecular speciation for MTB complex 
and detection of resistance to INH and RMP was performed using the 
GenoType MTBDRplus assay (HAIN Lifescience GmbH) (Appendix 20: MTB 
speciation, INH & RMP resistance detection). The specimen was also 
processed using GenoType MTBC (HAIN Lifescience GmbH) to identify the 
MTBC species, including M. bovis BCG. 
Specimens that were negative for MTB complex were further analysed using 
LJ medium and GenoType Mycobacterium CM/AS assays (HAIN Lifescience 
GmbH) to determine if the growth was any of the 24 most common 
non-tuberculous mycobacteria (NTM) or 19 additional NTM species and 
reported as NTM (“negative for MTB”).  
In the case of indeterminate results from the LJ media and GenoType 
systems, DNA extracts of MGIT culture were sent for DNA sequence analysis 
to the Emerging Bacterial Pathogens Unit, WHO Supranational Reference 
Laboratory for Tuberculosis (SRL-TB), Division of Immunology, 
Transplantation and Infectious Diseases, San Raffaele Scientific Institute, 
Milan, Italy. If organisms other than MTB or NTM were identified, for example 
Nocardia, then the specimen was reported as  “contaminated”. 
Laboratory report forms (LRF) no 2, 5, 6 and 7 were used to report MGIT 
culture, speciation and DST results as processed (Appendix 21). 
 
Xpert® MTB/RIF (Cepheid) Assay 
Xpert testing was performed on each FNA-in-PBS specimen following the 
Xpert MTB/RIF test for FNA protocol (Appendix 22). Half of the FNA-in-PBS 
sample per participant (approximately 0.35ml) was treated with a sodium 
hydroxide and isopropanol-containing reagent (Sample Reagent) in a 2:1 ratio 
(SR:sample) for 15 minutes. The treated sample was transferred, using a 
demarcated (defined volume) disposable pipette, into a single-use plastic 
cartridge ready-manufactured with preloaded liquid buffers and lyophilized 
reagent beads. The cartridge was then loaded into the GeneXpert instrument 
where sample processing, DNA extraction and hemi-nested real-time PCR 
were automated. 
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Figure 8: Sample of an Xpert MTB/RIF report 
 
Results were generated (Figure 8) through the system software programmed 
algorithm and reported as MTB NOT DETECTED or MTB DETECTED (if at 
least two of the five rpoB probes are bound within two cycles of each other) 
(Figure 4).  Semi-quantitative estimates of MTB concentration were reported 
in the cases of MTB DETECTED as either LOW, MEDIUM or HIGH based on 
cycle number at threshold (Ct) values from the real-time monitoring of 
amplification. As the samples were collected from participants suspected of 
having TB, it was not unreasonable to assume the presence of active M. 
tuberculosis infection, in the case of a positive assay.  
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The five rpoB probes are designed to bind to the wild type sequence in the 
region where the most prevalent rpoB mutations occur. They do not bind to 
mutant sequences; therefore the assay detects mutations based on the 
absence of probe molecular beacon signals. If there was a 3.5 cycle or 
greater difference in the cycle threshold between the earliest and latest rpoB 
signals (delay) then this was also reported as RIF resistance (Helb et al., 
2010; Blakemore et al., 2010). 
 
Ustar EasyNATTM TB IAD (Biotech) Assay  
EasyNAT testing was performed following the Ustar EasyNAT TB IAD Assay 
Protocol (Appendix 23) on each FNA-in-PBS specimen (remaining after 
Xpert analysis). Sample preparation involved a boiling and chemical 
extraction protocol. Up to 1ml of the FNA-in-PBS specimen was centrifuged in 
a 1.5ml centrifuge tube >10 minutes at >10,000rpm. The supernatant was 
discarded and 40µl of DNA extract solution added to the pellet, vortexed to 
mix well and incubated at 95-100C for 10 minutes. The tube was cooled at 
room temperature for 5 minutes and centrifuged at >10,000rpm for >5 
minutes. The supernatant was either immediately analysed as the 
amplification template for the next step, or stored at -20C for not more than 
one week until analysed. 
For the amplification and hybridization step, Reaction Mix (glassified) tubes 
were labelled; one per specimen and one for the negative and positive control 
each (as recommended to be done for every test batch). Fifteen microlitres of 
Resuspension Buffer were added into each tube (containing lyophilized 
reaction mix) and kept at room temperature for 2-3 minutes to allow complete 
dissolution. Four microlitres of ddH2O was added to the tube for the negative 
control, 4μl of positive control into the positive control tube and 4µl 
amplification template per specimen into each of the specimen-labelled tubes. 
The contents of each tube were individually mixed thoroughly using the 
micropipette on application of each template, and the tube lids closed never to 
be opened again. 
The tubes were centrifuged for 3 to 5 seconds at >4,000rpm and incubated at 
63C for 60 minutes. At the end of the incubation period, each tube was 
placed individually into device cartridges (without opening the tube lids). 
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These were then inserted into detection devices and the device lids snapped 
shut, at which point the reaction tubes were automatically pierced to release 
the PCR product onto the lateral-flow detection strip. Results were read 
visually from the strips, 10 to 30 minutes after placing the tubes in the 
detection devices (Figure 9). 
 
 
Figure 9: Strip detection for TB using EasyNATTM TB IAD strips and 
cartridges 
 
 
 
Figure 10: Interpretation of strip detection in EasyNATTM TB IAD 
 
A valid result was one that showed a clear control band (PCR was successful) 
with a test band for presence of MTB or control positive, and no test band in 
the absence of MTB (Figure 10). A negative control showed only the control 
band. 
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Figure 11: Intensity scale, EasyNATTM TB IAD insert (Ustar 
Biotechnologies, 2009). 
C indicates the control band and T the test band. 
Specimen positivity for TB was determined by the intensity of the test band in 
relation to an intensity scale provided in the kit (Figure 11). A test band with 
intensity of L4 and above was considered positive for MTB, while intensity of 
less than L3 was considered negative for MTB. Repeat testing was done to 
obtain conclusive results when the test-band intensity was between L3 and 
L4. Results read after 30 minutes were not valid (Ustar Biotechnologies, 
2009). EasyNAT results were reported on USTAR Result Form (Appendix 
24). 
 
STATISTICAL ANALYSES 
Four participants were excluded from the analyses because of incomplete 
data due to; death after recruitment, loss of contact, relocation and subsiding 
lymph node more than 4 weeks after general antibiotic treatment, 
respectively. All FNA diagnostic outputs, clinical assessment scores and 
composite reference standards created, were analysed for sensitivity, 
specificity and Cohen’s kappa () using Stata software version 12.1 
(StataCorp, College Station, Texas, USA). Latent Class Analysis (LCA) was 
performed on all FNA diagnostic outputs (Appendix 25), using Statistical 
Analysis Systems (SAS) Software version 9.2 SAS version 9.2 (SAS Institute 
Inc., Cary, NC, USA). 
C 
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GENERAL DISCUSSION 
 
Tuberculosis is treatable and usually curable. Unfortunately, the greatest 
obstacle in managing the disease globally, still is the lack of effective, 
accessible point-of-care (POC) testing for all forms of TB, leading to 
challenges in treatment aimed at curbing disease progression, onward 
transmission and death. Between 2007 and 2011, there was a surge of WHO 
recommendations for diagnostic systems, in a concerted effort to improve TB 
diagnosis and management. The methods recommended at the time were: 
 liquid culture media, such as the mycobacterial growth indicator tube 
automated platform (WHO, 2007) 
 rapid species identification, such as with the Capilia rapid speciation test to 
distinguish TB from non-tuberculous mycobacteria (WHO, 2007) 
 line probe assays for rapid detection of multi-drug resistant (MDR) TB, 
such as the GenoType MTBDRplus assay (WHO, 2008) 
These technologies are suited for reference laboratory, research institution 
and private sector healthcare facilities, based on their infrastructural and 
resource requirements, and therefore cannot function as POC tests for use at 
low-resource TB-endemic primary care settings. 
During the same period (2007-2011), the techniques recommended by the 
WHO, particularly for low- and middle-resource settings were: 
 same-day diagnosis by microscopy (WHO, 2011c) 
 fluorescence microscopy (WHO, 2011d) and 
 non-commercial culture and DST methods (WHO, 2011e) 
 the automated GeneXpert MTB/RIF real-time PCR NAAT (WHO, 2011f), 
updated (WHO, 2013c) 
By the end of 2014, 69% of the TB high burden countries (HBCs) reported 
that national policy indicated the use of Xpert MTB/RIF as the initial diagnostic 
test for people at risk of drug-resistant TB, and 60% reported that national 
policy indicated its use as the initial diagnostic test for people living with HIV 
(WHO, 2015a). Unfortunately, even with improved access of the Xpert system 
to HBCs through efforts from the Foundation for Innovative New Diagnostics 
(FIND), wide-scale implementation of Xpert technology has only occurred in 
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South Africa, with other HBCs still relying heavily on smear microscopy (Pai 
and Schito, 2015). Some of the reasons for this stunted roll-out may be the 
high cost of the instrument and that the system was not designed for lower 
tiers of the healthcare system, based on the need for stable electrical power 
and on-site calibration. Therefore, there is still dire need for an effective POC 
test to impact TB management globally. The WHO has yet to recommend a 
new TB diagnostic test since the Xpert recommendation of 2010 (updated 
2013). 
 
INNOVATIONS IN THE FIELD 
There have not been more recent meta-analyses or systematic reviews from 
TB review groups on commercially available NAATs for the diagnosis of TB, 
other than those for the diagnosis of TB lymphadenitis (Daley et al., 2007) and 
pulmonary tuberculosis (PTB) in respiratory specimens (Ling et al., 2008). 
The results of these reviews showed inconsistent outcomes for use of NAATs 
in diagnosing TB lymphadenitis and cautioned on the limitations of the review, 
while for respiratory specimens the analysis recommended for improved 
sensitivity of NAATs before they may be considered in place of conventional 
tests. Notwithstanding, there have been several recent systematic reviews 
evaluating the Xpert MTB/RIF NAA system. One such review was on the 
effectiveness of Xpert in diagnosing pulmonary tuberculosis and rifampicin 
resistance in adults, wherein further research was recommended into the use 
of the Xpert system in TB programmes in high TB burden settings (The 
Cochrane Collaboration and Steingart et al., 2014). Another review was on 
Xpert use for the diagnosis of EPTB, wherein Xpert was recommended over 
conventional tests for diagnosis of TB in lymph nodes and other tissues, and 
as the preferred initial test for diagnosis of TB meningitis (Denkinger et al., 
2014). 
Despite these positive reviews, Xpert technology still does not impact the 
on-going disease management challenges globally, of latent TB infection 
(LTBI), MDR and extensively drug-resistant (XDR) TB detection. Towards 
improving the impact on TB management Cepheid is designing the ‘Omni’, a 
new platform to specifically address many of the logistical constraints faced in 
microscopy centres, whilst using cartridges already in use for the current 
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GeneXpert® platforms (WHO, 2015b). Other developments in Cepheid 
technology are the Xpert MTB/RIF ‘Ultra’ and ‘XDR’. The Ultra is an upgrade 
over the Xpert MTB/RIF system by way of: the sample-processing cartridge 
that doubles the amount of purified DNA delivered to the PCR reaction; four 
newly-designed probes that replace the earlier five probes that detect 
mutations in the rpoB gene; additional real-time MTB detecting probes 
targeting the IS6110 and IS1081 sequences; high-resolution melt-curve 
detection generating specific fluormetric fingerprints for each probe binding to 
its amplified complement allowing for better discrimination of allelic variance 
within each probe region; and optimization of cartridge fluidics and PCR 
cycling. It was reported in a February 2015 Conference on Retroviruses and 
Opportunistic Infections (CROI) presentation, that from an on-going trial the 
Xpert MTB/RIF Ultra was found to have a much better TB-detection sensitivity 
than Xpert MTB/RIF and was comparable to culture, increasing the potential 
for TB detection in smear-negative patients. With a better RIF-resistance 
specificity than Xpert MTB/RIF, the Ultra assay will also be able to provide 
more reliable RIF resistance detection (Alland et al., 2015; WHO, 2015b). The 
Ultra assay is scheduled to be evaluated in 2016 as a potential replacement 
for conventional diagnostic culture (WHO, 2015a). The XDR assay is being 
designed to detect isoniazid (INH), fluoroquinolone (FLQ) and aminoglycoside 
(AMG) resistance, the latter two being important second-line anti-TB drugs 
(WHO, 2015b). 
Following the double CPA gyrB gene targeting EasyNATTM TB IAD kit 
production, there have only been two evaluation studies of this kit (Fang et al., 
2009; Mhimbira et al., 2015) and no further endorsement from the WHO for its 
use in TB detection, other than trial status (WHO, 2011b). Since 2009, Ustar 
Biotechnologies (China) have developed three more isothermal cross-priming 
amplification (CPA) based kits for detection of TB, and rifampicin as well as 
isoniazid resistance-conferring mutations (WHO, 2013a). The only trial 
evaluating one of these new kits targeting the IS6110 sequence of MTB (TB 
detection), demonstrated lower sensitivity and specificity outputs than those of 
the earlier EasyNAT kit targeting the gyrB gene (Ou et al., 2014). This status 
renders none of the new Ustar developments eligible for recommendation by 
the WHO. 
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A development that has potential solutions for some key limitations of the 
NAATs under investigation in my study, is the TBDx system being developed 
by the Keck Graduate Institute of Applied Life Sciences, Claremont, 
California, in conjunction with Claremont BioSolutions, Upland, California, 
USA and Ustar Biotechnologies (Hangzhou), amongst others (WHO, 2015b). 
The pertinent limitations from my study were: the need for stable electrical 
power and the cost of the Xpert system (instrument cost of $17,500 and $9.98 
per test for subsidy-eligible TB-endemic countries) (Foundation for Innovative 
New Diagnostics, 2012); and the extensive hands-on time for DNA extraction 
and the need for separate amplification and detection platforms for the 
EasyNAT system. 
In the initial development of the TBDx system, Roskos et al. (2013) employed 
isothermal LAMP and comparative Exponential Amplification (EXPAR) 
reactions to detect MTB genomic DNA, coupled with nucleic acid lateral flow 
(NALF) technology (similar to the EasyNAT system) for visual endpoint 
detection, into a single prototype cartridge. Sample preparation was not 
incorporated into the cartridge a the time (Roskos et al., 2013). The current 
model uses a derivative of Claremont BioSolutions’s PureLyse® technology (a 
novel solid-phase extraction in a microbead beater, that does not require 
chaotropic salts or organic solvents) within the amplification and detection 
cartridge, to capture MTBC cells, wash, lyse and elute the DNA, from liquefied 
and disinfected sputum. The eluted DNA is used to dissolve CPA specific 
reagents (similar to the EasyNAT assay) for an MTBC assay. 
Immunochromatographic strip detection is used and scored visually. All 
on-board liquid handling processes within the cartridge are operated through 
inexpensive electrolytic pumps (epumps). The TBDx is scheduled to be ready 
for use, by the second quarter of 2018, with the current cost estimated at US$ 
150 for the instrument (no onsite calibration required) and under US$ 8 per 
test cartridge (WHO, 2015b). 
One other development of key interest is the VerePLEX Biosystem by 
STMicroelectronics (Geneva, Switzerland), marketed by Veredus Laboratories 
(Republic of Singapore), for rapid diagnosis of MDR TB. It is a lab-on-chip 
(LoC) technology, involving single disposable devices comprising microfluidic 
PCR and microarray modules. Processing and detection are semi-automated, 
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with sensitivities of over 97.8% for MTBC, rifampicin and isoniazid resistance 
detection (mutations on rpoB, katG and inhA genes) in clinical isolates and 
smear-positive specimens, when assessed against Sanger sequencing and 
GenoType® MTBDRplus (Hain Lifescience, Nehren, Germany) based 
detection (Cabibbe et al., 2015). This technology offers promise for a fast and 
simple diagnostic tool for MDR in referral laboratories. 
There are several similar developments in the TB diagnostics arena that are 
set to be launched over the next few years. They will all require evaluation 
and clinical-performance assessment before they are recommended for use in 
TB-endemic low-resource settings (WHO, 2015b). 
 
Extrapulmonary Tuberculosis 
In the field of EPTB detection by NAATs, a 2014 study of the Amplified MTB 
Direct test (AMTD; Gen-Probe Inc); a rapid isothermal technique for 
amplification of TB 16S-rRNA from urine of patients with EPTB, found the 
technique useful in early detection of EPTB with a sensitivity of 70%, but not 
as effective in diagnosing pulmonary TB (18%) (Fortún et al., 2014a). 
With the aim of augmenting information on biomarkers for EPTB detection, 
the same group studied the serum of patients with EPTB. Levels of interferon-
gamma, tumour marker Ca-125, adenosine deaminase, chemokine ligand-9 
and mannose-binding lectin (MBL) were determined from patients with PTB, 
EPTB and health individuals. Levels of all the biomarkers were significantly 
higher in the PTB and EPTB cases than in the control cases. There were no 
significant differences in levels between the PTB and EPTB cases with the 
exception of MBL, which were significantly higher in patients with EPTB than 
in patients with PTB. Some of the biomarkers are not specific to MTB 
infection, but they do present as acute phase reactants and may be utilized to 
confirm MTB infection, while MBL may specifically be assessed to distinguish 
between PTB and EPTB (Fortún et al., 2014b). 
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CONTRIBUTIONS, STATISTICAL PECULIARITIES AND LIMITATIONS OF 
MY STUDY 
Fine needle aspiration biopsy 
Studies have demonstrated that fine needle aspiration cytology has significant 
benefits in aiding in the diagnosis of TB in resource-limited settings (Mittal et 
al., 2011; Wright et al., 2009a). In my study, 24% of the FNA specimens were 
positive for TB by cytology, with 19.6% being unsuitable for analysis 
compared to 12.5% in a similar study (Wright et al., 2008). There are several 
factors that could have influenced the success or failure of detecting the 
presence of TB in FNAB specimens. One key consideration is the naturally 
uneven proliferation of TB within lymph nodes and the paucibacillary nature of 
TB in lymphadenitis and EPTB. The site of FNAB may not have been the 
point of greatest TB proliferation, potentially leading to the patient being 
erroneously declared negative for TB disease, in the absence of other disease 
markers (Vadwai et al., 2011). 
Considerations for future studies to maximize the yield of MTB in FNAB 
specimens, would be the use of the “bleach method”, initially used to 
concentrate sputum specimens to improve direct microscopy (Wilkinson and 
Sturm, 1997). In this method, the specimens are incubated in NALC (N-acetyl-
L-cysteine-sodium hydroxide) for 15 minutes and centrifuged at 3000g for 15 
minutes, after addition of phosphate buffered saline, and the sediment 
retained for analysis (Tadesse et al., 2015; Annam et al., 2009a).  
 
Mycobacterial culture 
Mycobacterial culture positivity from lymph node aspirates was low in my 
study (12%). Earlier publications have also shown that the performance of TB 
culture in FNAB and extrapulmonary specimens is poor (Al-Nakeeb et al., 
2013; Trajman et al., 2008; Khan et al., 2006; Chakravorty et al., 2005). A 
high proportion of the specimens being contaminated (48%) may have 
impacted culture positivity outcomes. A key source of contamination could 
have been the opening of the MGIT tubes during inoculation. There have 
been studies on transport media that potentially lower TB culture 
contamination rates through FNA inoculation without removal of lids in the 
field (Wright et al., 2010). These transport bottles contained 1 ml Middlebrook 
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7H9 broth (with 0.2% glycerol and 0.05% Tween 80 added) in 10 ml 
headspace glass vials, sealed with 20 mm TFE/Sil Septa and 20 mm 
aluminium open top seals, prepared in a laminar flow cabinet and autoclaved. 
Such considerations should be made in order to lower contamination rates 
when implementing FNA TB culture analyses in the field. 
 
BCG disease 
Two cases of Mycobacterium bovis (BCG) (22% of MTB culture positives) 
were reported in this study, isolated from FNAB of lymph nodes of 
HIV-negative participants. Disseminated BCG disease is a rare complication 
of BCG vaccination and is usually associated with immune deficiency. Local 
complications from vaccination and regional BCG lymphadenitis however, 
have been reported in immune-competent BCG recipients ranging from 0.5% 
to 17.6% (Braun and Cauthen, 1992). A more recent study of BCG-infected 
infants reported an incidence as high as 24% of BCG disease in 
immune-competent infants and linked this to a year 2000 change in vaccine 
policy from use of a Tokyo-strain BCG vaccine administered percutaneously 
to a Danish-strain BCG vaccine administered intradermally (Hesseling et al., 
2006). Wright et al. (2008) also report an incidence of 23% BCG infection of 
lymph nodes from the MTB culture positive cases seen in that study. 
 
Nucleic acid testing 
The minimal hands-on time, automated extraction and modular design of the 
Xpert system allowed for random testing of fresh FNA samples. Due to the 
protracted extraction and PCR preparation protocols of the EasyNAT assay, 
specimen analysis was done on stored (-20ºC) FNA samples in batches, for 
purposes of time and resource efficiency. There was no significant difference 
in performance observed between fresh and stored sample analyses, 
between and within the two NAATs. 
The two NAAT under study differed significantly in their nucleic acid extraction 
protocols, which could have contributed to the vast distinction in performance 
of each assay. The Xpert process involved capture of MTB on a filter, 
sonication to break open the cells and elution of the nucleic acid material, all 
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fully-automated within the cartridge. The EasyNAT process was manual and 
involved the use of sodium hydroxide (NaOH) for decontamination and 
liquefaction in the case of pus-like FNA specimens, which were then pelleted 
and washed twice. There may have already been nucleic acid (NA) loss at 
this stage. For standard FNA samples and further to the pelleting step for 
purulent samples, there was an Extraction Solution step at the end of which 
the supernatant was saved for processing. Here too there was potential loss 
of NA material. Aliquots of these extracts were then used in the PCR mix, 
which further diluted the NA content. Based on these distinctions in protocols 
and the consideration that lymph node proliferation by TB is paucibacillary in 
nature, loss of NA material through extraction processes may have played a 
significant role in the sensitivity of the tests; the Xpert performing significantly 
better than the EasyNAT method. 
Regarding alternative options for DNA extraction in the EasyNAT protocol, the 
package insert had a “Cautions” page with a point (No. 4) stating: “We provide 
nucleic acid extraction solution inside the kit for you to extract nucleic acid. 
However, you can also choose other reliable products for nucleic acid 
extraction”. As the performance of the EasyNAT kit specifically was being 
tested, the extraction protocol provided in the instructions-for-use was 
adhered to. Only in a more recent kit insert, not included in the kits received 
during the project, EasyNAT Ustar Biotechnologies suggested that the DNA 
extraction protocol might be performed using an alternative method that they 
provide, not requiring centrifugation. The alternative method is based on 
boiling-lysis, binding of the material to a lysis buffer, washing with an ethanol--
containing buffer and elution, all using a syringe method. The syringe method 
may improve NA yield and in so doing, the sensitivity of the EasyNAT assay. 
There have been further developments in MTB-DNA stabilization, transport 
without need for cold-chain, and nucleic acid extraction and concentration 
technologies for sputum, which may be adapted for use on FNAB specimens. 
The OMNIgene® SPUTUM by DNA Genotek Inc. (Ottawa, Canada; a wholly 
owned subsidiary of Orasure Technologies Inc.; USA) liquefies and 
decontaminates samples, allowing for transport without refrigeration. These 
samples may be used for microscopy, culture including MGIT, Xpert® 
MTB/RIF and other molecular detection methods testing for TB. The prepIT® 
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MAX technology by the same company, is a chemical-lysis and DNA 
ethanol-precipitation method that circumvents the need for mechanical lysis. 
Samples first treated with OMNIgene® SPUTUM can be subsequently 
processed with this kit to concentrate nucleic acids for further analysis. A 
direct-to-PCR method and direct integration into automated extraction 
systems are also under development. DNA Genotek Inc. is working with the 
STOP-TB Partnership, WHO, Foundation for Innovative New Diagnostics 
(FIND) and the Global Laboratory Initiative (GLI) to determine appropriate 
paths forward for technical evaluations of these technologies and to facilitate 
adoption by countries receiving donor funds (WHO, 2015b). 
The PrimeStore Molecular Transport Medium® (PS-MTM®) by Longhorn 
Vaccines & Diagnostics (USA) is another product under consideration 
specifically for NAAT solutions (Daum et al., 2014a). It contains chemical 
denaturants that permit lysis of MTB cells with subsequent stabilization of 
MTB DNA, allowing for transportation without cold chain, and found suitable in 
one study for PCR analysis within 7 days of collection (Daum et al., 2014b).  
To-date, the Xpert kit instructions do not have a protocol for processing of 
non-respiratory specimens. Although the EasyNAT kit instructions do not 
particularly mention lymph node aspirates, they have specified processes for 
sample preparation and DNA extraction from fluid non-respiratory specimens, 
which were followed for FNA samples in my study. The focus here therefore, 
is on the deviation from protocol for Xpert testing, of FNA in my study. The 
instructions direct for the use of Sample Reagent (SR [NaOH and 
isopropanol]) in a ratio of 2:1 for expectorated sputum samples and 3:1 for re-
suspended sputum sediments. In my study, the specimens collected were 
FNA washed into 0.7ml phosphate-buffered saline (PBS). Half this volume per 
specimen was used for Xpert analysis (the other half for EasyNAT testing), to 
which SR was added to a total volume of just over 2mls. Depending on the 
total specimen volume available, the range of specimen volumes used in 
Xpert analysis was 0.2ml (in the case of repeat analysis) to 0.7ml. A large 
proportion of cases had a SR to sample ratio of 5:1 (1.8ml:0.35ml), while the 
remaining ranged between 10:1 and 2:1. There was no evident correlation 
between decreased sample volume (decreased ratio) and test positivity, 
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although there appeared to be a positive correlation between purulent 
samples and test positivity. 
With reference to the current WHO Xpert MTB/RIF Implementation Manual 
based on a 2014 systematic review of studies using Xpert for diagnosis of 
extrapulmonary TB, there is no recommendation for the processing of lymph 
node aspirates, only for lymph node biopsies or tissues (WHO, 2014a; 
Denkinger et al., 2014). Studies in the systematic review included those by 
Vadwai (2011), wherein they added SR to the specimen to a total volume of 
2ml for CSF, while Ligthelm (2011) increased sample volume to 0.7ml with 
PBS and then added SR (SR to sample ratio being 3:1) (Vadwai et al., 2011; 
Ligthelm et al., 2011). Moure (2012) added 3ml (2ml SR and 1ml sediment) to 
the cartridge, which is not desirable as this volume exceeds the 
recommended volume for the cartridge, while Malbruny (2011) concentrated 
all specimens except CSF and had a SR to sample ratio of 3:1 (Moure et al., 
2012; Malbruny et al., 2011). 
CSF specimens are fluid, and similar to lymph node aspirates, are 
paucibacillary in TB infection and often with small aspiration volumes. The 
WHO Xpert MTB/RIF Implementation Manual recommendations for CSF are 
based on sample volume availability, whereby concentration of specimens by 
centrifugation is recommended for volumes of 5ml and more, while an equal 
volume of SR is recommended for samples of 1 to 5ml. Most relevant, is the 
recommendation for sample volumes of 0.1 to 1ml, wherein adding SR to the 
whole sample to a final volume of 2 ml, is recommended. All of the mixture is 
then added directly to the Xpert MTB/RIF cartridge. Accordingly, my study 
followed the most appropriate sample processing protocol for Xpert testing for 
FNA specimens. 
 
Statistical analyses 
The use of a composite reference standard (CRS) to assess the accuracy of 
diagnostic kits has been highly recommended by Denkinger et al. (2014) and 
Naaktgeboren et al. (2013), while options for the use of CRS, latent class 
analysis (LCA) and other accuracy measures have been categorized well by 
Reitsma et al. (2009): (Denkinger et al., 2014; Naaktgeboren et al., 2013; 
Reitsma et al., 2009). 
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Composite Reference Standard 
Examples of studies that have used CRS to assess the performance of Xpert 
MTB/RIF on lymph node specimens are Tadesse et al. (2015 – CRS: culture 
and/or smear microscopy) Ligthelm et al. (2011 - CRS: culture and histology), 
Tortoli et al. (2012 - CRS: culture, histology and improvement with anti-TB 
therapy), Vadwai et al. (2011 – CRS: culture, radiology and improvement with 
anti-TB therapy), Van Rie et al. (2013 – CRS: culture, histology and smear 
with species identification) and Zeka et al. (2011 – CRS: culture, histology and 
radiology): (Tadesse et al., 2015; Ligthelm et al., 2011; Tortoli et al., 2012; 
Vadwai et al., 2011; Van Rie et al., 2013; Zeka et al., 2011). With culture as 
the conventional gold standard and cytology performing well in my study, 
analyses were done with “culture and/or cytology” as the CRS, to assess the 
performance of the other diagnostic modalities. Concordance to the reference 
standard of each modality went down, compared to that with either culture or 
cytology as the reference standard. This outcome using a CRS, may suggest 
a more credible assessment of the modalities, which demonstrated highest 
concordance to the CRS by Xpert, followed by EasyNAT and ZN microscopy. 
Latent Class Analysis 
Mycobacterial culture positivity of FNAB in my study was low (12%). This 
made culture an uncertain reference standard against which to assess the 
performance of alternative TB diagnostic tools. The true TB status of 
participants could not be confirmed without AFB visualization (microscopic) or 
MTB growth. Clinical assessment has previously been shown to overestimate 
the incidence of TB disease (Fox et al., 2013) and similarly in my study, it 
does not correlate well with diagnostic outcomes. Resolution of lymphadenitis 
of alternative infectious aetiologies other than TB, through use of TB therapy, 
is not uncommon (Low, 2009; Rayner and Munckhof, 2005). Resolution of 
lymphadenopathy could therefore not be used as a proxy for TB diagnosis. 
In cases of imperfect or missing reference standards, latent class analysis 
(LCA) has been recommended to assess the efficacy of diagnostic tools 
(Reitsma et al., 2009; Denkinger et al., 2014). There are no published studies 
using LCA to assess the accuracy of Xpert to-date. There are limited studies 
evaluating EasyNAT, none of which employ CRS or LCA for accuracy 
estimation.  
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I used LCA to analyse the performance of all the diagnostic modalities used to 
test FNAB in my study. LCA was used to create a “true TB status” per 
participant, based on probability statistics applied to the diagnostic outputs 
from my study (Appendix 25). The 100% sensitivity output from LCA of 
cytology was possibly an overestimation, due to the wide spread of cytology 
positives over positive cases calculated by LCA. This propensity for 
over-estimation through LCA has previously been identified (Pouillot et al., 
2002; Alonzo and Pepe, 1998; Vacek, 1985). Beyond this limitation, LCA 
outputs for the other diagnostic modalities correlated well with the prior 
statistical analyses; demonstrating superiority of cytological analysis over 
culture for TB detection in FNA of lymph nodes and that there was added 
value in the use of Xpert in a diagnostic algorithm. 
A 2014 systematic review on the use of Xpert for the diagnosis of 
extrapulmonary TB, demonstrated a very low proportion of non-interpretable 
results by Xpert overall (1.2%) and concluded that Xpert was highly sensitive 
in diagnosing TB lymphadenitis, both from tissue and aspirate samples 
(Denkinger et al., 2014). The review also stipulated that culture was an 
imperfect reference standard for TB lymphadenitis and recommended the use 
of CRS and LCA for accuracy estimation of diagnostic tests. No distinction 
was found between TB detection by Xpert on lymph node specimens from 
HIV-positive and HIV-negative participants. Also pertinent was the need, as 
identified from the review, for more studies on the use of Xpert for 
extrapulmonary specimens in a primary or secondary care TB-endemic 
setting, as was the case in my study. The review was used to guide a WHO 
recommendation for the use of Xpert over conventional tests for diagnosis of 
TB in lymph nodes in adults and children (WHO, 2014a).  
The overall statistical outcomes of my study demonstrated that 
cytomorphology is a feasible and effective technique for detection of TB in 
lymph node aspirates, that may complement TB culture where available, and 
that Xpert was superior in performance to EasyNAT and ZN analyses 
respectively. Adding either of the latter 2 tests to a diagnostic algorithm that 
already included Xpert testing would have no added value. Smear microscopy 
is often the only test available in many TB endemic settings, but there has 
been substantial progress in availing Xpert testing in these resource-limited 
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countries and the technology is gaining endorsement as a key diagnostic tool 
particularly on varied specimen types in paediatric TB detection (Raizada et 
al., 2015). 
 
SIGNIFICANT OUTPUTS AND CONCLUSION 
Nucleic acid based methods for TB detection have the advantage of speed 
and sensitivity, particularly in specimens with minute amounts of nucleic acid. 
Currently, there are several tests in late-stage development or on-track for 
evaluation by the WHO, including several NAATs, antibody/antigen-detection 
based (including LAM in urine), VOC based, and automated-imaging based 
technologies for TB diagnosis and/or DST (HIV i-Base/Treatment Action 
Group, 2015). Some of these are newly developed while others are 
second- and third-generation developments from technologies already 
recommended. With the exception of very few of these test candidates 
(dipstick for LAM in urine, the Xpert MTB/RIF Ultra, stronger supporting 
evidence for GenoType MTBDRsl and PURE-LAMP) it is envisaged that “no 
test under development is likely to be on the market with policy endorsements 
within the next three to five years” (WHO, 2014b). 
Two of the key recommendations by the HIV/HCV/TB 2015 Tuberculosis 
Diagnostics Pipeline Report were: 
 To “Improve the quality of research studies, e.g., for follow-on NAA 
technologies, which have the potential to be cheaper, more portable, and 
more accessible than Xpert MTB/RIF, but for which evidence of their 
effectiveness has been sorely lacking” and 
 To “Intensify investments in comparative studies of new TB diagnostics 
and algorithms to optimize the use of current and emerging approaches in 
all important settings” 
My study was able to address a substantive component of these 
recommendations including assessing the performance of a cheaper 
alternative NAAT to the Xpert (Appendix 26) and has contributed to the 
overall pool of knowledge. 
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Through concerted efforts by the Foundation for Innovative New Diagnostics 
(FIND) over the recent years, GeneXpert technology is now available in the 
public sector of 116 of the 145 TB high burden countries eligible for 
concessional pricing (WHO, 2015a). With the protocol defined in my study, 
performing Xpert analysis on lymph node FNA is very feasible for the 
diagnosis of TB lymphadenitis in children. 
A significant outcome of my study was the value of FNA cytology in detection 
of TB in lymph nodes, which performed better than Xpert testing. Having basic 
and cheap sample collection and transportation requirements, introducing this 
test modality into TB-endemic low-income settings is very plausible, requiring 
investment mainly in training for cytomorphological analyses (Mittal et al., 
2011). 
From my study, a functional diagnostic algorithm for suspected childhood TB 
lymphadenitis would be the combination of clinical assessment according to 
WHO guidelines (WHO, 2014c), with lymph node cytomorphology, and Xpert 
MTB/RIF, a fast NAAT detecting TB and rifampicin resistance. EasyNAT 
appears unsuitable for diagnosis of tuberculous lymphadenitis in children.  
There is still significant value in TB culture for purposes of confirming TB 
infection and for drug susceptibility testing; the challenge remains its 
availability at the grassroots level in low-income endemic settings. 
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Ifakara Health Institute (IHI)  
Bagamoyo Research and Training 
Centre (BRTC) 
P.O. Box 74 
Bagamoyo                                                The Aga Khan Hospital, Dar es Salaam 
United Republic of Tanzania 
INFORMATION SHEET  
 
TO THE PARENTS OR LEGAL GUARDIANS OF CHILDREN SUSPECTED TO HAVE TB. 
 
ADDITIONALLY, AN ASSENT FORM WILL BE MADE AVAILABLE FOR CHILDREN > 7 
YEARS AGE AND SIGNED BY THE MINOR IF HE/SHE UNDERSTANDS THE CONTENT 
AND AGREES TO THE STUDY 
 
STUDY TITLE: 
EVALUATION OF XpertTM MTB/RIF (GeneXpert) AND Ustar!  IAD TB (Biotech) ON 
CYTOLOGICAL ASPIRATES FOR DIAGNOSIS OF EXTRAPULMONARY 
TUBERCULOSIS IN CHILDREN 
 
Name of patient:  _____________________________________  
 
 
Date:   _____________________________________  
 
 
Study ID Number: _____________________________________  
 
 
Thank you for taking time to read this information. Your child is invited to participate in a research 
study on new diagnostics for tuberculosis (TB). Before you decide, it is important that you 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Feel free to ask us if there is 
anything that is not clear or if you would like more information. You are completely free to choose 
whether or not you wish to take part.  Please take your time to decide. 
We have selected your child because he/she is suffering from symptoms which are likely to be 
caused by TB, but can also be caused by another disease. We invite you to you read this form and 
ask any questions you may have before agreeing to study. 
This study is being conducted by Ifakara Health Institute (IHI)/Bagamoyo Research and Training 
Centre (BRTC) in cooperation with different research institutes in Africa and Europe.  The study is 
funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) and European 
Governments.  
The study protocol has been approved by the IHI Institutional Review Board and the Medical 
Research Coordination Committee (MRCC) / NIMR of Tanzania. 
 
Study Purpose 
TB is difficult to diagnose, in children even more than in adults. The purpose of this study is to find 
out whether new diagnostic methodologies are more precise in detecting childhood TB than the 
existing approaches. We hope that the newly developed tests will diagnose TB in an easier and 
more reliable way than the current widely used methodologies and might also help to monitor TB 
treatment.  
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Who can take part? 
Children older than 8 weeks and younger than 16 years of age who are suspected having TB of 
parts of the body where there are swollen glands known as lymph nodes and have not been treated 
for TB in the past 12 months can take part in this study.  Whether or not your child takes part in the 
study is entirely up to you, and you do not have to give a reason if you don’t want to be in the study.  
If you decide that your child does not take part your child will not have a disadvantage.  If you 
decide that your child takes part in the study, but change your mind later, you will be free to 
withdraw from the study at anytime without giving a reason.  If you withdraw from the study it will not 
affect the medical care of your child.  
Study Procedures 
In the first days of our study the following will be carried out: Initially, we will examine your child 
thoroughly and will ask questions about his/her medical history and your household.  Furthermore, 
we will collect sputum [maximum 2x5 ml] for diagnosis of TB. In addition, we will draw blood [3 ml] 
for standard investigations (e.g. blood cell count, HIV tests and CD4 count). 
 
A standard tuberculin skin test will be performed in each participating child. Additionally, x-ray of 
the chest and probably of other parts of the body will be necessary. Biopsy of enlarged lymph 
nodes and the collection of other samples as described in the sample donation form will be 
essential to confirm or rule out the diagnosis. 
 
Your child will have a test for HIV. This is recommended for everyone suspected having TB and is 
required for this study. Before and after testing an experienced counsellor will explain the tests and 
the results and will give support to your child and the family. In case your child is tested positive, a 
second confirmatory test will be employed.  If this test confirms that your child is HIV positive, we 
will strongly recommend to attend the Care and Treatment Centre and probably anti-retroviral 
therapy will be provided there. 
 
If we confirm, that your child has or most likely has TB, immediate TB treatment will be 
recommended according to the national guidelines of Tanzania. There will also be cases where a 
preventive TB treatment (e.g. less than 5 year old child with contact with smear positive adult) has 
to be recommended. The definite decision for TB treatment will always be the responsibility of the 
Physician of the Paediatric Department and the local coordinator of the national TB control 
programme. Any other disease will also be treated by the Paediatric Department of our 
collaborating hospital according to national guidelines. 
 
We will carry out one follow-up visit after 5 months, which will include clinical examination and 
medical questionnaire. All procedures will be explained by the physician in charge to you and your 
child. 
Risks of Study Participation 
The study has the following risks: Taking the blood will cause some pain. Venous puncture and 
biopsy might lead in very rare case to infection or bleeding, which will be treated immediately. 
Adherence to strict hygiene regulations and standard operational procedures will minimize this risk.   
Participating in the study and thereafter revealing your child’s health status might be psychologically 
disturbing for you and your child. We have a trained counsellor to help in these difficult moments. 
Benefits of Study Participation 
There is no monetary benefit in this study. However, your child will be quickly and reliably 
diagnosed and actively monitored during the observation period using advanced diagnostics in a 
standardised way. The community will benefit from the information that will be obtained from this 
study. The collected data will help to improve TB diagnostics for children and treatment monitoring 
in the future.  
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Study Costs/Compensation 
There will be no costs for you if your child participates in the study. You will not get paid for 
participation. However you will be compensated for time, travelling and inconvenience by 7,000 Tsh 
for each of visit. 
Confidentiality 
The records of this study will be kept private. In any publications or presentations, we will not 
include any information that will make it possible to identify your child as a subject. The records for 
the study may, however, will be reviewed by the participating research institutes with appropriate 
regulatory oversight.  If any study data will be transmitted via the Internet, files are encrypted and 
password-protected to guarantee privacy. 
Voluntary Nature of the Study 
Participation in this study is voluntary. Your decision whether or not your child will participate in this 
study will not affect your current or future relations with the Temeke District Hospital, the Aga Khan 
Hospital, the Ifakara Health Institute (IHI) / Bagamoyo Research and Training Centre (BRTC) or any 
decisions made for medical care. 
Contacts and Questions 
The researchers clinically conducting this study are: Ms. Maira Bholla (PI) and Dr. Nuruddin Lakhani 
(Co-Investigator). You may ask any questions you have now, or if you have questions later, you are 
encouraged to contact them at the Aga Khan Hospital, Dar-es-Salaam / Temeke District Hospital. 
 
 
Ms. Maira Bholla (PI) 
Phone: 0684600599 
 
Dr. Fredrick Haraka (Co-PI) 
Phone: 0754 539 673 
 
Dr. Nuruddin Lakhani (Co-Investigator) 
Phone: 0783004301 
 
You will be given a copy of this form to keep for your records. You do not have do decide 
immediately about your participation in the study. For your consideration 24 hours are given. 
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Informed Consent Form 
Study Title:  EVALUATION OF Xpert
TM
 MTB/RIF (GeneXpert) AND Ustar!  IAD TB (Biotech) 
ON 
CYTOLOGICAL ASPIRATES FOR DIAGNOSIS OF EXTRAPULMONARY 
TUBERCULOSIS IN CHILDREN 
Principal Investigator:  Ms. Maira Bholla 
 
Name of patient:  _____________________________________ 
 
Study ID Number: _____________________________________ 
 
I confirm that I have read and understand the information sheet, dated 2 June 2011 (version 1.0) 
for the above study.  I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
!  
-------- 
I understand that the participation of my child is voluntary and that I am free to withdraw at any 
time, without giving any reason, without medical care or legal rights being affected. !  
-------- 
I understand that participation in the trial will require my child to have an HIV test. The result of 
this will be kept confidential and will not be given to me or my child without my permission.  I have 
been given a chance to think it over and to ask questions. 
!  
-------- 
I understand that sections of any of my child’s medical notes and data collected during the study 
may be looked at by responsible individuals of the research consortium conducting this trial, from 
regulatory authorities or from the hospital, where it is relevant to my taking part in this research.  I 
give permission for these individuals to have access to my records.                             
!  
-------- 
I agree that my child takes part in the above study !  
-------- 
All 5 boxes must be initialled or marked for the consent to be valid. 
 
 
________________________  ________________ _______________________  
Name of Parent/Guardian   Date Signature or thumb print of  
   Parent/ Guardian 
 
 
________________________  ________________ _______________________  
Name of Witness (if appropriate) Date Signature 
 
 
 
________________________  ________________ _______________________   
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_______________________  ________________ _______________________   
Researcher Date  Signature 
 
 
 
When completed 1 copy for patient; 1 copy for researcher site file; 1 copy (original) to be kept in patient’s medical notes 
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Sample Donation Form  
 
Study Title:  EVALUATION OF Xpert
TM
 MTB/RIF (GeneXpert) AND Ustar!  IAD TB (Biotech) 
ON 
CYTOLOGICAL ASPIRATES FOR DIAGNOSIS OF EXTRAPULMONARY 
TUBERCULOSIS IN CHILDREN 
Site Principal Investigator: Ms. Maira Bholla 
 
Name of patient:  _____________________________________ 
 
Study ID Number: _____________________________________ 
 
Information: 
Your samples (blood, sputum and biopsy samples of lymph nodes) will be kept in the TB CHILD 
specimen bank of our institute for up to ten years, after which they will be destroyed. They will be 
identified only by a code number, and only the project leaders will have access to the code. In 
future, we may use the sample for other scientific studies solely related to tuberculosis. The 
samples can be shipped to cooperating research institute for special investigations on TB research. 
 
Statement: 
I voluntarily donate the required samples to the above mentioned study. The samples will be used 
for TB research, which might be unknown at this point of time.  
 
___________________________________ 
Printed Name of parent/guardian 
 
___________________________________ 
Signature of parent/guardian (or fingerprint) 
 
___________________________________ 
Date         
 
___________________________________  
 Printed Name of Witness 
 
___________________________________ 
 Signature of Witness 
 
___________________________________ 
Date 
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Ifakara Health Institute (IHI)  
Bagamoyo Research and Training 
Centre (BRTC) 
P.O. Box 74 
Bagamoyo                                                           The Aga Khan Hospital, Dar es Salaam 
United Republic of Tanzania 
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ASSENT FOR MINORS 
 
AN ASSENT FORM WILL BE MADE AVAILABLE FOR CHILDREN > 7 YEARS AGE 
AND SIGNED BY THE MINOR IF HE/SHE UNDERSTANDS  
THE CONTENT AND AGREES TO THE STUDY 
 
 
Study Title:  EVALUATION OF Xpert
TM
 MTB/RIF (GeneXpert) AND Ustar!  IAD TB (Biotech) 
ON 
CYTOLOGICAL ASPIRATES FOR DIAGNOSIS OF EXTRAPULMONARY 
TUBERCULOSIS IN CHILDREN 
Site Principal Investigator: Ms. Maira Bholla 
 
Name of patient:  _____________________________________ 
 
Study ID Number: _____________________________________ 
 
Who are we? 
We are doctors and scientist from Temeke District Hospital, Aga Khan Hospital Dar es Salaam / Ifakara Health 
Institute (IHI) / Bagamoyo Research and Training Centre (BRTC). 
Why are we meeting with you? 
We want to tell you about a study that involves children like yourself. We want to see if you would like to be in 
this study too. 
Why are we doing this study? 
We want to find out why you are sick and want to help you. In the same moment we are also looking at an 
illness called tuberculosis. It is up to now very difficult to find out if a child is suffering from this illness. This 
study will hopefully help us and other doctors to diagnose and control tuberculosis more easily and to help 
many children in future. 
What will happen to you if you are in the study? 
After explaining the study to your parents and you, we will ask questions about your health and examine you. 
Furthermore, x-ray and other examinations will be done. These examinations will be explained to you as they 
are done. And we want to collect sputum, draw blood and other body fluids from you at different times of the 
study.  
What are the good things and bad things that may happen to you if you are in the study? 
The good thing about this study is that we are using very good methods to diagnose your illness and to help 
you. Besides, many children will benefit in future from the results of this study.  
The bad thing is that in this study, we want to draw blood several times and body fluids at least once from you. 
That might be a bit painful.  
Do you have to be in the study? 
No you don’t. No one will get angry or upset with you if you don’t want to do this. 
Just discuss it with you parents and tell us if you don’t want to be in the study. And remember, you can change 
your mind later if you decide you don’t want to be in the study anymore. 
Do you have any questions? 
You can ask questions at any time. You can ask now. You can ask later. You can talk to me or you can talk to 
someone else at any time during the study. 
If you want to be in the study, sign your name on the line below: 
 
 
Signature of Child: ___________________________________________________ ____ Date: ____________ 
 
 
Signature of Witness: _____________________________________________________ Date: ____________ 
 
 
Signature of PI or Designee: _______________________________________________ Date: ____________ 
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Appendix 4: Medical history enrolment v1.1, 14.04.11 
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Appendix 5: Clinical examination v1.1, 14.04.11 
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Appendix 6: X-ray v1.1, 14.04.11 
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Appendix 7: NTLP TB Score Chart for children under 6 yrs 
Guidelines (2006 & 2012) 
 
Score 0 1 2 3 4 Score 
Duration of illness 
 
< 2 
weeks  
2-4 
weeks 
 More than 4 weeks   
Failure to thrive 
or weight loss 
Weight 
gain 
 No weight 
gain 
 Weight 
loss 
 
TB contact None Reported, 
not 
proven 
 Proven EPTB, Smear + Proven 
Smear + 
 
Malnutrition    Not improved after 4 
weeks 
  
Chronic infant 
disease 
   Not improved after 4 
weeks 
  
Frequency of 
illness 
 Recurrent  No response to 
antibiotics 
  
Chest x-ray    TB-suggestive features 
like infiltration, cavity, or 
hilar lymph nodes 
  
Lymph nodes    Cervical, sub-
mandibular 
  
Swelling of bones 
or joints 
   Suggestive feature on 
x-ray 
  
Ascites   No 
abdominal 
mass 
With abdominal mass   
Meningitis 
 
   Chronic CNS signs   
Angle deformity 
of the spine 
    X-ray 
feature 
 
TOTAL SCORE  
A score of 7 or more indicates a high likelihood of TB. Refer the child for TB treatment. 
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Appendix 9: Universal Blood Sample Transfer Form 12.12.11-V02 
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Appendix 10: Diagnosis and Medication EPTB v1.2, 31.05.11 
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Appendix 11: Medical history follow up v1.1, 14.04.11 
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1. Purpose  
 
The purpose of this SOP is to describe the procedure of TST administration and reading in the 
TB CHILD study. (Study title: Evaluation of new and emerging diagnostics for childhood 
tuberculosis in high burden countries (TB CHILD)).The skin test is used to evaluate 
participants for TB infection.  
 
 
2. Definitions and Abbreviations 
 
BDH:          Bagamoyo District Hospital 
BRTC:       Bagamoyo Research and Training Centre 
CRF:  Case Record Form 
IHI:            Ifakara Health Institute 
SOP:          Standard Operating Procedure 
TB:         Tuberculosis 
PPD:               Purified Protein Derivative 
TST:                Tuberculin Skin test 
  
3. Scope 
 
This procedure applies to all research staff working at the Ifakara Health Institute - BRTC 
who is involved in TST administration and reading (e.g. medical and clinical officers, clinical 
trial assistants, nurse). 
 
4. Responsibilities 
 
The site Principal Investigator or the designated Project Leader will have overall 
responsibility for the procedures in the SOP. The Head of the Clinical Section or designated 
medical officers will supervise the procedures for this SOP. The delegated staff responsible to 
perform the procedures described will be included in the site Delegation Log 
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5. Procedures 
 
5.1 Patient Information 
 
· Inform the participant and/or guardian that TST is one of the procedures in assessing TB 
infection in the study 
· Explain the procedure to the participant and/or guardian as detailed: 
o Tell parent that the procedure involves injecting a drug on the fore arm, it takes 
about 10 minutes, and is read after 48 - 72 hours, which will take again about 
10 minutes. 
o Tell her/him the expected date of return visit will be explained by the study 
secretary. 
o Participant and/or guardian should not massage or wash the injection site. 
o Should not apply any oil, cream or similar substances at the injection site. 
o Explain to the participant and/or guardian that we expect the injection site to 
swell. This should not be a reason to get scared. 
o Let the participant and/or guardian know that in rare cases site may be itchy 
and at times blister. Should this happen, participant and/or guardian should 
report at the TB Research Clinic. 
· Obtain the verbal consent for the procedure. 
 
5.2 TST administration 
· Prepare and set materials for the test/procedure 
· Ensure aseptic techniques 
o Wash hands with soap 
o Clean the injection site with distilled water. In case alcohol is used to swab the 
skin; it must be allowed to evaporate before test is done. 
· Prepare a tuberculin syringe (disposable 1ml syringe graduated in hundredths of millilitre) 
or similar syringe 
· Use prepared syringe to withdraw 0.1 ml of the tuberculin 
· On a firm, well-lit surface, expose the patient’s arm and slightly flex it at the elbow. 
Choose injection site the middle third of the inner part of the fore arm (preferably the left 
arm).  
· The area selected should be free of any barriers to placing and reading the skin test such 
as muscle margins, heavy hair, veins, sores, or scars.  
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· The skin should be lightly stretched and the needle point will be inserted with the bevel 
upwards in the direction of the forearm into the superficial layer of the skin (intradermal). 
The plunger is not touched until the needle point has been satisfactorily inserted. 
· The volume of exactly 0.1 mL is slowly injected, and the finger removed from the end of 
the plunger before the needle is withdrawn. The injection should raise a flat anaemic 
wheal with pronounced pits and a steep border. 
· If there is significant leakage of tuberculin (at the onnection of the needle and syringe or 
because the needle was not appropriately inserted) or if the test was subcutaneous rather 
than strictly intradermal, the test is repeated on the opposite arm 
· Leave the injection site uncovered 
· Do not massage the area 
· Record in the TST Log, the date and time of the injection and the location of the injection 
site. 
 
5.2 Reading and recording results 
 
· The test must be read 48 - 72 hours after being administered. 
· Identify the injection site, by palpating the area for the induration. 
· The basis of reading the skin test is the presence or absence of induration, which is a hard, 
dense, raised formation. This is the area that is measured. 
· Sometimes the site has erythema, a reddening of the skin that can also have swelling. The 
erythema should NOT be measured. 
· Measure the diameter of the induration (not erythema) transverse to the long axis of the 
arm. 
· A soft, flexible, transparent ruler, calibrated in millimetres is used. 
· Record the results in mm 
· Record results in TST Log and Clinical Examination Form of the participant. 
!
5.3 TST Log
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Bagamoyo Research and Training Centre 
  
 
Patient ID Initials Date of TST 
administration 
Time of TST 
administration 
Administered 
by:  
Date of TST 
reading 
Time of TST 
reading 
Read         
by: 
Measurement of 
induration (mm) 
Adverse event 
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1. Purpose  
The purpose of this SOP is to describe the procedure of fine needle aspiration biopsy of 
peripheral lymph nodes in the EPTB CHILD study. (Study title: Evaluation of Xpert MTB/RIF 
(GeneXpert) and Ustar IAD TB (Biotech) on cytological aspirates for diagnosis of 
extrapulmonary tuberculosis in children. 
 
2. Definitions and Abbreviations 
AKHD: Aga Khan Hospital, Dar es Salaam 
BRTC:       Bagamoyo Research and Training Centre 
CRF:  Case Record Form 
FNAB:  Fine needle aspiration biopsy 
NAA:  Nucleic acid amplification 
PBS:  Phosphate Buffered Saline 
PI:  Principal Investigator 
SOP:          Standard Operating Procedure 
TB:         Tuberculosis 
TDH:          Temeke District Hospital 
  
3. Scope 
This procedure applies to all research staff working at the Temeke District Hospital TB Clinic 
who are involved in fine needle aspiration biopsy procedures (e.g. medical and clinical 
officers, clinical trial assistants, nurse). 
 
4. Responsibilities 
The site Principal Investigator or the designated Project Leader will have overall 
responsibility for the procedures in the SOP. The Head of the Clinical Section or designated 
medical officers will supervise the procedures for this SOP. The delegated staff responsible 
to perform the procedures described will be included in the site Delegation Log. 
 
5. Procedures 
TB FNA procedure at TDH TB Clinic (Wednesdays) 
 
RECEPTION:  
Registration 
The nurse at the TDH TB Clinic courteously welcomes the participant and registers the 
participant in the visit log after checking the ID card. The nurse asks if there are any changes 
of the contact information and makes a note where required. The nurse retrieves the 
participant study file and takes it to the doctor’s room. 
 
DOCTOR’S ROOM:  
Medical history and clinical examination: 
The medical officer or a designated person carries out a brief clinical examination to ensure 
that the participant does not require immediate medical attention or hospital admission. The 
findings are recorded on a source document not intended for data entry.  
The medical officer in charge or a designated person takes the medical history and examines 
the participant briefly and systematically, and confirms the presences of lymph nodes, mass 
or swelling which needs the fine needle biopsy on that day. 
 
Participant information: 
The medical officer in charge or a designated person informs the participant and/or guardian 
that fine needle aspiration biopsy is a way to check a mass or a lump to determine the cause 
of the swelling and is an established way to assess TB infection. The medical officer in 
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charge or a designated person further explains that a small needle is put into the mass and 
gently moved back and forth while suction is applied and one or two drops of fluid are 
removed. That the most common complication is a slight bruising or tenderness of the area 
for a few days following the procedure and that infection at the site of biopsy is rare. 
The FNA procedure is already described in the general consent form the participant has 
signed in the first visit. Additional oral consent is obtained from the participant/guardian after 
this specific information talk. 
 
SAMPLE COLLECTION ROOM:  
Preparations 
The PI makes sure the following are available for the procedure: 
Equipment 
Needle   not larger than 22G (black) 
Syringe    10ml 
Pencil  
Slides       glass slides with ground glass edge 
Fixative     95% ethanol and 100% Methanol in leak-proof containers to hold slides            
MGIT  tubes PANTA prepared for culture 
PBS   sterile 0.7ml per sample in 2ml polypropylene tubes for GeneXpert and Ustar  
tests 
Anaesthesia 
- No local anaesthetic to be used 
- Sedatives for children like: i.v.Diazepam (Valium) or intranasal Midazolam (Dormicum) 
- Topical anaesthetic (Emla cream) may be used 
 
Positioning of participant 
If possible lying down on examination couch, but for small supraclavicular nodes – sitting 
 
FNA procedure 
· Tell participant/guardian that the procedure involves injecting a needle in the enlarged 
lymph nodes 
· Children who are agitated should receive sedative premedication and need to be 
monitored by using a pulse oximeter 
· Clean skin on and around lymph node using alcohol swab 
· After locating and stabilisation of the mass for biopsy and using careful palpation the 
needle is passed into the mass 
· The largest superficial node in a particular group of lymph nodes is the best choice. 
Multiple sites of enlarged lymph nodes can be aspirated 
· The target size and distance from overlying skin should be assessed by palpation. In 
small lesions (1cm) aim for the centre of the lesion. In very large lesions (greater than 
5cm) the lymph node periphery is preferred, because there may be central necrosis. In 
medium sized lesions (2-4cm) two different areas, one to the side of the centre and 
another in the mirror image position of the previous aspiration should be targeted. 
· Maintain 1-2 ml suction throughout aspirate. Once suction has been applied, the needle 
tip must be moved back and forth (or up and down) within the boundaries of the target. 
· Aspirate using cutting motion until materials appears in hub of needle. 
· Release suction (if required) before withdrawing needle. 
· Always perform a minimum of 2 needle passes. Always use a sterile needle and syringe 
for each pass. 
· Place cotton wool on insertion site and ask guardian or participant to apply pressure. 
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· Remove needle from syringe, introduce 5-10 ml air into syringe, re-attach needle and, 
holding needle onto syringe, use air by pushing the plunger swiftly through the syringe to 
express material in needle onto glass slide. 
 
SMEAR PREPARATION: 
· Slides will be labelled with participant initials, identifying number and site of aspiration if 
multiple sites are aspirated 
· Each pass yields 2 slides  
· Average aspirate should yield 4 slides per participant (2 for ZN and 2 for Papanicolau 
staining) 
· To prevent splattering, the tip of the needle should rest on the slide closer to the frosted 
end of a clean slide 
· The material in the needle is often expelled in form of a droplet onto the slide 
· The slide is picked up by its frosted end between thumb and forefinger (of the non 
dominant hand) with the other fingers creating a firm platform beneath the slide 
· A second clean slide (spreader) is held by its frosted end (in the dominant hand), its 
lower edge placed against the 1st slide at 45-degree angle proximal to the droplet 
· The top slide is then lowered until it touches and covers the droplet and the two slides are 
flush 
· The material is then spread in one swift motion by pulling the top slide along the entire 
length of the bottom slide 
· Slides meant for papanicolau staining should immediately be put into 95% ethanol, while 
those for ZN should be air dried for at least 5 min and then put into 100% methanol 
· Transport to the AKHD laboratory as per SOP: TEMEKE_EPTB 
CHILD_FNAB_Transport_01 
 
FOR TB CULTURE: 
· For TB culture, rinse the needle and syringe in TB medium (MGIT tube) prepared as per 
SOP: TEMEKE_EPTB CHILD_FNA_MGIT_001_V01 (Appendix 15) pre-labelled with the 
participants ID. Store tubes at room temperature away from direct sunlight and 
transport to BRTC as per SOP: TEMEKE_EPTB CHILD_FNAB_Transport_01 
 
FOR NAA TESTS: 
· The needle and syringe from a second FNAB pass should be rinsed in sterile 0.7ml 
phosphate buffered saline (PBS) in a 2ml screw-cap tube pre-labelled with the 
participants ID. Transport tubes to BRTC on ice as per SOP: TEMEKE_EPTB 
CHILD_FNAB_Transport_01 
 
The medical officer fills the specimen transfer forms for each test (Appendix 8: FNA, CRF 
version 1.1, 14.04.11 for ZN and cytology; Appendix 13: Specimen transfer form  - FNA 
MGIT; and Appendix 14: Specimen transfer form  - FNA Molecular) and ensures that each 
form is appropriately labelled with ID stickers per patient (Appendix 16). The specimens are 
sent to the laboratory according to guidelines in Appendix 17: TEMEKE_EPTB 
CHILD_FNAB_Transport_01. 
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1. Objective 
To describe the safety procedures for packing, transporting and submitting FNAB 
specimens for diagnosis of tuberculosis 
 
2. Definition  
Abbreviations: 
BRTC - Bagamoyo Research and Training Centre 
FNAB - fine needle aspiration biopsy 
MGIT - Mycobacterium Growth Indicator Tube 
PBS - Phosphate buffered saline 
SOP  - Standard operating procedure 
TB - Tuberculosis 
TDH - Temeke District Hospital, Dar es Salaam 
 
3. Scope 
This document contains procedures for packing, transporting and submitting fixed slide 
samples, MGIT tubes for culture and frozen PBS tubes for molecular testing of FNAB to 
the designated laboratory for diagnosis of tuberculosis. 
 
4. Responsibilities 
The EPTB PI and clinicians at TDH TB clinic. 
 
5. Procedures 
5.1 General description:  
This document details the method for packing, transporting and submitting FNAB 
specimens on slides, in MGIT tubes and in 2ml screw cap polypropylene tubes with PBS, 
to respective laboratories for diagnosis of tuberculosis. 
 
5.2 Materials and Equipment required  
· Permanent marker 
· FNA requisition form for ZN and cytology (Appendix 8: FNA CRF version 1.1, 
14.04.11) 
· TB CHILD FNA Specimen Transfer Form Mycobacteriology (Version 1.0, valid 
from: 15.02.12) (Appendix 13) 
· TB CHILD FNA Specimen Transfer Form Molecular Testing (Version 1.0, valid 
from: 15.02.12) (Appendix 14) 
· Leak proof containers with screw cap for slide transport in alcohol  
· Zip-lock bag or box or container indicating bio hazardous sign 
· Black ink pen 
 
5.3 Packing and transporting procedures of FNAB-slides:  
· Ensure the collected slides of FNAB are marked clearly with the patients ID number 
and initials as well as other identifiers as required. If more than one site is sampled, 
the slide must clearly be marked with site information.  
· Put the first slide immediately into the primary container containing fixative (95% 
ethanol) and other slides into 100% methanol after air-drying for about 5mins. The 
 APPENDICES 131 
 
Temeke District Hospital SOP Code : TEMEKE_EPTB CHILD_FNAB_Transport_01 Page 4 of 5 
 
optimal design feature of the container should be easily opened container, stay 
closed during transportation, made by shock resistant material and having enough 
room to prevent slides from adhering to one another or the container 
· Then place a container with slides in fixative into a transporting bag/box/container to 
avoid leakage during transportation. FNA requisition forms (Appendix 8: FNA CRF 
version 1.1, 14.04.11) that accompany slides in fixative that should be placed in an 
outside pocket to avoid exposure to any leakage of fixative. Note: enclosure of slides 
in fixative into the transport bag or box or container indicating biohazardous contents 
is prudent whether it is delivered manually or by courier system 
· Transport the FNAB slides in fixative following guidelines on transportation of clinical 
specimens 
· Slides in fixative should be submitted in leak proof containers that protect against 
breakage and the slides clearly labelled with patient’s ID and specimen site(s). 
 
5.4 Packing and transporting procedures of FNAB-MGIT tubes: 
· Ensure that all MGIT tubes are appropriately labelled with patient ID labels 
· Ensure that MGIT tubes are not broken in any way and the caps are securely 
screwed on 
· Inoculated MGIT tubes should be stored and transported to BRTC away from direct 
sunlight and at temperatures of above 8 degrees and well below 37 degrees 
centigrade 
· FNA Mycobacteriology request forms (Appendix 13 Specimen transfer form  - FNA 
MGIT) should accompany the specimens in a separate pocket in case of sample 
leakage 
 
5.5 Packing and transporting procedures of FNAB-PBS tubes for molecular 
testing:  
· FNAB-PBS tubes should be well labelled with patient ID label 
· Immediately after sample addition to PBS, the tubes should be placed in a 2-8°C 
freezer for not longer than 12 hours. 
· The PBS tubes should be transported to BRTC Laboratory frozen and on ice pack in 
a cooler box 
· The FNA Molecular Testing requisition forms (Appendix 14: Specimen transfer form  
- FNA Molecular) should be packed separately as they will get wet due to the ice 
pack and condensation 
 
5.6 Submission of FNAB specimens to the responsible laboratory 
· The FNAB slides will immediately be delivered to AKHD laboratory after sample 
collection. A staff at AKHD laboratory will sign a copy of the list of specimens being 
delivered. The original list will be left at the AKHD laboratory and the copy retuned for 
filing at TDH TB Clinic. 
· The inoculated MGIT tubes and PBS frozen tubes will immediately be delivered to 
Mwananyamala IHI TB Clinic for transportation to BRTC with the next scheduled 
transport. The last three rows of specimen labels (Appendix 16) per participant will be 
cut out and sent with the relevant specimens to BRTC. The driver will deliver the 
transportation box with MGIT and PBS tubes to BRTC Laboratory where the staff 
receiving will inspect the tubes and received them for forwarding the relevant section 
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of the laboratory for analysis. A list of specimens and forms delivered to BRTC will be 
signed and filed at BRTC. 
 
6. References 
1. NCCLS. Procedure for handling and transport of Diagnostic Specimens and Etiologic 
Agents-Third Edition: Approved Standard (1994). NCCLS document H5-A3 NCLS, 
940 West Valley Road, Suite 1400 Wayne, Pensylvania19087-1898 USA, 1994. 
 
2. NCCLS. Fine Needle Aspiration Biopsy (FNAB) Techniques; Approved Guideline 
Second Edition. NCCLS document GP10-A2 [ISBN 1-56238-000-0]. NCCLS, 940 
West Valley Road, Suite 1400 Wayne, Pensylvania19087- -1898 USA, 2002. 
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1. Objective 
       To describe the procedures for preparation and inoculation of MGIT with FNA 
2. Definition  
Abbreviations: 
BRTC - Bagamoyo Research and Training Centre 
EPTB - Extrapulmonary tuberculosis 
FNA - Fine needle aspiration 
MGIT - Mycobacterium Growth Indicator Tube 
PI - Principal Investigator 
SOP  - Standard operating procedure 
TB          - Tuberculosis 
TDH - Temeke District Hospital, Dar es Salaam 
3. Scope 
These procedures are applicable to the Clinician performing FNA and the PI or staff 
responsible for preparing MGIT tubes for inoculation at TDH. 
4. Responsibilities 
The PI of the EPTB Study and Clinician involved in FNA at TDH.  
5. Procedures 
5.1. Principle 
A fluorescent compound is embedded in silicone on the bottom of 16 x 100 mm 
round bottom tubes. The fluorescent compound is sensitive to the presence of 
oxygen dissolved in the broth. Initially, the large amount of dissolved oxygen 
quenches emissions from the compound and little fluorescence can be detected. 
Later, actively respiring microorganisms consume the oxygen and allow the 
fluorescence to be detected. 
Tubes entered into the BACTEC MGIT 960 System are continuously incubated at 
37 °C and monitored every 60 min for increasing fluorescence. Analysis of the 
fluorescence is used to determine if the tube is instrument positive, i.e., the test 
sample contains viable organisms. An instrument positive tube contains 
approximately 105 to 106 colony-forming units per millilitre (CFU/ml). There is no 
direct correlation of biomass and Growth Unit (GU) at the time of instrument 
passivity. Culture vials which remain negative for a minimum of 42 days (up to 56 
days) and those which show no visible signs of positivity are removed from the 
instrument as negatives and sterilized prior to discarding. 
5.2. Safety measures  
· Working with Mycobacterium tuberculosis grown in culture requires biosafety level 
3 practices, containment equipment and facilities. 
· All inoculated MGIT tubes have to be treated as bio-hazardous waste. 
· In case of accident see safety SOP# BRTC_LAB_111_V01  
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5.3. Specimen 
FNA material obtained as per SOP: Temeke_EPTB CHILD_FNA_01, is directly 
inoculated into MGIT tubes. 
5.4. Equipment and Material 
· Biological safety cabinet class II 
· Refrigerator 
· Pipette pump 
· Sterile transfer pipettes 
5.5. Procedure  
Preparation for test 
· Switch on the safety cabinet approximately 15 min before use. 
· Label all MGIT tubes with the specimen number. 
· Sort the samples according to ascending sequence of numbers. 
 
Sample preparation 
Consideration: 
o Prior to use, each MGIT tube should be examined for evidence of 
contamination or damage. Discard any tubes if they appear unsuitable. 
o Dropped tubes should be examined carefully. If damage is seen, the tube 
should be discarded. 
· Reconstitute MGIT PANTA with 15 ml MGIT growth supplement. Mix until 
completely dissolved. This mixture is stable for 5 days if stored at 5 ± 3 °C. 
· Aseptically add 0.8 ml of this enrichment to each MGIT tube prior to inoculation 
of specimen (preferably not more than 30 min before). Do not add 
PANTA/enrichment after the inoculation of specimen. Do not store MGIT tube 
after the addition of enrichment/ PANTA. 
· Unscrew the cap on the MGIT tube and with the needle and syringe from the 
first FNAB pass (after preparation of smears), aspirate approximately 1ml of 
MGIT culture medium and dispense it back into the liquid medium. Tightly 
recap the MGIT tube and mix well by inverting the tube several times. 
· Store at room temperature and transport to BRTC within 24 hours as per 
TEMEKE_TB CHILD_FNAB_Transport_01. 
5.6. Sources of error and interference factors  
· The reconstitution of the MGIT PANTA with the MGIT Growth Supplement must be 
done under sterile conditions. 
· For best results, the addition of Growth Supplement / MGIT PANTA Antibiotic 
Mixture should be performed just prior to specimen inoculation, preferably not more 
than 30 minutes before adding the FNA material. 
6. References 
1. BD BBL
TM
 MGIT
TM
 Instruction, Becton, Dickinson and Company, Sparks, 
Maryland, USA 
2. Instruction BD BACTECTM MGITTM 960 System, BD Diagnostic Systems 
3. MGIT 960 Operating and Maintenance Manual 
4. Salman H. Siddiqi, Sabine Rüsch-Gerdes. Procedure manual For BACTEC™ 
MGIT 960™ TB System. 2006 
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TB CHILD 
SPECIMEN TRANSFER FORM 
Mycobacteriology   
Specimen Unique Number ATTACH LABEL 
LABORATORY SECTION Completed by the Lab. Techn. / Ass. 
Specimen received 
 
!!  !!   !! 
             day              month                year 
 
!! : !! 
time 
Temperature of transport box [° C]  
Condition of FNA sample 
! normal    ! bloody    ! mucoid     
! other, specify:____________________________ 
Volume of the FNA sample [ml]  
Did you have to contact study clinician / 
nurse because of problems with transport or 
specimens?   
! yes   ! no 
Name of contact: Specify 
problems:(fill out 
reverse side) 
Laboratory staff 
Name: 
 
Signature: 
 
 
 
 
COMMENTS / CLARIFICATION:  
(document details of telephone call, eg. time, solution of problem, etc.) 
 
 
_______________________________ ___________________________________________  
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
___________________________________________________________ _______________ 
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
 
 
Laboratory staff:          ____________________________________  
        Date & Signature 
 
 
 
 
Attending physician / nurse:   ____________________________________  
        Date & Signature 
r 
 
 
Version 1.0, valid from: 15.02.12 
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TB CHILD 
SPECIMEN TRANSFER FORM 
Molecular Testing   
Specimen Unique Number ATTACH LABEL 
LABORATORY SECTION Completed by the Lab. Techn. / Ass. 
Specimen received 
 
!!  !!   !! 
             day              month                year 
 
!! : !! 
time 
Temperature of transport box [° C]  
Condition of FNA sample 
! normal    ! bloody    ! mucoid     
! other, specify:____________________________ 
Volume of the FNA sample [ml]  
Did you have to contact study clinician / 
nurse because of problems with transport or 
specimens?   
! yes   ! no 
Name of contact: Specify 
problems:(fill out 
reverse side) 
Laboratory staff 
Name: 
 
Signature: 
 
 
 
 
COMMENTS / CLARIFICATION:  
(document details of telephone call, eg. time, solution of problem, etc.) 
 
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
________________________________________________ __________________________  
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
__________________________________________________________________________  
 
 
 
Laboratory staff:          ____________________________________  
        Date & Signature 
 
 
 
 
Attending physician / nurse:   ____________________________________  
        Date & Signature 
r 
 
 
Version 1.0, valid from: 15.02.12 
 
 APPENDICES 142 
Appendix 19: MGIT culture and Reporting 
 
 
Bagamoyo Research and Training Centre 
 
 
 
 
 
 
 
DATE CHANGE REASON FOR CHANGE 
24.11.2011 Decontamination of 
contaminate MGIT vial 
according. Page 7 
HighRif 2 Study specific changes 
 
 
 
 
TITLE:  Procedures for Preparation and                
inoculation of MGIT and Results interpretation. 
VERSION: 02  PAGE:  1 of  10 
SOP  Code:  BRTC_LAB_099_V02 AREA: Laboratory 
WRITTEN BY: 
Name   .                  Date        Signature 
Jugheli, L 
REVISED BY: 
Name                   Date                         Signature 
Rutaihwa, L. 
 
  
APPROVED BY QA: 
Name                       Date                    Signature 
 
AUTHORIZED BY BRTC 
LEADER: 
Mugittu, K. 
Signature: 
EFFECTIVE 
DATE: 
ORIGINAL LANGUAGE: ENGLISH 
TRANSLATED BY: 
Name                       Date                    Signature 
Not applicable 
TRANSLATION VERIFIED BY: 
Name                       Date                    Signature 
Not applicable 
CHANGES 
 APPENDICES 143 
 
Bagamoyo Research and Training Centre            SOP Code : BRTC_LAB_099_V02 Page 2 of 10 
  
Table of Contents 
 
 
1. Objective ................................ ................................ ................................ .....................  3 
2. Definition ................................ ................................ ................................ ....................  3 
3. Scope ................................ ................................ ................................ ...........................  3 
4. Responsibilities ................................ ................................ ................................ ........... 3 
5. Procedures ................................ ................................ ................................ ...................  3 
5.1. Principle ................................ ................................ ................................ ..............  3 
5.2. Safety measures ................................ ................................ ................................ .. 4 
5.3. Specimen ................................ ................................ ................................ ............. 4 
5.4. Equipment and Material ................................ ................................ ......................  4 
5.5. Procedure ................................ ................................ ................................ ............ 4 
5.6. Sources of error and interference factors ................................ ............................  9 
5.7. Quality assurance ................................ ................................ ................................  9 
5.8. Further handling of the samples after the investigation ................................ .... 10 
6. References ................................ ................................ ................................ .................  10 
 
 APPENDICES 144 
 
Bagamoyo Research and Training Centre            SOP Code : BRTC_LAB_099_V02 Page 3 of 10 
  
1. Objective 
       To describe the procedures of preparation and inoculation of MGIT 
2. Definition  
Abbreviations: 
BRTC - Bagamoyo Research and Training Centre 
SOP  - Standard operating procedure 
MGIT - Mycobacterium Growth Indicator Tube 
TB          -           Tuberculosis 
3. Scope 
      These procedures are applicable to the Microbiology - TB section within BRTC. 
4. Responsibilities 
All trained Laboratory Personnel of BRTC Microbiology - TB section are responsible 
for the whole content  of this SOP.  
5. Procedures 
5.1. Principle 
A fluorescent compound is embedded in silicone on the bottom of 16 x 100 mm 
round bottom tubes. The fluorescent compound is sensitive to the presence of 
oxygen dissolved in the broth. Initially, the large amount of dissolved oxygen 
quenches emissions from the compound and little fluorescence can be detected. 
Later, actively respiring microorganisms consume the oxygen and allow the 
fluorescence to be detected. 
 
Tubes entered into the BACTEC MGIT 960 System are continuously incubated at 
37 °C and monitored every 60 min for increasing fluorescence. Analysis of the 
fluorescence is used to determine if the tube is instrument positive, i.e., the test 
sample contains viable organisms. An instrument positive tube contains 
approximately 10
5
 to 10
6
 colony forming units per milliliter (CFU/ml). There is no 
direct correlation of biomass and Growth Unit (GU) at the time of instrument 
passivity. Culture vials which remain negative for a minimum of 42 days (up to 56 
days) and which show no visible signs of positivity are removed from the 
instrument as negatives and sterilized prior to discarding. 
 
The BACTEC MGIT Growth Supplement is added to each MGIT tube to provide 
substances essential for the rapid growth of mycobacteria. Oleic acid is utilized by 
tubercle bacteria and plays an important role in the metabolism of mycobacteria. 
Albumin acts as a protective source. Catalase destroys toxic peroxides that may be 
present in the medium. 
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Growth of contaminating flora from the sample is reduced when supplementing the 
BBL MGIT broth base with BACTEC MGIT Growth Supplement/BBL MGIT 
PANTA antibiotic mixture prior to inoculation with a clinical specimen 
5.2. Safety measures  
· For the entire procedure a biological safety cabinet class II is needed. 
· Working with Mycobacterium tuberculosis grown in culture requires biosafety 
level 3 practices, containment equipment and facilities. 
· All inoculated MGIT tubes have to be treated as bio-hazardous waste. 
· In case of accident see safety SOP# BRTC_LAB_111_V01  
5.3. Specimen 
Acceptable specimens types are digested and decontaminated clinical 
specimens (except urine), and sterile body fluids (except blood) using the 
NALC-NaOH method. 
5.4. Equipment and Material 
· Biological safety cabinet class II 
· Bactec-MGIT 960 instrument 
· Refrigerator 
· Pipette pump 
· Micro tube 2.0 ml, PP; (for performance and storage of extracted DNA from 
decontaminated sputum/pellet) 
· Sterile transfer pipettes 
· 1 ml plastic sterile pipette 
· Rack 
· Lockable container with submitted disinfectant (e. g. Dettol). 
· Autoclave bag 
· BBL MGIT Mycobacteria Growth Indicator Tubes 7 ml 
· BACTEC MGIT 960 Supplement Kit  
5.5. Procedure  
 
Preparation for test 
· Switch on the safety cabinet approximately 15 min before use. 
· Label all MGIT tubes with the specimen number. 
· Sort the samples according to ascending sequence of numbers. 
Sample preparation 
 
Consider: 
o Prior to use, each MGIT tube should be examined for evidence of 
contamination or damage. Discard any tubes if they appear 
unsuitable. 
o Dropped tubes should be examined carefully. If damage is seen, 
the tube should be discarded. 
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· Reconstitute MGIT PANTA with 15.0 ml MGIT growth supplement. Mix 
until completely dissolved. This mixture is stable for 5 days if stored at 5 ± 
3 °C. 
· Aseptically add 0.8 ml of this enrichment to each MGIT tube prior to 
inoculation of specimen (preferably not more than 30 min before). Do not 
add PANTA/enrichment after the inoculation of specimen. Do not store 
MGIT tube after the addition of enrichment/ PANTA. 
· For each specimen, label a MGIT tube with the sample ID number 
· Add 0.5ml of resuspended pellet generated as per SOP_LAB_098_VO1  
to MGIT tube. Dispose of transfer pipette into the autoclave bag. 
· Tightly recap the MGIT tube and mix well by inverting the tube several 
times. 
· If contamination is detected the procedure is repeated with the remaining 
pellet, using the reverse side of MGIT Report Form (form# 
BRTC_LAB_099_APP01_V01). 
· Leave the inoculated MGIT tube in the rack for 30 min. 
· Tubes inserted into the BACTEC-MGIT 960 instrument will be 
automatically tested for the duration of the 42 day testing protocol 
 
Results 
 
Instrument Positive:  
An instrument-positive sample is determined by the BACTEC MGIT 960 
instrument and confirmed by an acid-fast smear. 
i. Print an “Unloaded positive report” from the MGIT instrument with details of 
all instrument positive bottles. Add the corresponding ID number and sign off 
the print out. This print out must be kept in the unloaded positives folder. The 
MGIT will record the date the tube was flagged as positive and the number of 
days and hours taken to reach positivity. 
ii. Simultaneously do the preparation for a ZN smear and the inoculation of a 
blood agar plate: 
! Using a sterile transfer pipette, remove an aliquot from the bottom of the 
tube (approx. 0.1 ml) for AFB stain preparation and blood agar plate 
inoculation.  
o The slide and the blood agar plate should be labeled with the specimen 
number, and the abbreviation for this medium (“M”). 
o Heat fix and stain the smear as for Ziehl-Neelsen staining protocol (see 
SOP# BRTC_LAB_097_V01). 
o Examine the smear for the presence of acid fast bacilli (AFB). 
Describe AFBs i.e. typical, atypical and whether cording is seen and 
record the results in BRTC_LAB_099_APP01_VO1 
o Incubate the inoculated blood agar plate along with the MGIT tube 
(using labeled rack `MGIT with inoculated BA`) in the incubator at 37 
± 2 °C for 48 hours.  
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These procedures will give the information that AFBs and a contamination 
are present or not. 
iii. After 48 hours check the blood agar plate for bacterial contamination.  
iv. Depending on the results of ZN stain and blood agar plate proceed as 
following noted in Table 2.  
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ZN stain Blood agar plate Action taken 
AFB positive No growth  
 
Result is valid MGIT positive and should be reported on form# BRTC_LAB_099_APP01_V01. 
Place the tube on the respective labeled racks for:  
o Molecular Identification (see SOP# BRTC_LAB_101_V01) 
o Inoculation (100 – 200 ! l) of LJ slope and incubate at 37 ± 2°C up to day 56 or up to there is any growth 
detectable. (Rack labeled with: `LJ Subcultures from first MGIT tube`). After detected growth the slope 
should be stored at a cool dark place. 
 
AFB positive Growth  MGIT tube is contaminated and is a mixed culture (AFB+). 
Do the following: 
· Transfer the entire MGIT broth into a 50 ml centrifuge tube. 
· Add an equal quantity of 4% sterile NaOH solution. 
· Mix well and let stand for 15-20 minutes, mixing and inverting the tube 
       periodically. 
· Add phosphate buffer pH 6.8 after 20 minutes up to 50 ml mark. Mix well. 
· Centrifuge at least at 3000x g for 20 minutes. 
· Pour off the supernatant fluid. 
· Re-suspend the sediment in 0.5 ml of buffer and mix well. 
· Inoculate 0.5 ml into a fresh MGIT tube supplemented with MGIT growth supplement/PANTA. 
If the sample has already been retreated once and is still contaminated – this should be reported as contaminated  
AFB negative Growth MGIT tube is contaminated 
-Re-treat the stored sputum pellet (see SOP# BRTC_LAB_098_V01) and reinoculate a new MGIT and LJ slope. 
If the sample has already been retreated once and is still contaminated – this should be reported as contaminated 
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ZN stain Blood agar plate Action taken 
For HighRif study decontaminate the content of MGIT vial as discribed in above section (ZN – AFBpos, BA – 
Growth) 
 
 
ZN stain Blood agar plate Action taken 
AFB negative No growth  Possible false positive – need to confirm absence of AFBs 
o Redo the slide to double check for AFB 
o Look at the tube – is it turbid or could it be a true false positive (from chemical or pH problems) 
o Label the tube on top with the date of the final smear (in 3 days) to be performed and re-insert the tube into 
the MGIT instrument to allow further M.tuberculosis growth. After this 3 days repeat the AFB stain. 
If no AFBs are present, inoculate a labeled LJ slope (Lab.-Accession and study number – or screening number if 
pre-enrolment), Date of inoculation, and “M”). Put the LJ slope on the rack `LJ subculture – MGIT instrument 
pos., AFB neg.` and incubate this tube at 37°C for the next 4 weeks (put a respective label with the last incubation 
date on top). If AFBs are present, follow the instructions as described above. If AFBs are not present, no further 
action. 
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Instrument Negative: 
At the end of six weeks incubation,  
i. Print an “Unloaded negative report” from the MGIT instrument. Add the 
corresponding specimen number and sign off the print out.  
ii. The print out must be kept in the ring binder “MGIT printouts - Instrument 
negative”. The sample will be reported as MGIT culture negative and the 
result is recorded on the form # BRTC_LAB_099_APP01_V01 – MGIT 
Result.  
iii. The MGIT tubes will be discarded as biohazard waste. 
 
5.6. Sources of error and interference factors  
 
· Incorrect procedure of the decontamination and enrichment. 
· The reconstitution of the MGIT PANTA with the MGIT Growth Supplement 
must be done under sterile conditions. 
· For best results, the addition of Growth Supplement / MGIT PANTA 
Antibiotic Mixture should be performed just prior to specimen inoculation, 
preferably not more than 30 min before adding 0.5 ml of the concentrated 
specimen suspension 
· Before insertion of the tubes into the instrument, tightly recap the tubes and 
mix well and leave untouched under the Safety cabinet at room temperature 
for approximately 30 min. 
· Contamination of (or by) neighboring samples during the procedure. 
 
5.7. Quality assurance 
 
a. Decontamination procedure 
1) Check of contamination rates: The weekly contamination rates 
for MGIT culture should be 3 – 8%.  
 
b. Culture Media 
1) Procedure: see SOPs# BRTC_LAB_114_V01, BRTC_LAB_112_V01. 
2) Forms: see form# BRTC_LAB_114_APP01_V01, 
BRTC_LAB_112_APP01_V01 
3) QA/QC check of blood agar plates. 
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5.8. Further handling of the samples after the investigation 
Identification  
All AFB positive cultures should be identified by MTBDRplus test and 
further by MTBC or Mycobacterium CM/AS tests. 
            Sample storage 
AFB positive MGIT tube is to be stored at 36 ± 1 °C until the results of 
Molecular speciation by HAIN system, and/or the DST are known,  
           Sample disposal 
The disposal of the sample containers into the autoclave bag is done by the 
responsible coworker. 
6. References 
 
1. BD BBLTM MGITTM Instruction, Becton, Dickinson and Company, Sparks, 
Maryland, USA 
2. Instruction BD BACTECTM MGITTM 960 System, BD Diagnostic Systems 
3. MGIT 960 Operating and Maintenance Manual 
4. Salman H. Siddiqi, Sabine Rüsch-Gerdes. Procedure manual For BACTEC™ 
MGIT 960™ TB System. 2006 
 
 APPENDICES 152 
Appendix 20: MTB speciation, INH & RMP resistance detection 
 
 
Bagamoyo Research and Training Centre 
 
 
 
TITLE: Molecular Speciation of M.tb complex and 
detection of resistance to INH and RMP 
VERSION: 02  PAGE:  1 of  15 
SOP  Code:  BRTC_LAB_101_V02 AREA: Laboratory 
WRITTEN BY: 
Name                    Date         Signature 
Jugheli, L. 
 
          
 
REVISED BY: 
Name                Date             Signature                    
Rutaihwa, L.K 
Mickson, S 
Mswata, S. 
  
APPROVED BY QA: 
Name                Date             Signature 
 
AUTHORIZED BY BRTC 
LEADER: 
 
Signature: 
EFFECTIVE 
DATE: 
ORIGINAL LANGUAGE: ENGLISH 
TRANSLATED BY: 
Name                       Date                    Signature 
Not applicable 
TRANSLATION VERIFIED BY: 
Name                       Date                    Signature 
Not applicable 
 
 
 
 
 
DATE CHANGE REASON FOR CHANGE 
21/10/2010 Added Figure 1 
 
Added graphical explanation of DNA 
extraction 
Adjusted centrifugation 
speed on page 8. 
The maximum speed of the centrifuge in 
BSL3 lab is 14680 g 
 
 
 
 
CHANGES 
 APPENDICES 153 
 
 
Bagamoyo Research and Training Centre       SOP Code : BRTC_LAB_101_V02 Page 2 of 15 
  
 
 
Table of Contents 
1. Objective ................................ ................................ ................................ .................  3 
2. Definition ................................ ................................ ................................ ................  3 
3. Scope ................................ ................................ ................................ .......................  3 
4. Responsibilities ................................ ................................ ................................ ....... 3 
5. Procedures ................................ ................................ ................................ ...............  3 
5.1 Purpose ................................ ................................ ................................ ..................  3 
5.2 Principle ................................ ................................ ................................ ................  3 
5.3 Safety measures ................................ ................................ ................................ .... 4 
5.4 Specimen ................................ ................................ ................................ ...............  4 
5.5 Equipment and Material ................................ ................................ ........................  4 
5.6 Procedure ................................ ................................ ................................ ..............  5 
5.7 Sources of error and interference factors ................................ ............................  14 
5.8 Quality assurance ................................ ................................ ................................  15 
5.9 Further handling of the samples after the investigation ................................ ...... 15 
6. References ................................ ................................ ................................ .............  15 
 
  
 
 APPENDICES 154 
 
 
Bagamoyo Research and Training Centre       SOP Code : BRTC_LAB_101_V02 Page 3 of 15 
  
 
1. Objective 
To describe the procedures of Molecular speciation of M.tb complex and detection of 
resistance to INH and RMP by GenoType MTBDRplus test. 
2. Definition  
Abbreviations: 
BRTC -        Bagamoyo Research and Training Centre 
SOP  -        Standard Operating Procedure 
INH  -        Isoniazid 
RMP  -        Rifampicin 
3. Scope 
These procedures are applicable to the Microbiology and Molecular TB section within 
BRTC. 
4. Responsibilities 
All trained personnel of BRTC Microbiology and Molecular TB section are responsible 
for the whole content of this SOP.  
5. Procedures 
5.1 Purpose 
The GenoType® MTBDRplus test is based on the DNA-Strip technology and 
permits the molecular genetic identification of the Mycobacterium tuberculosis 
complex and its resistance to rifampicin and/or isoniazid from cultivated 
samples or pulmonary smear-positive direct patient material 
5.2 Principle 
The identification of rifampicin resistance is possible by the detection of the 
most significant mutations of the rpoB gene (coding for the ! -subunit of the 
RNA polymerase). 
For testing of high level isoniazid resistance, the katG gene (coding for the 
catalase peroxidase) is examined and for testing of low level isoniazid 
resistance, the promoter region of the inhA gene (coding for the NADH enoyl 
ACP reductase) is examined. 
The whole procedure is divided into three steps:  
· DNA isolation  
· a multiplex amplification with biotinylated primers and 
· a reverse hybridization. 
The hybridization includes the following steps: 
· chemical denaturation of the amplification products, 
· hybridization of the single-stranded, biotin-labeled amplicons to 
membrane-bound probes, 
· stringent washing,  
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· addition of a streptavidin / alkaline phosphatase (AP) conjugate, and  
· AP mediated staining reaction. 
A template ensures the easy and fast interpretation of the banding pattern 
obtained 
5.3 Safety measures  
· Samples from suspected patients and cultures isolated from those samples 
must always be handled under suitable safety conditions. 
· Specimen treatment and sample preparation must be carried out in class II 
safety cabinet with an exception of heat inactivation. 
· Before the heat inactivation step, samples must be centrifuged in an 
aerosol-tight rotor. 
· Working with Mycobacterium tuberculosis grown in culture requires 
biosafety level 3 practices, containment equipment and facilities. 
· Always wear suitable protective clothing and gloves. 
· Observe the usual precautions for amplification set-up. It is essential that 
all reagents and materials used for DNA isolation and amplification set-up 
are free from DNases. 
· The Denaturation Solution (DEN) contains <2 % NaOH and is irritating to 
eyes and skin  
· The Substrate Concentrate (SUB-C) contains Dimethyl Sulfoxide and is 
irritating. 
5.4 Specimen 
· Cultured material (liquid culture / solid culture) 
o Sample amount: 
Liquid medium: 1.0 ml.  
Using too many bacteria for isolation may lead to inhibition of PCR. 
When densely grown cultures are used, the amount of starting 
material should be reduced. 
Solid medium: a loopful of bacteria.  
o Sample keeping until the starting procedure: 
Samples must be kept in incubator at 37 ± 2 °C. 
· Previously isolated DNA; any DNA isolation procedure producing 
amplifiable MTBC-DNA from bacteria can be used 
5.5 Equipment and Material 
 
· GenoType MTBDRplus; HAIN LIFESCIENCE. 
A test kit contains:  
 
! Membrane strips 
! Primer Nucleotide Mix (PNM) 
! Denaturation Solution (DEN) 
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! Hybridization Buffer (HYB) 
! Stringent Wash Solution (STR) 
! Rinse Solution (RIN) 
! Conjugate Concentrate (CON-C) 
! Conjugate Buffer (CON-D) 
! Substrate Concentrate (SUB-C) 
! Substrate Buffer (SUB-D) 
! Tray, evaluation sheet 
! Manual, template 
 
 
· HotStarTaq DNA Polymerase; 
· Water, molecular biology grade, bi-distilled, sterilized;  
· Distilled water. 
· Safety cabinet biological class II 
· Thermal cycler 
· TwinCubator 
· Water bath 
· Vortexer 
· Microcentrifuge (with angel rotor for 1.5 and 2 ml tubes) 
· Heating block (for 1.5 and 2 ml tubes) 
· Refrigerator 
· Freezer 
· Timer 
· Pencil 
· Tweezers 
· Sterile centrifuge tubes, 50 ml,  
· Sterile transfer pipettes, 3.5 ml; 
· Rack for micro centrifuge tubes and PCR tubes 
· Micro centrifuge tubes 1.5 ml. 
· PCR tubes, 0.2 ml 
· Absorbent paper 
· Adjustable pipettes for 10, 20 200 and 1000 " l 
· Disposable sterile pipette tips with filter;  
· Disposable gloves 
· Lockable container with submitted disinfectant (e. g. Kohrsolin) 
· Autoclave bag. 
5.6 Procedure  
 
The whole procedure is divided into four steps:  
1) DNA isolation from cultured material 
2)   Preparation of PCR master mix 
3) a multiplex amplification with biotinylated primers and 
4) a reverse hybridization. 
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a. Preparing measures 
1) Switch on the safety cabinet approximately 15 min before use. 
2) Sort the samples according to ascending sequence of numbers. 
3) Label all tubes with specimen numbers. 
4) Fill for each investigation material a min sheet and fill out the 
evaluation sheet (BRTC_LAB_103_APP01_V01 and 
BRTC_LAB_103_APP02_V01). 
5) Heat a heating block to 95°C. 
 
b. Sample preparation 
Consider: 
· The following steps have to be performed in the safety cabinet! 
· The working area must be free from amplified DNA. 
· It is crucial to heat samples to 95 – 105 °C for at least 15 – 20 min in order 
to totally lyse cells and to inactivate vegetative bacteria from cultured 
material. 
 
1) DNA isolation (see Figure 1): Preparing measures only for cultured 
material (from liquid or solid medium): 
Raw material are mycobacteria grown on liquid (MGIT) or solid (LJ) 
medium. 
1a) If using bacteria grown in liquid media: 
" Directly apply 1.0 ml of the medium to a 2.0ml micro centrifuge 
tube. Using too many bacteria for isolation may lead to inhibition 
of PCR. When densely grown cultures are used, the amount of 
starting material should be reduced. 
" Centrifuge for 15 min at 10000 x g (use aerosol protection hood!) 
" Carefully remove the supernatant with transfer pipette ensuring 
that pellet remains in the tube 
" Add 100 " l of water (molecular biological grade) (using a filtered 
pipet tip) and re-suspend the pellet completely by vortexing 
1b) If using bacteria grown in solid media: 
" Collect bacteria with a sterile inoculation loop and suspend in 300 
" l water (molecular biology grade) (using a filtered pipet tip). 
Using too many bacteria for isolation may lead to inhibition of 
PCR. When densely grown cultures are used, the amount of 
starting material should be reduced. 
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s
d
fa
s
fd
 
1-2 colonies 
+ 
300 " l water 
500 " l 1000 " l 
15 min 
10’000 g 
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1c) If using prior isolated DNA, continue with step 4). 
2) Incubate bacteria from 1a) and 1b) for 20 min in a heating block at 100 
°C (95 – 105 °C). 
3) Spin down for 5 min at full speed (14680 g). 
4) Transfer supernatant to a new centrifuge tube, which is labeled with 
the sample ID number.  
5) The working area has to be cleaned with Hypochlorite 0.5 % solution 
and alcohol 70 % 
2) Preparation of PCR master mix: 
Prepare the amplification mix (45 " l) in a “Pre-PCR” room (Media 
preparation room). 
 
Important 
· To minimize chance of cross-contamination, all reagents 
and DNA extracts stored in 1.5-2.0 ml tubes should be 
vortexed and short-spun before use.  
· Always wear “clean” gloves (not used to handle DNA 
samples) when handling reagents in Pre-PCR room 
· Wear designated “clean” lab coat when preparing master 
mix 
· PCR tubes to be handled with  tweezers. 
· Taq to be taken out of the freezer only when is to be added 
and immediately returned to the freezer afterwards. 
· Taq to be added last when preparing the master mix. 
 
a. The amount needed is calculated by taking the number of samples 
to be analyzed + control samples. A negative control sample, for 
example, contains 5 " l of water (molecular biology grade) instead 
of DNA extract.  
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Table 1. Buffer-Master-Mix preparation depending on number of samples. 
 
No. of samples 1 2 3 4 5 6 7 8 9 10 11 12 13* 
PN-Mix 35† 70 105 140 175 210 245 280 315 350 385 420 455 
PCR Buffer 5 10 15 20 25 30 35 40 45 50 55 60 65 
MgCl2 2 4 6 8 10 12 14 16 18 20 22 24 26 
H2O 3 6 9 12 15 18 21 24 27 30 33 36 39 
HotStarTaq-
Polymerase
‡
 
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 
* Always prepare master mix for one sample more then actual number of samples; 
† All amounts in " l.  
‡ HotStarTaq-Polymerase: 5 U/" l 
 
b. The resulting Buffer-Master-Mix is mixed carefully by pipetting 
up and down and 45 " l is added to each PCR tube (samples + 1 
negative control) for amplification. 
 
3) Amplification 
Addition of DNA: 
The DNA sample should be added in a separated area (PCR room). If you are 
working on frozen extracted DNA, perform a short spin before you continue 
with the following steps, to avoid a contamination. 
c. Add 5 " l of the extracted DNA (or water for negative control) to the master mix 
d. The tubes are transferred to the ThermoCycler and the respective programme is 
started. Duration: approximately 2.5 h. 
The amplification profile at the ThermoCycler by using HotStarTaq-
Polymerase is following: 
 
   Table 2. Amplification profile at the ThermoCycler 
    
 Culture samples 
Programme name MTBDR-culture 
15 min 95 °C 1 cycle 
30 sec 95 °C 
2 min 58 °C 
10 cycles 
25 sec 95 °C 
40 sec 53 °C 
40 sec 70 °C 
20 cycles 
8 min 70 °C 1 cycle 
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e. Amplification products can be stored at 4 °C to -20 °C. 
 
4) Hybridization: 
The hybridization is done in the “Post-PCR”. 
Consider:  
· Always wear gloves and lab coats when working in Post-PCR room. 
These gloves and coats should NEVER be used outside the Post-PCR 
room and should be either discarded (gloves) or washed (coats) in 
bleach; 
· Take care not to spill solution into the neighboring wells; 
· The strips must be completely covered by the solution and the coated 
side (identifiable by the colored marker near the lower end) must face 
upward; 
· Using tweezers turn over strips which might have turned when 
immersed in the solution. Carefully clean tweezers after each use to 
avoid contamination. 
Preparation: 
- Prewarm the water bath to 42 °C (the acceptable range is 37°-45° C) 
and heat up solutions HYB and STR. The reagents must be free from 
precipitates (note, however, that solution CON-D is opaque. Mix if 
necessary. 
- Warm the remaining reagents with the exception of CON-C and SUB-
C to room temperature. 
- Using a falcon tube, dilute Conjugate Concentrate (CON-C, orange) 
and Substrate Concentrate (SUB-C, yellow) 1:100 with the respective 
buffer (CON-C with CON-D, SUB-C with SUB-D) in the amounts 
needed. Mix well and bring to room temperature. For each strip, add 
10 " l concentrate to 1 ml of the respective buffer. Dilute CON-C 
before each use. Diluted SUB-C is stable for 4 weeks if stored at room 
temperature and protected from light. 
 
 
Performance: 
 
i. Start the programme number 1 on the TwinCubator and pause to pre-warm the 
heating block. 
ii. Dispense 20 µl of Denaturation Solution (DEN, blue) in a corner of each of the 
wells used.  
 
iii. Add to the solution 20 µl of amplified sample, pipette up and down to mix well 
and incubate at room temperature for five minutes.  
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iv. Meanwhile, take strips out of the tube using tweezers and mark them with a pencil 
underneath the colored marker. This should be done on a paper towel. Always 
wear gloves when handling strips. 
v. Carefully add to each well ml of pre-warmed Hybridization Buffer (HYB, green). 
Gently shake the tray until the solution has a homogenous color. Take care not to 
spill solution into the neighboring wells.  
vi. Place a strip in each well. The strips must be completely covered by the solution 
and the coated side (identifiable by the colored marker near the lower end) must 
face upward. Using tweezers turn over strips which might have turned when 
immersed in the solution. Carefully clean tweezers after each use to avoid 
contamination.  This also applies to all following steps. 
vii. Place tray in shaking TwinCubator and incubate for 30 minutes at 45 °C. 
viii. Completely aspirate Hybridization Buffer. For example, use a Pasteur pipette 
connected to a vacuum pump or simply pour off to a waste container and remove 
excess fluid by turning the tray upside down gently tapping on an absorbent paper. 
ix. Add 1ml of Stringent Wash Solution (STR, red) to each strip and incubate for 15 
minutes at 45°C in TwinCubator. 
x. Work at room temperature from this step forward. Completely remove Stringent 
Wash Solution. Pour out Wash Solution in a waste container and remove all 
remaining fluid by turning the tray upside down and gently striking it on an 
absorbent paper. This also applies to all other wash steps. 
xi. Wash each strip once with ml of Rinse Solution (RIN) for minute on TwinCubator 
(pour out RIN after incubation). 
xii. Add 1 ml of diluted Conjugate (see above) to each strip and incubate for 30 
minutes on TwinCubator. 
xiii. Remove solution and wash each strip twice for minute with ml of Rinse Solution 
(RIN) and once for 1 minute with approx. 1 ml of distilled water (e.g. use wash 
bottle) on TwinCubator (pour out solution each time). Make sure to remove any 
trace of water after the last wash.  
xiv. Add 1 ml of diluted substrate (see above) to each strip and incubate protected 
from light without shaking. Depending on the test conditions (e.g. room 
temperature), the substrate incubation time can vary between 3 and 20 minutes. 
Extended substrate incubation times can lead to increased background staining 
and might impair interpretation of the results. 
xv. Stop reaction by briefly rinsing twice with distilled water.  
xvi. Using tweezers remove strips from the tray and dry them between two layers of 
absorbent paper. 
 
 
c. Evaluation and interpretation of results 
" Paste the developed strips in the designated fields by aligning the bands 
CC and AC with the respective lines on the evaluation sheet 
(BRTC_LAB_103_APP02_V01). 
" The supplied template also serves as an aid for evaluation and must be 
aligned with the bands CC and AC of the strip as well. 
" Each strip has a total of 27 reaction zones (Figure 2). 
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" Figure 2. Reaction zones on the strip.Not all bands of a strip have to show 
the same signal strength. 
" Determine the resistance status and note down in the respective column. 
" Validation: 
· Conjugate Control (CC): 
A line must develop in this zone, documenting the efficiency of 
conjugate binding and substrate reaction. 
· Amplification Control (AC): 
When the test is performed correctly, a control amplicon generated 
during amplification will bind to the AC zone on the strip. A missing 
band therefore indicates mistakes during amplification set-up or the 
carry-over of amplification inhibitors with the isolated DNA. In case 
of a positive test result, the signal of the AC zone can be weak. In this 
case, however, the amplification reaction was performed correctly and 
the test does not have to be repeated. 
· M.tuberculosis complex (TUB): 
This zone hybridizes, as known, with amplicons generated from all 
members of the M.tuberculosis complex. If the TUB zone is negative, 
the tested bacterium does not belong to the M.tuberculosis complex 
and cannot be evaluated by this test system. 
· Locus Controls (rpoB, katG, inhA): 
The Locus Control zones detect a gene region specific for the 
respective locus and must always stain positive. 
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" Evaluation and Interpretation: 
Wild type probes (WT) and Mutation probes (MUT): 
- The wild type probes comprise the most important resistance 
areas of the respective genes. The strain tested is sensitive for 
the respective antibiotic, when all wild type probes of a gene 
stain positive (there is no detectable mutation within the 
examine regions). 
- In case of a mutation, the respective amplicon cannot bind to 
the corresponding wild type probe. The absence of a signal for 
at least one of the wild type probes hence indicates a 
resistance of the tested strain to the respective antibiotic. 
- Each pattern that deviates from the wild type pattern indicates 
resistance of the tested strain. 
- The banding patterns obtained with the rpoB probes allows to 
draw a conclusion about a rifampicin resistance of the strain 
tested. 
- The banding patterns obtained with the katG probes allows to 
draw a conclusion about a high level isoniazid resistance, the 
inhA probes a low level isoniazid resistance, respectively. 
" Note the following special cases: 
- There is a possibility that the specimen tested contains a 
heterogeneous strain. If, at investigation, this strain has 
developed only a partial resistance, one of the mutation probes 
as well as the corresponding wild type probe may appear. 
- There is a possibility that the tested specimen contains more 
than one M.tuberculosis complex strain (due to mixed culture 
or contamination). If at least one of these strains harbors a 
mutation, one of the mutation probes as well as the 
corresponding wild type probe may appear. 
 
" Evaluation examples (Figure 3): 
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o Strips were not completely immersed during incubation steps. 
o Tray was not shaken properly. 
· High background color: 
o CON-C and/or SUB-C used too concentrated. 
o Washing steps were not performed with the necessary care. 
o Wash solutions too cold. 
· Unexpected result: 
o Wrong incubation temperature. 
o Hybridization Buffer and/or Stringent Wash Solution were not 
properly pre-warmed or mixed. 
o Contamination of isolated DNA and/or amplification agents with 
isolated and/or amplified DNA. In case amplification agents are 
contaminated a negative control sample also shows the respective 
banding pattern. 
o Contamination of neighboring wells by spillage during addition of 
Hybridization Buffer. 
o Depending on the amount of amplified DNA used and on the 
specific reaction conditions, a strong and fast color development 
may occur. In such cases, dis-continue the substrate incubation as 
soon as the signals are clearly visible in order to prevent the 
development of cross-hybridization bands. 
o No pure culture as starting material or more than one mutation in 
the tested strain. 
o Silent mutation in probe region. 
5.8 Quality assurance 
 
In order to validate the correct performance of the test and the proper 
functioning of reagents, each strip includes 5 control zones: 
· a Conjugate Control zone to check the binding of the conjugate on the 
strip and a correct chromogenic reaction 
· an Amplification Control zone to check for a successful amplification 
reaction 
· three Locus Control zone (rpoB, katG, inhA) checking the optimal 
sensitivity of the reaction for each of the tested gene loci. 
 
5.9 Further handling of the samples after the investigation 
d. Sample storage 
Store extracted DNA samples on -20°C. 
6. References 
a) HAIN LIFESCIENCE Manual, Nehren, Germany 
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Appendix 21: MGIT culture and speciation Report 
 
 
 
 
Report form for MGIT culture 
Bagamoyo Research and Training Centre 
 
Specimen Unique Number 
 
ATTACH LABEL 
 
Patient initials   !!! 
RESULT SECTION – First MGIT tube - Completed by the operator 
Final concentration of NaOH  
used for decontamination ! 1% ! 1.5% ! 2% 
 
 
Date of inoculation 
/ Date started 
1
 
!!  !!  !! 
      day               month             year 
 Initials 
 
 
 
MGIT tube No. 
1
 !!  !!  !!!!!!!! 
Instrument result 
1
 
!  pos. !!  !!  !! 
        day               month             year 
Time to 
detection (TTD) 
/ to positivity: 
!! . !!    
      Days                Hours  
!  neg. !!  !!  !! 
        day               month             year 
Initial 
 
 
 
If instrument positive: Blood agar plate:             ! done          ! not done 
Date of evaluation / 
test 
2
: 
!!  !!  !! 
        day               month             year 
Result ! pos.    ! neg.    Initial 
  
 
If instrument positive: Ziehl-Neelsen stain: 
Date of  
microscopy 
2
 
!!  !!  !! 
      day               month             year 
Result: 
AFB ! . 
! pos.    ! neg.     
Initial 
  
 
! cording        !  typical          ! atypical    
Subculture on LJ 
slope ! done          ! not done – Reason(s): Initial   
 
Result of ZN stain 
from colonies on LJ ! AFB pos.  ! AFB neg. Initial   
 
 
Comments 
 
 
 
 
 
Lab. Supervisor * 
 
 
 
Date & Signature 
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Report form for MTBC 
Bagamoyo Research and Training Centre 
 
 
 
Specimen Unique Number ATTACH LABEL 
Patient initials   !!! 
RESULT SECTION 
DNA extracted from 
! 
Fresh sputum 
! 
Frozen Sputum  
! 
Stored pellet 
! 
Liquid Culture 
! 
Solid Culture 
Date of DNA extraction     !!  !!  !! 
               day              month             year 
Initial 
 
 
 
Date of PCR 
 
    !!  !!  !! 
               day              month             year 
 
 
 
 
Date of hybridisation 
 
    !!  !!  !! 
               day              month             year 
Initial 
 
 
 
 
Reaction zones Visible bands No visible bands 
Conjugation Control (CC) ! ! 
Universal Control (UC) ! ! 
M. tuberculosis complex (MTBC) ! ! 
 
Reaction zones 
Bands more or as 
intensive as UC 
Bands less 
intensive than UC No visible bands 
4 ! ! ! 
5 ! ! ! 
6 ! ! ! 
7 ! ! ! 
8 ! ! ! 
9 ! ! ! 
10 ! ! ! 
11 ! ! ! 
12 ! ! ! 
13 ! ! ! 
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Report form for MTBC 
Bagamoyo Research and Training Centre 
 
 
 
Specimen Unique Number ATTACH LABEL 
INTERPRETATION 
M.tuberculosis complex 
 
!  Yes 
 
!   No 
 
! Not interpretable 
Species 
! M.tuberculosis ! M.bovis ssp bovis ! Not interpretable 
!   M.africanum !   M.bovis BCG 
 
! M.microti ! M.bovis caprae 
 
Comments 
 
 
 
 
 
 
 
 
 
Lab. Supervisor* 
  
 
 
 
 
  
 
 
Date Signature  
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Report form for Mycobacterium CM 
Bagamoyo Research and Training Centre 
 
 
Specimen Unique Number ATTACH LABEL 
INTERPRETATION 
Species 
! M.tuberculosis complex   
!   M.avium !   M.chelonae ! M.abscessus 
!    M.fortuitum !   M.gordonae ! M.intracellulare 
!   M.scrofulaceum !   M.interjectum ! M.kansasii 
!   M.malmoense !   M.peregrinum !   M.xenopi 
!   M.marinum / M.ulcerans  ! Not interpretable 
FURTHER ACTIONS 
Further speciation with  
Mycobacterium AS required: !  Yes !   No 
 
Comments 
 
 
 
 
 
 
 
 
 
Lab. Supervisor* 
  
 
 
   
 
 
Date Signature  
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Report form for Mycobacterium AS 
Bagamoyo Research and Training Centre 
 
 
 
 
 
 
 
Specimen Unique Number ATTACH LABEL 
INTERPRETATION 
Species 
!   M.simiae !   M.mucogenicum ! M.goodii 
!    M.celatum !   M.smegmatis ! M.genavense 
!   M.lentiflavum !   
M.heckeshornense 
! M.szulgai 
!   M.phlei !   M.haemophilum !   M.kansasii 
!   M.ulcerans !   M.gastri !   M.asiaticum 
!   M.shimoidei  !   Not interpretable 
Comments 
 
 
 
 
 
 
 
 
 
Lab. Supervisor* 
  
 
 
   
 
 
Date Signature  
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Appendix 22: Xpert MTB/RIF test for FNA 
 
 
Bagamoyo Research and Training Centre 
 
 
 
TITLE:  The Xpert MTB/RIF test for FNA VERSION: 01  PAGE:  1 of  9 
SOP  Code: BRTC_LAB_129_V01_FNA AREA: Laboratory 
WRITTEN BY: 
Name                    Date                  Signature 
Maira Bholla 
 
REVISED BY: 
Name                      Date                         Signature 
 
  
APPROVED BY QA: 
Name                       Date                    Signature 
 
AUTHORIZED BY BRTC 
LEADER: 
Signature: 
EFFECTIVE 
DATE: 
ORIGINAL LANGUAGE: ENGLISH 
TRANSLATED BY: 
Name                       Date                    Signature 
Not applicable 
TRANSLATION VERIFIED BY: 
Name                       Date                    Signature 
Not applicable 
 
 
 
 
 
DATE CHANGE REASON FOR CHANGE 
   
 
CHANGES 
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1. Purpose 
The Xpert MTB/RIF test for use with the Cepheid GeneXpert® System is a semi-
quantitative nested real-time PCR in-vitro diagnostic test for: 1) the detection of 
Mycobacterium tuberculosis complex DNA in sputum samples or concentrated sediments 
prepared from induced or expectorated sputa that are either acid-fast bacilli (AFB) smear 
positive or negative; and 2) the detection of rifampin resistance associated mutations of the 
rpoB gene in samples from patients at risk for rifampin resistance. The MTB/RIF test is 
intended for use with specimens from untreated patients for whom there is clinical 
suspicion of tuberculosis (TB). Use of Xpert MTB/RIF for detection of M. tuberculosis 
(MTB) or determination of rifampin susceptibility has not been validated for patients who 
are receiving treatment for tuberculosis. 
 
2. Scope 
This procedure applies to all personnel working at the BRTC TB laboratories in Bagamoyo 
and Mwananyamala TB Clinic, Dar es Salaam. 
 
3. Principle 
The GeneXpert Dx System integrates and automates sample processing, nucleic acid 
amplification, and detection of the target sequences in simple or complex samples using 
real-time PCR and reverse transcriptase PCR. The system consists of an instrument, 
personal computer, barcode scanner, and preloaded software for running tests on collected 
samples and viewing the results. The system requires the use of single-use disposable 
GeneXpert cartridges that hold the PCR reagents and host the PCR process. Because the 
cartridges are self-contained, cross-contamination between samples is eliminated. For a full 
description of the system, see the GeneXpert Dx System Operator Manual. Xpert MTB/RIF 
includes reagents for the detection of tuberculosis and RIF resistance as well as a sample 
processing control (SPC) to control for adequate processing of the target bacteria and to 
monitor the presence of inhibitor(s) in the PCR reaction. The Probe Check Control (PCC) 
verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye 
stability. 
 
The primers in the Xpert MTB/RIF assay amplify a portion of the rpoB gene containing the 
81 base pair “core” region. The probes are able to differentiate between the conserved wild-
type sequence and mutations in the core region that are associated with rifampin resistance. 
 
4. Safety measures  
· Treat all biological specimens, including used cartridges, as if capable of transmitting 
infectious agents. Because it is often impossible to know which might be infectious, all 
biological specimens should be treated with universal bio-safety precautions. 
· Guidelines for specimen handling are available from the U.S. Center for Disease Control 
and Prevention and the Clinical and Laboratory Standards Institute (formerly National 
Committee for Clinical Laboratory Standards). 
· Wear protective disposable gloves, laboratory coats and eye protection when handling 
specimens and reagents. Wash hands thoroughly after handling specimens and test 
reagents. Follow your institution’s safety procedures for working with chemicals and 
handling biological samples. 
 
5. Specimen 
· Sputum specimens: a minimum of 1 ml of sputum per specimen should be processed. 
Specimens should be held at 2–8 °C prior to processing whenever possible. However, if 
necessary the specimens can be stored at a maximum of 35 °C for !  3 days and at 4 °C for 
4-10 days  
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· Sputum sediments obtained after the decontamination process using the NALC-NaOH 
method: at least 0.5 ml of resuspended sediment should be available to run Xpert 
MTB/RIF. If they are not immediately processed for Xpert MTB/RIF, store re-suspended 
sediments at 2-8°C not for more than 12 hours. 
· Fine Needle Aspiration (FNA) specimens collected in 0.7ml phosphate buffered saline 
(PBS) should be held at 2-8°C for not more than 48 hours. If the volume of the specimen is 
still 0.7ml, then 0.35ml of the specimen should be available to run for Xpert MTB/RIF. If 
they are not immediately processed for XpertMTB/RIF, store FNA PBS specimens at -20 
°C for not more than 4 months. 
 
6. Sources of error and interference factors  
· Use of non-respiratory specimens such as blood, CSF, stool or urine 
· Specimens processed by methods other than NALC-NaOH 
· Use of an Xpert MTB/RIF cartridge that has been open for more than 30 minutes. Do not 
open a cartridge until you are ready to perform the test. 
· Use of the cartridge 7 days after opening the package because its stability is reduced.  
· Use of a cartridge that has been dropped or shaken after you have added the treated sample. 
· Use of a cartridge if it appears wet or if the lid seal appears to have been broken. 
· Use of a cartridge that has a damaged reaction tube. 
· Use of reagents or cartridges that have passed the expiration date. 
· Reusing of spent cartridges. Each single-use Xpert MTB/RIF cartridge is used to process 
one test.  
· Specimens with obvious food particles or other solid particulates. 
· Processing more than four samples at one time 
· Specimens not held at the indicated temperatures (see Section 5).  
 
7. Materials: Reagents / test components 
Materials Provided 
The Xpert MTB/RIF kit (CGXMTB/RIF-10) contains sufficient reagents to process 10 patient 
or quality control specimens. The kit contains the following (as per kit instruction sheet): 
· Xpert MTB/RIF cartridges with integrated reaction tubes (10 units) 
· Bead 1 (freeze-dried) (2 per cartridge) 
o Primers 
o Probes 
o KCl 
o MgCl2 
o HEPES, pH 8.0 
o BSA (bovine serum albumin) 
· Bead 2 (freeze-dried) 2 per cartridge 
o Polymerase 
o KCl 
o MgCl2 
o dNTPs 
o HEPES, pH 7.2 
o BSA (bovine serum albumin) 
· Bead 3 (freeze-dried) 1 per cartridge 
o Sample Processing Control (SPC) approx. 2000 non-infectious sample 
preparation control spores (Bacillus globigii) 
· Reagent 1 (Tris Buffer, EDTA, and surfactants) (4 mL per cartridge) 
· Reagent 2 (Tris Buffer, EDTA, and surfactants) (4 mL per cartridge) 
· Sample Reagent (Sodium Hydroxide and Isopropanol) (10 x 8 mL bottles) 
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· Sterile disposable transfer pipettes (12 units) 
 
Materials Required but Not Provided 
· GeneXpert Dx System equipped with GX2.1 software (catalog number varies by 
configuration): GeneXpert instrument, computer, barcode wand reader, and Operator 
Manual 
· Printer (See GeneXpert Dx System Operator Manual for compatibility guidelines) 
· Sterile screw-capped specimen collection containers 
· Lab gown and disposable Gloves 
· Labels and/or indelible labeling marker 
· Sterile pipettes for sample processing 
· Discard jar containing appropriate liquid disinfectant 
 
8. Production of reagents, solutions etc.  
 
· Storage conditions and shelf life:  
o Store the Xpert MTB/RIF cartridges and reagents 2 ± 28 °C 
· Manufacture regulations: not applicable. 
 
9. Devices, instruments and aids (listing) 
· Safety cabinet biological class II 
· Vortexer 
· Timer 
· GeneXpert Dx System equipped with GX2.1 software (catalog number varies by 
configuration): GeneXpert instrument, computer, barcode wand reader, and Operator 
Manual 
· Sterile transfer pipettes, 3.5 ml; SARSTEDT; Catalog no. 86.1172.001 /  840 pcs 
· Micro tube 1.5 ml, PP; SARSTEDT; Catalog no. 72.62.105 / 1000 pcs 
· Sterile Falcon tubes (16.5x120 mm); 15 ml; BD; Catalog no. 352096 / 500 pcs 
· Barcode labels for cartridge identification 
· Lockable container with submitted disinfectant  
· Autoclave bag 
· Refrigerator 
· Rack for Falcon tubes of 15 ml 
· Disinfectant for surface and skin 
· Disposable gloves. 
 
10. Procedure  
a. Procedure – Sputum Sediments 
o Label each Xpert MTB/RIF cartridge with the sample ID (write on the side of the cartridge 
or affix ID label). Note: Do not put the label on the lid of the cartridge or obstruct the 
existing 2D barcode on the cartridge. 
o Transfer at least 0.5 ml of the total resuspension pellet to a conical, screw-capped tube for 
the Xpert MTB/RIF using a sterile transfer pipette. Alternatively, the entire sample may be 
processed in the original tube. 
o Store re-suspended sediments at 2–8 °C if they are not immediately processed for Xpert 
MTB/RIF. Do not store for more than 12 hours. 
o Add 1.5 ml of Xpert MTB/RIF Sample Reagent (SR) to 0.5 ml of resuspended sediment 
sample using a sterile transfer pipette and shake vigorously 10 – 20 times. Note: One back-
and-forth movement is a single shake. 
o Incubate the specimen for 15 minutes at room temperature. At one point between 5 and 10 
minutes of the incubation, again shake the specimen vigorously 10 – 20 times. Samples 
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should be liquefied with no visible clumps of sputum. Particulate matter may exist that is 
not part of the sample. 
 
b. Procedure – Expectorated Sputum Samples 
o Label each Xpert MTB/RIF cartridge with the sample ID (write on the side of the cartridge 
or affix ID label). Note: Do not put the label on the lid of the cartridge or obstruct the 
existing 2D barcode on the cartridge. 
o For each of the samples; unscrew lid of original leak-proof sputum collection container; add 
Sample Reagent 2:1 (v/v) to sample, replace the lid, and shake vigorously 10 - 20 times. 
Note: One back-and-forth movement is a single shake. 
o Incubate for 15 minutes at room temperature. At one point between 5 and 10 minutes of the 
incubation again shake the specimen vigorously 10 – 20 times. Samples should be liquefied 
with no visible clumps of sputum. Particulate matter may exist that is not part of the 
sample. 
 
c. Procedure – Fine Needle Aspirate Samples in PBS 
o Label each Xpert MTB/RIF cartridge with the sample ID  (write on the side of the cartridge 
or affix ID label). Note: Do not put the label on the lid of the cartridge or obstruct the 
existing 2D barcode on the cartridge. 
o Use fresh FNA in PBS specimen or thaw out frozen FNA in PBS and mix thoroughly by 
inverting several times. Spin down specimen in centrifuge at low speed for 30 seconds to 
remove specimen residue on lid of 1.5 ml tube. Transfer at least 0.35 ml of the FNA in PBS 
to a conical, screw-capped tube using a sterile transfer pipette. If more than 0.7ml specimen 
available, transfer at least 0.5ml of the FNA in PBS to the conical, screw-capped tube. 
o Store remaining FNA sample at -20 ºC if not immediately used for another test. 
o Add 1.8 ml of Xpert MTB/RIF Sample Reagent (SR) to the 0.35 ml of PBS specimen or 
make up the original specimen volume to just over 2ml with SR (i.e. 1.6ml for 0.5ml 
specimen) using a sterile transfer pipette and shake vigorously 10 – 20 times. Note: One 
back-and-forth movement is a single shake. 
o Incubate the specimen for 15 minutes at room temperature. At one point between 5 and 10 
minutes of the incubation, again shake the specimen vigorously 10 – 20 times. Samples 
should be liquefied with no visible clumps of sputum. Particulate matter may exist that is 
not part of the sample. 
 
d. Procedure - Preparing the Cartridge 
o Using the sterile transfer pipette provided in the Xpert kit, aspirate the liquefied sample into 
the transfer pipette until the meniscus is above the minimum mark (approximately 2ml). Do 
not process the sample further if there is insufficient volume. 
o Open the cartridge lid. Transfer sample into the open port of the Xpert MTB/RIF cartridge. 
Dispense slowly to minimize the risk of aerosol formation. 
o Close the cartridge lid. Make sure the lid snaps firmly into place. Remaining liquefied 
sample may be kept for up to 12 hours at 2 – 8 ºC should repeat testing be required. 
o Important: Be sure to load the cartridge into the GeneXpert Dx instrument and start the test 
within 30 minutes of preparing the cartridge. 
 
e. Starting the Test 
Before you start the test, ensure that the system is equipped with the GX2.1 software, and 
the Xpert MTB/RIF assay is imported into the software). This section lists the basic steps of 
running the test. For detailed instructions, see the GeneXpert Dx System Operator Manual. 
o Turn on the computer, and then turn on the GeneXpert Dx instrument. 
o On the Windows® desktop, double-click the GeneXpert Dx shortcut icon. 
o Log on to the GeneXpert Dx System software using your user name and password. 
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o In the GeneXpert Dx System window, click Create Test. The Scan Cartridge Barcode 
dialog box appears. 
o Scan the barcode on the Xpert MTB/RIF cartridge. The Create Test window appears. Using 
the barcode information, the software automatically fills the boxes for the following fields: 
Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date. 
o In the Sample ID box, scan or type the sample ID. Make sure you type the correct sample 
ID. The sample ID is associated with the test results and is shown in the “View Results” 
window and all the reports. Type in initial sample volume and any comments about the 
nature of the sample (pus/blood stained etc) into the comments. 
o Click Start Test. In the dialog box that appears, type your password. 
o Open the instrument module door with the blinking green light and load the cartridge. 
o Close the door. The test starts and the green light stops blinking. When the test is finished, 
the light turns off. 
o Wait until the system releases the door lock at the end of the run, then open the module 
door and remove the cartridge. 
o Dispose of used cartridges in the appropriate specimen waste containers according to your 
institution’s standard practices. 
!
f. Results 
The results are interpreted by the GeneXpert DX System from measured fluorescent signals 
and embedded calculation algorithms and will be displayed in the “View Results” window. 
Lower Ct (cycle number at threshold) values represent a higher starting concentration of 
DNA template; higher Ct values represent a lower concentration of DNA template. 
 
A. MTB DETECTED (MTB target DNA is detected) 
o MTB Detected—The MTB result will be displayed as High, Medium, Low or Very 
Low depending on the Ct value of the MTB target present in the sample. Table 1 
lists the Ct value ranges for the displayed MTB results.  
 
Table 1. MTB result name and Ct value range 
MTB (result according to the 
concentration of DNA template)  
 
Cycle number at 
threshold (Ct) range 
 
High <16 
Medium 
 
16-22 
 
 
Low 
 
22-28 
Very Low 
 
>28 
 
 
A.1 EVALUATION OF RIFAMPICIN SUSCEPTIBILITY 
This result will be displayed only in MTB DETECTED results and will be on a 
separate line from the MTB DETECTED result (see above) 
o Rif Resistance DETECTED; a mutation in the rpoB gene has been detected that 
falls within the valid delta Ct setting. 
o Rif Resistance INDETERMINATE; the MTB concentration was very low and 
resistance could not be determined. 
o Rif Resistance NOT DETECTED; no mutation in the rpoB gene has been detected. 
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o SPC— NA (not applicable); SPC signal is not required since MTB amplification 
may complete with this control. 
o Probe Check—PASS; all probe check results pass. 
 
 
B. MTB NOT DETECTED (MTB target DNA is not detected, SPC meets acceptance 
criteria) 
o MTB NOT DETECTED—MTB target DNA is not detected 
o SPC— Pass; SPC has a Ct valid range and endpoint above the endpoint minimum 
setting. 
o Probe Check—PASS; all probe check results pass. 
 
C. RIF NOT DETECTED (RIF target DNA is not detected, SPC meets acceptance 
criteria). 
o RIF NOT DETECTED—RIF target DNA is not detected 
o SPC— Pass; SPC has a Ct valid range and endpoint above the endpoint minimum 
setting. 
o Probe Check—PASS; all probe check results pass. 
 
D. INVALID (Presence or absence of MTB cannot be determined, repeat test with 
extra specimen. SPC does not meet acceptance criteria, the sample was not 
properly processed, or PCR is inhibited) 
o MTB INVALID—Presence or absence of MTB DNA cannot be determined. 
o SPC—FAIL; MTB target result is negative and the SPC Ct is not within valid 
range. 
o Probe Check—PASS; all probe check results pass. 
 
E. ERROR 
o MTB—NO RESULT 
o SPC—NO RESULT 
o Probe Check—FAIL*; one or more of the probe check results fail. 
*If the probe check passed, the error is caused by a system component failure. 
 
F. NO RESULT 
o MTB—NO RESULT 
o SPC—NO RESULT 
o Probe Check—NA (not applicable) 
 
G. REASONS TO REPEAT THE ASSAY (Repeat the test using a new cartridge or 
initiate alternate procedures if one of the following test results occurs):  
o An INVALID result indicates that the SPC failed. The sample was not properly 
processed or PCR was inhibited. 
o An ERROR result indicates that the Probe Check control failed and the assay was 
aborted possibly due to the reaction tube being filled improperly, a reagent probe 
integrity problem was detected, or because the maximum pressure limits were 
exceeded or there was a GeneXpert module failure. 
o A NO RESULT indicates that insufficient data were collected. For example, the 
operator stopped a test that was in progress. 
 
11. Data reporting 
The result of each sample will be printed from the report generated by the proprietary software. 
   
12. Quality assurance / quality control  
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(Each test includes a Sample Processing Control (SPC) and probe check (PCC). 
a. Sample Processing Control (SPC)—Ensures the sample was correctly processed. The 
SPC contains non-infectious spores in the form of a dry spore cake that is included in each 
cartridge to verify adequate processing of MTB. The SPC verifies that lysis of MTB has 
occurred if the organisms are present and verifies that specimen processing is adequate. 
Additionally, this control detects specimen associated inhibition of the real-time PCR 
assay. The SPC should be positive in a negative sample and can be negative or positive in 
a positive sample. The SPC passes if it meets the validated acceptance criteria. The test 
result will be “Invalid” if the SPC is not detected in a negative test. 
b. Probe Check Control (PCC)—before the start of the PCR reaction, the GeneXpert Dx 
System measures the fluorescence signal from the probes to monitor bead rehydration, 
reaction-tube filling, probe integrity and dye stability. Probe Check passes if it meets the 
assigned acceptance criteria. 
 
13. References 
a. BD BBLTM MGITTM Instruction, Becton, Dickinson and Company, Sparks, Maryland, 
USA 
b. BD BACTECTM MGITTM 960 System AST Instructions, BD Diagnostic Systems 
c. MGIT 960 Operating and Maintenance Manual 
d. GeneXpert Xpert® MTB/RIF (CGXMTB/RIF-10) Product Instruction Sheet 300-7810 Rev. 
A, April 2009 
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1. Purpose 
The Ustar EasyNAT TB Isothermal Amplification Diagnostic (IAD) Kit is an accurate, simple, 
rapid and cross-contamination proof nucleic acid detection kit. It is intended for the qualitative 
detection of Mycobacterium tuberculosis (MTB) in human samples, and as a clinical diagnostic 
test for TB infection. The reaction mix in this kit is in a glassified state (a form of drying and 
crystallization making them stable at room temperature). 
 
2. Scope 
This procedure applies to all personnel working at the BRTC TB laboratory 
 
3. Principle 
The Ustar EasyNAT TB IAD kit is a nucleic acid amplification and hybridization technique using 
cross-priming amplification (CPA) technology from an isothermal DNA amplification system. 
Using multiple cross-linked primers (six to eight primers) targeting the gyrB gene of M. 
tuberculosis a DNA target sequence is amplified at a constant temperature of 63 or 65°C. Using 
multiple displacement and cross primers, PCR products are generated as interval tandem repeats of 
the target region based on H37Rv sequence (BX842572.1, NT 5582-5789). 
 
Generation of cross-priming sites first occurs in the presence of Bst DNA polymerase through 
extension and displacement activity. Multiple primer binding sites are created which allow for 
multiple extensions and displacements, which occur at the cross-priming amplification stage. 
Mixed intermediate and end structures are then present with which bind the forward and reverse 
detector sequences to create single, double-stranded or partial double stranded sequences. Strip 
detection then occurs when these strands created through detector sequences bind to sites on the 
detection strips. The detection of amplified products is performed on a lateral flow strip housed in 
an enclosed, sealed plastic device to prevent the leakage of amplicons. Results are visualized as 
bands on the test strips present for positive samples and absent for negative results (Fang, Li et al. 
2009). 
 
4. Safety measures  
· Treat all biological specimens, including used cartridges, as if capable of transmitting 
infectious agents. Because it is often impossible to know which might be infectious, all 
biological specimens should be treated with universal precautions. 
· Guidelines for specimen handling are available from the U.S. Center for Disease Control and 
Prevention and the Clinical and Laboratory Standards Institute (formerly National Committee 
for Clinical Laboratory Standards). 
· Wear protective disposable gloves, laboratory coats and eye protection when handling 
specimens and reagents. Wash hands thoroughly after handling specimens and test reagents. 
Follow your institution’s safety procedures for working with chemicals and handling biological 
samples. 
 
5. Specimens 
· The specimens should be sputum, cerebrospinal, pleural, peritoneal, pericardial, ascites, and 
synovial fluid, but not saliva. 
· Specimens may be stored up to 48 hours at 2°C to 8°C before testing. Keep the specimens at -
20°C or colder for long-term storage. 
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· Dispose of all specimens, nucleic acid detection devices and other materials after use as bio-
hazardous waste. 
· Do not pipette by mouth. 
· The Sputum Liquefying Solution contains sodium hydroxide. Handle reagent carefully to avoid 
spills on work surface. Clean up spills with absorbent paper and water. 
· Optimal assay performance requires STRICT ADHERANCE to the assay procedures described 
in these instructions for use. Any procedure deviation may lead to aberrant results. 
 
9. Material: Reagents / test components 
Materials Provided 
Component Box I 
· Detection Device and Cartridge   20 devices Store at 2°C to 30°C 
(1pc each, packed in individually sealed aluminum pouch with desiccant) 
· Sputum Liquefying Solution (125ml)  1 bottle Store at 2°C to 8°C 
· Instructions For Use                                          1 copy  
· Intensity Scale                                                   1 copy 
 
Component Box II  
· Reaction Mix (glassified state)*   20 tubes  
· Resuspension Buffer (350ml)   1 tube 
DNA Extraction Solution (1ml)   1 tube   
· Mineral Oil (500ml)    1 tube  Store at -20°C 
· ddH2O (180ml)      1 tube 
· Positive Control (40ml)    1 tube    
* The Reaction Mix (glassified state) has no label, for better fitting into the PCR machine or 
isothermal heating block. 
 
Materials Required but Not Provided 
· Micropipette and disposable tips 
· Permanent marker 
· Heating block, water bath or any isothermal devices 
· Centrifuge, Vortex and Timer 
· 5 – 10 ml centrifuge tubes 
· 1.5 ml centrifuge tubes, with safe-lock feature 
· Normal saline 
 
10. Devices, instruments and aids (listing) 
· Safety cabinet biological class II 
· Vortex 
· Timer 
· Sterile transfer pipettes, 3.5 ml; SARSTEDT; Catalog no. 86.1172.001 /  840 pcs 
· Micro tube 1.5 ml, PP; SARSTEDT; Catalog no. 72.62.105 /  1000 pcs 
· Sterile Falcon tubes (16.5x120 mm); 15 ml; BD; Catalog no. 352096 /  500 pcs 
· Barcode labels for cartridge identification 
· Lockable container with submitted disinfectant  
· Autoclave bag 
· Refrigerator 
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· Rack for Falcon tubes of 15 ml 
· Disinfectant for surface and skin 
· Disposable gloves 
 
11. Procedure  
Bring Liquefying Buffer, DNA Extract Solution, Detection Device and specimens to room 
temperature before use. 
Sample preparation and DNA extraction 
Steps 1.1 and 1.2 are applicable to sputum samples ONLY. Other sample types such as cerebro-
spinal fluid, pleural effusion, peritoneal, pericardial, ascites, synovial fluid and FNA fluid should 
start from step 1.3 onwards, but pus-like samples should follow sputum-liquefying steps (including 
pus-like samples FNA in PBS). 
 
1.1. Transfer <5ml sputum specimens into 15ml centrifuge tubes (NOT provided) and add same 
volume of Liquefying Buffer into the tube. The volume of Sputum Liquefying Solution 
depends on the condition of the sample, usually a sputum:buffer rate of 1: 1 to 1:2.5, but 
more buffer may be needed for complete liquefying of some samples. 
1.2. Incubate the mixture at room temperature (RT) for 30 minutes; vortex 4 to 5 times during 
incubation to ensure proper mixing. 
Remark: More Liquefying Buffer can be added if the specimen appears to be very dense, but 
sample to buffer ratio should not exceed 1:2.5 
1.3. Transfer 1ml (all of the sample if the volume is less than 1 ml) of the liquefied sputum 
sample, OR non-liquefied form of other sample types into a 1.5ml centrifuge tube* (NOT 
provided), centrifuge at >10,000rpm for > 10 minutes. Decant the supernatant and keep the 
pellet for the next step. 
* Use tubes with safe-lock feature to prevent the caps from popping open during heating in 
subsequent steps. 
The liquefied sputum sample should proceed to step 1.4 while the other sample types to step 
1.6 directly. 
1.4. Wash the pellet two times with 1 ml normal saline (0.9%w/v NaCl), centrifuge at >10,000 
rpm for 10 minutes, decant the supernatant and keep the pellet for the next step. 
1.5. Thaw the DNA Extract Solution and ensure insoluble particles in the solution are evenly 
distributed by vortex or shaking. 
1.6. Pipette 40 ml of DNA Extract Solution (with the insoluble particles) into the tube containing 
the pellet (from step 1.3 or 1.4). Vortex to mix well. 
1.7. Incubate the mixture at 95 to 100°C for 10 minutes. 
1.8. Cool the tube at room temperature for 5 minutes. 
1.9. Centrifuge at >10,000 rpm for > 5 minutes and save the supernatant as amplification 
template. 
1.10. The amplification template can be used immediately or can be stored at -20°C for not more 
than 1 week. 
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12. Data reporting 
Write results on USTAR Result Form_v01_03.05.2013 
A valid test result MUST fulfill the following requirements (see Figure 2) 
1. The Positive Control – two bands should appear; one control line (C) and one test line (T). 
2. The Negative Control - ONLY a control line should appear. 
3. Every sample tested must produce one control line, with or without a test line. 
4. Invalid test results if the control line is absent (even if the test line appears, the result is still 
invalid) 
 
Interpretation of Test Results 
· Specimen with appearance of ONLY Control line indicates absence of M. tuberculosis DNA or 
the DNA copy number is below the detection limit. 
· Specimen with appearance of both control line and test line indicates presence of M. 
tuberculosis DNA. Compare the intensity of the test line to the Intensity Scale. 
· L4 and above: positive result 
· Below L3: negative result 
· Between L3 and L4: repeat the test for further confirmation 
 
13. Kit Performance 
A NEGATIVE result does not exclude the possibility of exposure to or infection with M. 
tuberculosis 
 
Specificity 
Cross-reactivity with positive samples to diseases such as Pneumococcus, brucellos, Pertussis 
vaccine, M. kansasii, M. marinum, M. Simiae, M. scrofulaceum, M. ranae, M. avium, M. 
intracellulare, M. Phlei, M. vaccae, M. smegmatis, M. fortuitmn, M. chelonae subs.chelonae and 
M. chelonae subs.abscessus was found to be insignificant. 
 
Detection limit 
Using M. tuberculosis H37RV strain, the detection limit was found to be less than ten bacteria. 
 
Reproducibility 
Repeat testing on a sample containing one hundred TB bacterial for 10 times, the positive results 
were reproducible. 
 
14. References 
1. WHO Diagnosis of Tuberculosis: countdown to new tools, executive Summary of Meeting 
Report, Geneva, Switzerland, 29-30 June 2000. 
2. Fang R, Li X, Hu L, You Q, Li J, Wu J, Xu P, Zhong H, Luo Y, Mei J, Gao Q. 2008.Cross 
Priming Amplification for Rapid diagnosis of Mycobacterium tuberculosis in sputum 
specimens,  J. Clin. Microbiol, 2009.47(3):845-7.  
3. Research of Assaying HBV-DNA using PCR Test strip (Chinese), 2006. Journal of Medical 
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4. New Detection Method of N. Gonorrhoeae (Chinese), 2006. Journal of Medical Research, 
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Parameter Estimates 
Gamma estimates (class membership probabilities): (Prevalence): Class: 1 2 
0.2283 0.7717 
 
Rho estimates (item response probabilities): 
Response category 1: (Specificity) 
Class:   1 2 
CultPosNeg: 0.2552 0.9028 
CytoPosNeg:  0.0000 0.9468 
UstarPosNeg: 0.7080  1.0000  
XpertPosNeg: 0.2929 0.9421 
ZNPosNeg:  0.8093 1.0000 
Response category 2: (Sensitivity) 
Class:  1 2 
CultPosNeg: 0.7448 0.0972 
CytoPosNeg: 1.0000 0.0532 
UstarPosNeg: 0.2920 0.0000 
XpertPosNeg: 0.7071 0.0579 
ZNPosNeg: 0.1907 0.0000 
Binary predictor variable correlation using a common latent random effect as TB score 
ZNPosNeg: 0.42 
XpertPosNeg: 0.82 
UstarPosNeg: 0.60 
CytoPosNeg: 0.87 
CultPosNeg: 0.82 
 
Latent Class Analysis (LCA) was performed on all FNA diagnostic outputs using 
Statistical Analysis Systems (SAS) Software version 9.2 SAS version 9.2 (SAS Institute 
Inc., Cary, NC, USA). The data were prepared for all cases per diagnostic modality; 1 
representing positive for TB and 2 to representing negative for TB. Blank cells indicated 
inconclusive outcomes or missing data. An algorithm is used to determine the probability 
of TB-presence or TB-absence per case, based on the data input. 
The output displays two ‘latent classes’ created: class 1 for TB-positive and class 2 for 
TB-negative, with probabilities of 0.228 and 0.772 respectively. The prevalence of TB 
lymphadenitis in this study population therefore was estimated as 22.8% (0.228). 
On creation of these latent classes (the probability of a case being positive or negative), 
the system assessed the performance of each diagnostic modality against the latent 
classes (Rho estimates). In ‘response category 2’ indicating “TB-present” (the 
probabilities of having positive values [class 1]) were the sensitivities of each diagnostic 
modality; Xpert 100%, cytology 74.5%, culture 70.7%, Ustar EasyNAT 29.2% and ZN 
(AFB microscopy) 19.1%. The negative predictive values (‘response category 1’ 
“TB-absent” [indicating the probabilities of having negative results]) were very high for all 
5 diagnostic modalities (range: 90.3% - 100%), implying good specificities. 
The binary predictor variable correlation, using a common latent random effect as TB 
score, was interpreted as concordance of the diagnostic modalities to the “true TB 
status” of the patients, as estimated by LCA. Accordingly, cytology had the highest 
concordance of 87% (p:0.87), followed by culture and Xpert at par (p:0.82 each), then 
Ustar (p:0.60) and ZN (p:0.42) 
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Mycobacterium tuberculosis by EasyNAT Diagnostic Kit in Sputum 
Samples from Tanzania. JCM  
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